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THESIS AT A GLANCE
PARKINSON’S DISEASE (PD)
Progressive, neurodegenerative disorder, characterized by motor and non-motor symptoms. Multifaceted and 
complex nature of PD offers a challenge for optimal management.
BODY WEIGHT 
Meta-analysis to evaluate whether patients with PD have a lower BMI than controls
Methods Literature search in 4 databases; 12 studies were included (total 871 patients and 736 controls).
Results PD patients had a significantly lower BMI. Pooled data of 7 studies showed that patients with HY stage 3 had  lower 
BMI than patients with HY 2.
Conclusions Since  low body weight is associated with negative health effects and poorer prognosis, monitoring weight and 
nutritional status should be part of PD management. 
Review on unintentional weight loss in neurodegenerative disorders
Illustrates multifactorial nature of unintentional weight loss in Parkinson’s, Alzheimer’s and Huntington’s disease, 
with common and unique features. Timely detection and involvement from multiple disciplines needed for 
adequate intervention. 
FALLS PREVENTION
Falls Task Force:  clinical practice recommendations that systematically address potential fall risk factors in PD
Methods Development of concept recommendations; evaluation by 27 professionals from multiple disciplines. Review of 
revised recommendations by 12 experts. Consensus  set at 66% agreement among experts.
Results Final overview including 16 generic (age-related) and 15 PD-specific fall risk factors. Nearly all factors required a 
multidisciplinary team approach, usually involving a neurologist and PD-nurse specialist.
Conclusions Set of consensus-based clinical practice recommendations for  management of falls in PD; can be directly used in 
clinical practice, pending further evidence. 
Evaluation of  reliability and user experiences of an automated telephone system: the Falls Telephone
Methods Prospective cohort study (n=119 PD patients). Entries were verified and user experiences evaluated.
Results Sensitivity to detect falls was 100% and specificity 87%. Convenient tool that might also save costs.
Conclusions The Falls Telephone is a convenient and reliable instrument to monitor falls.
TEAM-ORIENTED CARE IN PARKINSON’S DISEASE
Review on allied health care interventions and multidisciplinary team care
Describes the rationale and scientific evidence of allied health care and multidisciplinary care to manage PD. 
Evidence for allied health care is growing, yet, more research is needed and should address how to organize team 
models and evaluate (cost)effectiveness of team care. 
Effectiveness of  multidisciplinary PD care
Aim To establish whether tailored multidisciplinary care from a movement disorders specialist, PD nurses and social 
worker offers better outcomes compared to stand-alone care from a general neurologist. 
Methods RCT among 122 PD patients (100 analyzed; intervention n=51, control n=49) over 8 months follow-up.
Results Improvements on quality of life, motor scores, total UPDRS scores, depression and psychosocial functioning. No 
effect on caregiver strain.
Conclusions This trial gives credence to a multidisciplinary/specialist team approach. 
Effectiveness of  comprehensive, integrated PD care
Aim To evaluate effectiveness and costs of tailored integrated team care, including an assessment in an expert centre, 
complemented with care from allied health specialists in regional networks.  
Methods Controlled trial among 301 patients, comparing regions with this integrated model (n=150) with regions with  usual 
care (n=151) over 8 months follow-up.
Results Improvements on activities of daily living and quality of life, and tertiary health outcomes (e.g. non-motor 
symptoms). No differences in motor functioning, caregiver burden or costs. 
Conclusions Small positive effects on health outcomes, fueling the need for further research on how to organize team-based care 
in PD and design clinical trials to evaluate effectiveness. 
12
13
Introduction
1
Chapter 1
Introduction
Partly based on MA van der Marck, BR Bloem. How to organ-
ize multispecialty care for patients with Parkinson’s disease. 
Parkinsonism and Related Disorders 2013 xxx. 1
IntroductIon
Partly based on 
Marjolein A. van der Marck and Bastiaan R. Bloem. How to organize multispecialty care for 
patients with Parkinson’s disease. 
Parkinsonism and Related Disorders 2014; 20: Supplement 1. 
and 
Marjolein A. van der Marck M, Susan Lindval, Martijn van der Eijk, Bastiaan R. Bloem. 
Multidisciplinary care for people with Parkinson’s disease. In: Aquilonius S-M, Mouradian MM, 
editors. Parkinson’s disease Role of continuous dopaminergic stimulation: ESP Bioscience Ltd; 
2012, p.228-44.
IntroductIon
Partly based on 
Marjolein A. van der Marck and Bastiaan R. Bloem. How to organize multispecialty care for 
patients with Parkinson’s disease. 
Parkinsonism and Related Disorders 2014; 20: Supplement 1. 
and 
Marjolein A. van der Marck M, Susan Lindval, Martijn van der Eijk, Bastiaan R. Bloem. 
Multidisciplinary care for people with Parkinson’s disease. In: Aquilonius S-M, Mouradian MM, 
editors. Parkinson’s disease Role of continuous dopaminergic stimulation: ESP Bioscience Ltd; 
2012, p.228-44.
http://www.prd-journal.com/article/S1353-8020%2813%2970040-3/abstract
doi: 10.1016/S1353-8020(13)70040-3
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Introduction
1This thesis focuses on the broad symptom complex of Parkinson’s disease (PD). This multi-faceted symptomatology markedly affects the quality of lives of affected individuals, as well as their caregivers, family members and friends. Not surprisingly, this complex-ity makes PD a very costly disease. The associated costs for society will rise further in the 
next decades because of a marked increase in the number of PD patients due to ageing 
of our population. Taken together, this enormous burden on health, coupled with the 
high healthcare costs and the rising numbers of PD patients, stress the importance of 
an optimally organized healthcare approach for Parkinson patients. Current medical 
management thus far relies mainly upon pharmacotherapy and – for a selected number of 
patients – on deep brain surgical approaches. This thesis addresses the possible merits of 
care offered by a multispecialty team that also includes allied health professionals, social 
workers, dieticians and nurse specialists, as a complementary approach to current medical 
management. We will address the many challenges associated with this relatively new but 
rapidly emerging field, including issues 
dealing with the organisation of multi-
disciplinary team-based approaches. This 
thesis concludes with a formative evalua-
tion of a new approach towards compre-
hensive, integrated organisation of care 
that was studied in a large prospective 
controlled trial. 
Parkinson’s disease
Parkinson’s disease (PD) is a chronic and 
invariably progressive neurodegenerative 
disorder (Box 1).
PD is typically known for its motor 
features, including tremor, bradykinesia, 
rigidity, postural instability  and postural 
deformities.1,2 However, although the 
diagnosis of PD is currently still founded on 
the presence of these motor symptoms, they 
actually represent only the tip of the iceberg.3 
Particularly in the last decade, attention 
is increasingly focused on a broad variety 
of non-motor symptoms that constitute 
an integral and crucial part of PD.4 These 
include neuropsychiatric symptoms, sleep 
Box 1 Parkinson’s disease
The characteristics of Parkinson’s disease (PD) 
were first described in 1817 by James Parkinson 
based on the observation of six cases, three of 
whom he only casually met in the street.7 In his 
book ‘An Essay on the Shaking Palsy’, he described 
the highly afflicting and complex nature of the 
disorder, with a variety of disabling motor and 
non-motor symptoms. 
The symptoms observed in PD are caused to a 
large extent by degeneration of dopaminergic 
neurons in the substantia nigra, resulting in a 
neurotransmitter imbalance in the basal ganglia. 
These basal ganglia have an important role in 
motor performance, e.g. gait, balance, and speech. 
When approximately 80% of the neurotransmitter 
dopamine is lost, motor symptoms become 
evident. Several other areas within the brain 
and brain stem are also affected, including both 
dopaminergic and non-dopaminergic regions. The 
etiology and underlying pathogenic mechanism 
remains unclear and several mechanisms have 
been considered as contributing factors, including 
genetic and environmental factors, like pesticides. 
The diagnosis is based on clinical profile (leading 
to a possible or probable diagnosis of PD),28 but 
post mortem observation remains needed to 
confirm a definite diagnosis of PD.29 It is expected 
that these definitions will soon change, because of 
growing recognition that a variety of non-motor 
symptoms can precede the manifestation of overt 
motor symptoms.30
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disorders, autonomic symptoms, 
gastrointestinal dysfunction and sensory 
symptoms.5 Some of these symptoms, 
like olfactory deficits, sleep problems and 
constipation, can even be present in the 
“premotor” phase when motor symptoms 
have not yet appeared.6 Almost all patients 
experience non-motor problems, and a 
high prevalence has been reported with 
on average 8 to 12 different non-motor 
symptoms per patient.7-11 These non-motor 
features are an important issue from 
the patients‘ perspective,12 and have a 
great negative impact on quality of life, 
which is in fact even greater than motor 
symptoms.7, 8, 11
Box 2 provides a comprehensive overview of 
all symptoms related to PD. 
These many symptoms are understandably 
very disabling for PD patients and markedly 
influence their quality of life.13  Indeed, 
compared to other chronic conditions like 
arthritis, diabetes, coronary heart disease 
or stroke, patients with PD score lower on 
both physical and mental levels of quality 
of life.14 Due to the progressive nature of PD, 
patients constantly have to adapt to new impairments and to a gradual loss of motor and 
non-motor functioning during the course of the disease.
Because of this complex and multidimensional nature, PD also poses a significant challenge 
to medical specialists. This challenge relates not only to difficulties in correctly diagnosing 
this disorder, but also in the management of the wide variety of symptoms. Although the 
non-motor aspects are recognized as an important part of PD, these symptoms often 
remain unrecognized and are left untreated.4,11 An additional challenge is the fact that PD 
is a highly variable disease across individuals, with a wide diversity in clinical presentation 
between individuals in terms of manifestation and progression of symptoms.12 This great 
interindividual variation creates an even greater challenge to optimally treat the individual 
patient, particularly in this current era where patients increasingly demand a personalized 
approach with specific attention to their own, specific priorities.15-17  
Box 2 Clinical profile of PD including motor 
symptoms and non-motor symptoms. 2,5
Motor symptoms
l Classical motor symptoms 
 (typically asymmetrical)
  l Resting tremor
  l Rigidity 
  l Bradykinesia
  l Postural instability
l Other motor symptoms
  l Gait disturbances, including freezing 
   of gait
  l Micrographia
  l Masked face
  l Dysphagia, contributing to drooling
  l Dysarthria
  l Flexed posture and other postural 
   abnormalities
A wide range of non-motor symptoms including:
l	Neuropsychiatric changes, e.g. depression,  
 apathy, anxiety
l	Cognitive impairments and dementia
l	Autonomic symptoms, e.g. urogenital problems, 
 sweating, orthostatic hypotension, sexual 
 dysfunction
l	Gastrointestinal dysfunction, e.g. dysphagia, 
 choking, constipation
l	Sensory symptoms, e.g. pain, reduced smell 
 (hyposmia)
l	Sleep disorders, e.g. Rapid eye movement 
 (REM) sleep behavior disorder, excessive 
 daytime  somnolence, vivid dreaming
l	Other symptoms, like fatigue, visual dysfunction, 
 and weight changes
17
Introduction
1A multidimensional disorder PD is a complex disorder with disabling features in various domains. Traditionally, treatment has been aimed to control the classical motor symptoms. Over the last years, more attention has been given to other symptoms, including the non-motor symptoms. This thesis focuses on 
an integral organisation of care for PD patients, to control the multiple motor and non-motor 
symptoms. The multidimensionality of PD will be illustrated by highlighting two common 
problems that are clinically relevant to patients but that have thus far received relatively little 
attention in daily clinical management of PD. These two symptoms include unintentional 
weight loss and falls, which are both examples of complications of PD that result from a 
complex interplay between both motor and non-motor problems. Both symptoms nicely 
demonstrate the urgent need for a broad and multispecialty approach in both the diagnosis 
and treatment. The first two sections of this thesis address the approach to each of these two 
specific symptoms (weight loss and falls). An evaluation of the integrative management of PD 
will be investigated in the third part of this thesis.   
Nutritional problems
Unintentional weight loss is frequently reported by PD patients. It is a very relevant problem, 
as it can complicate the course of the disease and contribute to further morbidity and even 
mortality. Several symptoms in PD, both motor and non-motor, may influence energy balance 
and subsequently cause weight reduction. To allow for a timely detection and intervention, 
it is important to be aware of the underlying causes. In Chapter 2, we will review the diverse 
set of factors associated with PD that may all cause disturbances in energy balance. Since 
weight loss is not only common in PD, but also in other neurodegenerative disorders like 
Alzheimer’s disease and Huntington’s disease, these three major neurodegenerative disorders 
will be addressed in this review, to search for common denominators across these conditions. 
Several studies suggest that PD patients have a lower body weight compared to controls, but 
the scientific evidence remains inconsistent on this subject. For that reason, we will study the 
available literature on this topic, and also perform a meta-analysis to assess whether the Body 
Mass Index in PD patients is indeed different from that of controls (Chapter 3).
Fall prevention
Falls are common in PD patients and have serious health implications. Fall prevention is 
therefore needed in this population, but a comprehensive overview of all risk factors is 
lacking. In Chapter 4, we aim to create a set of fall prevention recommendations including 
all fall risk factors in PD patients. This overview may then serve two purposes: for use in 
currently daily clinical practice, as expert opinion pending further evidence; and as an active 
(but experimental) intervention in clinical trials, to obtain further evidence about (cost)
effectiveness.
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To evaluate whether fall prevention programs are indeed effective, a reliable and feasible tool 
to adequately monitor falls is required. Several tools have been developed to monitor falls, 
like questionnaires or falls diaries. However, these methods are often time-consuming and 
impractical, especially when used in large trials with long-lasting follow-up. We have therefore 
developed a computerized system to automatically follow-up fall incidents via telephone calls: 
the Falls Telephone. The reliability and user experiences of this automated Falls Telephone 
system to monitor falls will be evaluated in Chapter 5.  
Towards a multifaceted approach? 
Traditionally, healthcare interventions are provided in a relatively ‘monodisciplinary’ fashion, 
typically with one medical specialist who delivers the bulk of all care for PD patients. This 
is often a neurologist or geriatrician, who provides symptomatic treatment, primarily using 
dopaminergic medication. In Box 3, current medical management is described. 
Nonetheless, only a part of the symptoms respond well to dopaminergic stimulation, 
while others are insufficiently controlled or even worsen as a result of treatment.2,4 
Neurosurgical procedures can be considered, but these are only suitable for a selected 
group of patients. Taken together, current medical management is unable to satisfactorily 
control the multiple symptoms in PD, and this calls for a much broader approach. Indeed, 
Box 3 Medical management of PD
To date, there is no cure for PD. Because of the marked dopamine reduction in the PD brain, treatment is 
mainly focused on dopamine replacement. The dopamine precursor levodopa is the most widely used 
approach to cover this loss. In addition, drugs have been developed that stimulate dopamine receptors 
or block the metabolism of dopamine, including dopamine agonists, COMT inhibitors, and MAO-B inhibi-
tors.31,32
Levodopa is regarded as ‘gold standard’ treatment, which all patients eventually will require at some 
stage of the disease. Dopamine receptor agonists are also an effective way to compensate the reduction 
in central dopaminergic transmission. Such dopaminergic treatments are effective for most motor 
symptoms like rigidity and bradykinesia. However, other motor features, for example tremor, freezing 
episodes, postural instability, are not satisfactorily controlled or unresponsive to levodopa, or may even 
worsen due to dopaminergic treatment, as is the case for some elements of postural instability. Moreover, 
dopaminergic treatment typically has only limited effect for most non-motor symptoms and some of these 
may also worsen due to dopaminergic stimulation (e.g. orthostatic hypotension).2,4  Another shortcoming 
of levodopa is the fact that chronic use is complicated by motor complications, including the ‘wearing 
off’ phenomenon, in which there is a shorter time of effect, unpredictable response fluctuations and 
involuntary movements (dyskinesias).31 Surgical procedures, such as deep brain stimulation, can be 
considered when motor symptoms are insufficiently controlled with pharmacological treatment, mainly 
because side effects (response fluctuations) limit the ability to adequately dose dopaminergic treatment. 
However, these neurosurgical procedures are neither the complete answer: they are only suitable for a 
selected group of patients, and symptomatic effects will only be achieved for those symptoms that also 
responded to dopaminergic treatment prior to surgery. And, as with medication, symptoms may worsen 
again after surgery (because surgery does not cure the disease itself )33, and because adverse events can 
occur, like worsening of gait and balance.21
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Introduction
1it is becoming increasingly clear that a single-clinician approach is insufficient to treat the entire symptom complex as seen in patients with PD. A team-oriented model, including both pharmacological and non-pharmacological interventions, seems preferable. Such a team approach may potentially involve a wide range of different health professionals, including 
physiotherapists, occupational therapists and speech-language therapists (indeed, over 20 
different professional disciplines can offer potential value in the management of PD). Box 4 
provides a comprehensive overview of disciplines that might be involved in PD care. These 
allied healthcare therapists can complement standard medical management as it is offered 
by the medical specialist. Over the past years, several forms of allied health therapy have 
developed into a more evidence-based profession, with growing evidence from good studies 
to support these interventions. This emerging evidence in the field of allied healthcare is 
reviewed in Chapter 6 of this thesis. 
Box 4 Overview of disciplines (in alphabetical order) that may be involved in PD care. 
The large number of professionals reflects the complexity of this condition. (adapted from Bloem et al.19) 
Discipline Primary interest
Dietician (Risk for) Weight loss and malnutrition
Dietary advices related to medication or surgical procedures
Dysphagia
Constipation
General practitioner Recognition of symptoms and side-effects of treatment, with 
subsequent referral to neurologist
Geriatrician Elderly patients with complex set of comorbidities that need to be 
addressed, e.g. internal medicine, psychiatry, falls, or polypharmacy
Neurologist Diagnosis, inventory of spectrum of symptoms and disease process
Medical treatment, expert review of PD  and management of 
complications
Referral to other health professionals 
Neuropsychologist Changes in cognition, memory and behavior
Neurosurgeon Surgical procedures  
Occupational therapist Cognitive impairments related to functional tasks
Disabilities in activities of daily living, and safety and independence 
to perform these activities
Support for family and caregivers to help patients perform activities 
of daily living
Ophthalmologist Visual problems 
Oculomotor disorders, including vertical gaze palsy and diplopia
Parkinson’s
nurse specialist
Provide guidance, support and advice
Education to patient and caregiver
Observe symptoms and side-effects of medication
Notify increased demands for care, with specific attention to 
cognitive, psychosocial, sexual and mood problems
Close communication with neurologist, general practitioner and 
other healthcarers
Pharmacists Check for medication interaction
Enhance therapy adherence
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No standard template
Nowadays, a multifaceted approach is increasingly recognised as the optimal way to control 
a complex disorder like PD.18-19 Importantly, this recognition is also shared by patients 
themselves.15 Indeed, in current clinical practice, more different types of health professionals 
appear to become involved in PD care, but the effectiveness of their services in current clinical 
practice appears suboptimal.20 One problem is that, despite overlapping treatment goals, the 
various different specialists typically work in isolation and parallel to one another, instead of 
Physiotherapist Physical activity, general fitness, muscle strength
Safety and functional independence, safe use of assistive devices
Fear of falling, fear to move
Restrictions in performing transfers (e.g. standing up from a chair, 
rolling over in bed) and walking (like freezing)
Disorders of balance and postural control
Prevent falling
Motor learning and strategy training (e.g. breaking down activities)
Psychiatrist Apathy, loss of taking initiative
Behavioral problems
Delirium
Depression
Anxiety, panic attacks 
Psychologist Stress of patient or caregiver
Complex psychosocial problems
Coping
Problems with relationship
Mood and anxiety disorders
Rehabilitation specialist Observation and treatment of problems with activities of daily living, 
household activities, or participation
Provide assistive devices
Advice on job participation 
Sexologist Problems with sexual functioning 
Sleep medical specialist Diagnosis of complex sleep disorders. Treatment of sleep disorders, 
like insomnia, vivid dreaming and excessive daytime somnolence
Specialised elderly care
physician
Daycare, short-stay or long-stay, regarding complex motor and non-
motor pathology
Palliative care
Residential care
Speech-language 
therapist
Problems with speech or communication
Swallowing disorders
Social worker Psychosocial problems, e.g. coping or problems with daytime 
activities
Caregiver burden (psychological and financial)
Facilitate acquisition of services and inquiries, including legislation 
and regulation
Urologist Urinary problems, e.g., incontinence and urgency, to exclude other 
causes besides PD
Erection and ejaculation dysfunction 
Complementary and
alternative therapies 
These therapies (e.g., nutritional supplements, massage therapy, 
acupuncture, homeopathy) are used commonly by PD patients 
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Introduction
1delivering an integrated approach. At present, PD centres worldwide increasingly implement team-based care in their clinical practice, but there is no standard template. Consequently, organisation of team-based care varies widely across different centres.21 Even though there is a general feeling that these team-based approaches provide better care, the scientific 
evidence to support this feeling remains very limited, and the few trials published so far have 
showed inconsistent results.22-25
How to organise team care? 
There are several ways to organise team-oriented models, varying from a relatively simple 
approach, where independent health professionals share their expertise, to a more complex 
and seamless continuum of care, based on consensus between all team members.26 These 
models are illustrated in more detail in Box 5 and Box 6. As mentioned previously, there is 
currently no standard template for team-based PD care and it is unknown whether more 
complex organized models represent better care.
In this thesis, the organisation of two different approaches towards multispecialty team 
management is described and evaluated. These studies are among the first controlled trials 
that aim to evaluate the effectiveness of ongoing team care in PD. In Chapter 7, we describe 
an example of multidisciplinary care, featuring a movement disorders specialist supported 
Box 5 Models of Team Healthcare Practice (Based on Boon H. et al.26)
Parallel • independent health professionals
Consultative • independent health professionals who give expert advice to another
Collaborative • health professionals, normally working independent 
• distribute information concerning a shared patient 
Coordinated • team of health professionals working together
• coordination by  case coordinator or manager via communication 
and sharing of patient records
Multidisciplinary • team of healthcare professionals working together
• each team member makes own decisions and recommendations
• team leader integrates recommendations and plans patient care
Interdisciplinary • team of healthcare professionals working together
• group decisions, usually based on consensus, facilitated by regular, 
face to face meetings
Integrative • interdisciplinary, non-hierarchical approach 
• seamless continuum and shared decision making 
• each professional and patient contributes with knowledge and skills
• patient centered care and support, treatment of whole person 
* Increased complexity with growing number of determinants of health considered, diversity of outcomes and number 
of participants involved. Also, increased need for communication and synergy between participants, and importance 
of decision making by consensus. Growing emphasis on whole person and individualization of treatment, with an  
individually tailored approach.
Increased com
plexity*
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by PD nurses and a social worker, whose input is tailored to the patients’ individual needs. 
In this chapter, we describe the results of a randomized controlled trial on the effects on 
health outcomes of this approach. 
The ultimate model: an integrated, comprehensive approach  
With the wide variety of PD symptoms in mind, a comprehensive approach with involvement 
of professionals from various disciplines would appear preferable to treat PD.  In Chapter 8, 
we examine the effectiveness of one specific example of a comprehensive model, namely 
an integrated approach of PD care as we deliver this at our centre in the Netherlands. This 
healthcare approach offers patients two complementary elements: a tailored assessment by 
an extensive team of health professionals, resulting in an integrated treatment advice based 
on consensus and shared decision-making. This treatment advice is subsequently carried out 
by dedicated allied health professionals working within the direct vicinity of the patients’ 
homes, as part of specialised ParkinsonNet networks. These networks represent regional 
communities of closely collaborating allied health specialists, who are specifically trained to 
treat PD patients according to evidence-based guidelines. Besides increased PD expertise, 
these networks also aim to enhance interdisciplinary collaboration between specialists, to 
ultimately provide a seamless organization of care for those affected with PD.27 
 Box 6 Multidisciplinary versus Interdisciplinary/Integrative team care
MULTIDISCIPLINARY INTERDISCIPLINARY/INTEGRATIVE
• Team of health professionals
• Communicate
• May have (face-to-face) meeting
• Decisions made by each individual member
• Managed by team leader, integrates advices
• Work towards same goal
• Independent from each other
• Individual decisions and recommendations
• Team of health professionals
• Collaborate
• Regular (face-to-face) meeting
• Decisions made by group
• Shared leadership, consensus model
• Work together towards same goal
• Rely on each other to accomplish goals
• Integration of perspectives
Team leader
Treatment advices and recommendationsTreatment advices and recommendations
23
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Abstract
Unintended weight loss frequently complicates the course of many neurodegenerative disor-
ders, and can contribute substantially to both morbidity and mortality. This will be illustrated 
here by reviewing the characteristics of unintended weight loss in the three major neuro-
degenerative disorders: Alzheimer’s disease, Parkinson’s disease and Huntington’s disease. A 
common denominator of weight loss in these neurodegenerative disorders, is its typically 
complex pathophysiology. Timely recognition of the underlying pathophysiological process 
is of crucial importance, since a tailored treatment of weight loss can considerably improve 
the quality of life. This treatment is, primarily, comprised of a number of methods of increasing 
energy intake. Moreover, there are indications for defects in the systemic energy homeostasis 
and gastrointestinal function, which may also serve as therapeutic targets. However, the clini-
cal merits of such interventions have yet to be demonstrated.
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2IntroductionNeurodegenerative disorders are traditionally associated with cognitive, psychiatric and motor impairments. However, what is much less appreciated is that the course of many neurodegenerative disorders can also be complicated by an unintended loss of body weight. 
Weight loss can contribute to both morbidity (e.g. because of increased risk of systemic 
infections and pressure sores) and mortality.1-2  Moreover, recent findings suggest that changes 
in systemic metabolism could also directly influence the underlying neurodegenerative 
processes.3-4 It is, therefore, crucial to be aware of the underlying causes of unintended weight 
loss, which will allow for timely detection, and tailored interventions directed at improving 
nutritional status and increasing body weight.
Here we first delineate the characteristics of unintended weight loss in neurodegenerative 
disorders, using Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease 
(HD) as representative and complementary examples. We will, subsequently, present a 
comprehensive model of the pathophysiology of weight loss in these disorders. Finally, we 
will use this model to highlight a number of possible implications for clinical management 
and patient care.  
Characteristics of weight loss
Alzheimer’s disease
AD is the most common cause of dementia and is characterized by the progressive loss 
of cognitive modalities. Weight loss in AD was already described by Alois Alzheimer in his 
original report from 1906.5-6 Many epidemiological studies have since confirmed this initial 
observation. Weight loss is present in about 40% of AD patients, and can occur in all stages of 
the disease, even before a formal diagnosis has been made.7-8 According to current diagnostic 
standards, weight loss is now considered a concomitant criterion for dementia.9  A recent 
prospective follow-up study demonstrated that a decline in Body Mass Index (BMI) in older 
age is associated with both an increased risk of developing AD, and a faster rate of disease 
progression.8 This may indicate a causal relationship, whereby weight loss aggravates the 
pathogenic processes that mediate AD. Conversely, the association may also arise when 
disease progression induces weight loss.8 Age has a modifying effect on the relationship 
between body weight and the risk of dementia: being overweight in middle age (40-45 years) 
increases the risk of developing dementia later in life10, while the relation between body 
weight and the risk of dementia in older age (65-75 yrs) appears to be U-shaped.11 In even 
older age (≥ 76 years), a higher BMI is directly associated with a decreased risk of dementia.11
Parkinson’s disease
The core motor symptoms of PD include bradykinesia, resting tremor, rigidity, and postural 
instability.12 In addition, the disease is also frequently complicated by a variety of non-motor 
28
symptoms, including dementia and depression.13 Furthermore, numerous studies have 
revealed that patients with PD lose weight, and have a lower body weight when compared 
to matched control populations.14 Weight loss in PD can be ascribed, primarily, to a loss of 
fat tissue.14 A recent large-scale prospective study showed that weight loss in PD patients 
is a continuous, progressive process, which commences years before a formal diagnosis is 
made, and cannot be ascribed to a decreased energy intake.15 However, analogous to AD, 
being overweight in middle age is an independent risk factor for developing PD later in life.16
Huntington’s disease
HD is a hereditary, progressive, neurodegenerative disorder, characterized by motor, 
psychiatric, and cognitive disturbances.17 The motor disturbances include chorea, dystonia, 
hypokinesia, and rigidity.17 The disease is often accompanied by considerable weight loss, 
particularly in its final stages.18-19 Many studies have demonstrated that HD patients are either 
underweight, or tend to lose weight during the course of their illness, eventually becoming 
cachectic.20-22 Weight loss in HD is not associated with reduced intake due to anorexia, but 
rather with an increased appetite. 23-25 Although there are indications of a higher sedentary 
energy expenditure due to unwanted movements26, these findings do not explain the lower 
BMI found in either asymptomatic gene-carriers23-24 or HD patients who are in the early 
stages of the disease, when unwanted movements are absent or minimal.20 Undernutrition is 
common in HD patients19, and contributes to a higher rate of mortality.27 Conversely, a higher 
body weight at the time of diagnosis is associated with slower disease progression.28
Pathophysiological mechanisms
Weight loss results from a prolonged disequilibrium between intake, digestion and absorp-
tion of energy from nutrients on the one hand, and energy expenditure on the other hand 
(Figure 1). 
Figure 1 Negative energy balance. Weight loss occurs when energy expenditure exceeds energy intake. 
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2Total daily energy expenditure is determined by the resting metabolic rate, the thermogenic effect of food, and the extent of physical activity and repair.29 Through a process known as energy homeostasis, the central nervous system adjusts food intake in response to changing energy requirements, so as to promote stability in body weight over time.30 Information 
regarding nutrient status and energy stores is communicated to the brain through diverse 
endocrine (e.g. leptin) and afferent neural signals where it is subsequently integrated with 
cognitive, visual, olfactory, and taste cues.30-31Accordingly, it should not come as a surprise 
that diseases of the central nervous system are often complicated by disturbed body weight 
regulation. Here, we will focus on weight loss in neurodegenerative disorders, the aetiology 
of which is complex and multifactorial.  In this context, the factors which could disrupt energy 
balance can be divided into two groups: a) primary factors that are directly related to neuronal 
dysfunction and neurodegeneration, such as cognitive, psychiatric and motor disturbances, 
altered olfaction and gustation, and pathology of energy homeostatic centres in the brain, 
and b) secondary factors that are not directly attributable to neurodegenerative processes, 
but are, nevertheless, prevalent and can contribute to weight loss, such as side effects of 
medication, loss of autonomy, and a higher risk of co-morbidity (particularly infections 
like pneumonia and pressure sores).32 The most important factors are summarized in Table 
1. Although many of these factors could be involved in the pathogenesis of weight loss in 
all three of the major neurodegenerative disorders, some are of particular importance and, 
sometimes, unique to a specific disease (Table 1). 
 Table 1: Factors influencing energy balance
Examples Disorder References
Factors influencing energy intake
Cognitive 
disturbances
Neglect and agnosia (forgetting to eat), 
apraxia (difficulties with shopping and meal 
preparation), communication problems 
(desire to eat cannot be expressed)
AD 32,41
Psychiatric and 
behavioural 
disturbances
Depression (with vital features), afraid to eat, 
confusion, refusal to eat
AD, PD, HD 7,14,50,66
Motor disturbances Wandering/pacing
Tremor, tardive dyskinesias
Rigidity, dystonia
Chorea
Dysphagia
AD
PD
PD, HD
HD
AD, PD, HD
50
51-52
26,51-52,54 
26,86
57-59
Autonomic 
dysfunction
Swallowing difficulties PD, HD 14,32
Sensory functions Altered sense of smell and taste
Reduced vision, hearing and tactile sense
AD, PD, HD
AD
60
32
Orodental problems Caries and reduced oral hygiene AD, PD, HD 32,34 
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* For a large number of endocrine, metabolic and inflammatory changes an independent effect on weight loss has 
not been sufficiently investigated, although it has been suggested in a number of studies. 
ACTH adrenocorticotropic hormone; AD Alzheimer’s disease; HD Huntington’s disease; Il-1 interleukin-1; Il-6 inter-
leukin-6; PD Parkinson’s disease; T3 triiodothyronine; T4 thyroxine; TNF-α tumor necrosis factor-α; TSH thyroid-stim-
ulating hormone. 
For example, a putative loss of function of the normal huntingtin protein may affect body 
weight regulation in HD.33 An overview of commonly used drugs which may interfere with 
energy balance is presented in Table 2. 
Age and social 
factors
Isolation/loneliness
Poverty/ low social-economic position
AD, PD, HD 34
Decreased physical 
activity
Reduced appetite
Muscle atrophy
AD
AD, HD
32
23,44
Pathology of brain 
energy homeostatic 
centres
Pathology of hypothalamus, brainstem 
(autonomic centres), mesial temporal cortex 
and mesocorticolimbic reward circuits
AD, PD, HD 78-84 
Endocrine 
and metabolic 
abnormalities*
Reduction of endocrine and metabolic 
stimulants of energy intake
AD, PD, HD 78-79,87 
Inflammatory 
abnormalities* 
Anorexia due to increases in Il-1, Il-6, TNF-α AD, PD, HD  88-90 
Side effects of 
medication 
Nausea, dry mouth, altered ability to smell 
and taste, reduced appetite, dysphagia, 
gastrointestinal dysfunction, dyskinesias, 
esophagitis, vomiting, tardive dyskinesias 
AD, PD, HD see Table 2
Factors influencing energy absorption
Autonomic 
dysfunction
Slow stomach emptying,  reduced 
absorption, constipation
PD 58 
Side effects of 
medication
Gastrointestinal dysfunction, diarrhoea, 
vomiting
AD, PD, HD see Table 2
Factors influencing energy expenditure
Motor disturbances Wandering/pacing 
Tremor, tardive dyskinesias 
Rigidity, dystonia 
Chorea
AD
PD
PD, HD
HD
44
51-52 
26,51-52,54 
26,86 
Pathology of brain 
energy homeostatic 
centres
Hypermetabolic state due to pathology 
of hypothalamus, brainstem (autonomic 
centres), mesial temporal cortex 
AD, PD, HD
Endocrine 
and metabolic 
abnormalities*
Changes in: ACTH, cortisol, growth hormone, 
prolactin, TSH, T3, T4, testosterone and 
estrogen
Glucose intolerance
Abnormalities of fat and muscle tissue
Increased resting energy expenditure
ApoE4 genotype
Loss  of normal huntingtin function
AD, PD, HD
AD, PD, HD
HD
PD, HD
AD
HD
78-79,87,91-93     
 94-96 
26,51-52,54 
97
33
Inflammatory 
abnormalities* 
Procatabolic state due to increases in Il-1, 
Il-6, TNF-α
AD, PD, HD 88-90 
Side effects of 
medication
Dyskinesias, lipolysis AD, PD, HD see Table 2
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Evaluation of weight loss and malnutrition
Periodical weighing of patients is a simple and efficient way to monitor body weight and 
nutritional status.32 The following criteria could serve as a guide:34
• Does the patient have a low body weight? A BMI lower than 20 kg/m2 indicates an 
increased risk of malnutrition. For people aged 65 years and over, 21 kg/m2 is used 
as the cut-off point to compensate for age-related changes in body composition.34
• Has the patient lost weight unintentionally? Weight loss exceeding 5% in three 
months, or 10% in six months, is considered clinically relevant and indicates a 
greater risk of malnutrition.35
• Are there indications of decreased appetite or food intake (> 25% of food is not 
consumed in at least two out of three meals in the previous week)?35
Further examination is necessary when at least one of the above criteria is met. In addition, 
other instruments, such as the ‘Malnutrition Universal Screening Tool’36 and the ‘Mini 
Nutritional Assessment’37, are available for the systematic assessment of nutritional status. 
These two scales are easy to use, and have been validated in a variety of populations, although 
further corroboration is required in patients with neurodegenerative disorders38-39 (see the 
accompanying websites36-37 for further information).
Table 2: Medication with a negative influence on energy balance
Side effects Medication type
Anorexia Cholinesterase inhibitors, NSAIDs, MAOIs
Nausea Antibiotics, NSAIDs, levodopa, amantadine, dopamine 
agonists, MAOIs, toxic plasma levels of various drugs (e.g. 
digoxin, theophylline)
Altered sense of smell and taste Anticholinergics, antibiotics
Gastrointestinal dysfunction 
(particularly constipation)
Benzodiazepines, opioids, anticholinergics, tetrabenazine, 
tricyclic antidepressants
Dyskinesias Antipsychotics, tetrabenazine, levodopa
Dry mouth Anticholinergics, amantadine, COMT inhibitors, MAOIs, 
tricyclic antidepressants
Esophagitis Bisphosphonates
Dysphagia Phenothiazines, neuroleptics
Diarrhoea SSRIs, antibiotics, laxatives, COMT inhibitors
Lipolysis Levodopa, dopamine agonists
Partly adapted from White H.K.32 COMT catechol-o-methyltransferase; MAOIs monoamine oxidase inhibitors, 
NSAIDs non-steroidal anti-inflammatory drugs; SSRIs selective serotonin reuptake inhibitors.
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Therapeutic strategies and implications for patient care
Timely recognition of the risk of malnutrition, and its underlying causes, is of crucial 
importance for adequate intervention. Formulation of extensive recommendations for the 
treatment of malnutrition and unintended weight loss in general, are beyond the scope of 
this article; excellent clinical guidelines can be found elsewhere35,40 and are, generally, also 
applicable to neurodegenerative disorders. In this paper, we will limit ourselves to those 
aspects which are of specific importance to the treatment of malnutrition and weight loss in 
neurodegenerative disorders (Table 1).
Dementia and behavioural disturbances
Progressive dementia is an inherent feature of AD and HD and, to a lesser extent, PD. Getting 
patients with dementia to eat is generally a process of trial and error.32 It is important that food 
is not only offered during mealtimes but also in between them. Most patients need constant 
supervision and simple instructions during meals. Finger foods could be utilised when 
patients are unable to use cutlery.41 If appetite and vigilance are greater early in the day, it can 
be useful to increase the relative contributions of breakfast and lunch to the total daily energy 
supply.41 Food intake can also be stimulated by simplifying the eating environment, such as 
by removal of potential distractions, the creation of a calm atmosphere, e.g. through soft 
background music42, and by providing family style mealtimes.43 Promoting physical activity 
can also stimulate appetite and, in addition, prevent muscle atrophy.44
Psychiatric disturbances
Depression is the most common psychiatric disturbance to complicate the course of the three 
major neurodegenerative disorders. Moreover, of all the psychiatric disturbances, depression 
has the greatest influence on energy balance.45 Depression can lead to a  decrease in appetite, 
and induce a cascade of neuroendocrine changes that can lead to weight loss over time.45 
Treatment of depression could thus have a positive effect on body weight. Although tricyclic 
antidepressants can induce weight gain, their side effects, such as constipation and a dry 
mouth, render these drugs less suitable when compared to selective serotonin reuptake 
inhibitors (SSRIs). The initial concern that SSRIs might promote weight loss in the elderly 
has never been substantiated.46 and a number of them, particularly mirtazapine, are even 
associated with increased appetite and weight gain.47 Although some SSRIs, such as fluoxetine, 
can induce weight loss in the short term, prolonged use (> ½ year) is associated with weight 
gain.47 The effects of SSRIs on patients with dementia, both on depression and other outcome 
parameters, such as body weight, need further investigation. Furthermore, the application of 
neuroleptic medication for the treatment of psychosis in AD patients has been associated with 
weight gain.48-49 While neuroleptic medication is also frequently used for treating psychosis in 
PD and HD (and for the suppression of choreatic movements in HD), the relation between 
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2neuroleptics and body weight in PD and HD patients needs further investigation. In any event, serious side effects, such as extrapyramidal symptoms, place inherent limitations on the use of neuroleptics for the treatment of weight loss in neurodegenerative disorders. 
Dyskinesias
Abnormal motor behaviour, such as excessive pacing, has been associated with weight loss in 
patients with AD.50 However, in PD and HD patients, the relation between weight loss and motor 
disturbances, such as rigidity, tremor, dystonia and chorea, is still unclear. On the one hand, 
there are indications that dyskinesias could lead to a higher energy expenditure in both PD51-
53 and HD26,54 patients, whereas on the other hand, the total daily energy expenditure in both 
PD and HD patients does not appear to be significantly different from that of matched control 
subjects.26,55 This is probably explained by fewer spontaneous and voluntary movements.26,55 
Other findings that argue against the notion of dyskinesias being major determinants of 
weight loss in HD, are the lower BMIs, compared to controls, found in presymptomatic HD gene 
carriers and those patients who are at an early stage of the disease when motor disturbances 
are either absent or minimally present.20,56 In addition, the weight gain that is often observed 
in PD patients after pallidotomy and deep brain stimulation in the subthalamic nucleus, is not 
associated with improvements in dyskinesia scores.14,53  Therefore, it remains unclear whether 
reduced energy expenditure, due to improvement of the motor symptoms, could explain 
any weight gain after medical or surgical suppression of dyskinesias. However, dyskinesias 
can often impair food intake, particularly in PD patients with response fluctuations. A flexible 
feeding scheme adjusted to these response fluctuations may be helpful.14 Furthermore, many 
AD, PD, and HD patients experience chewing and swallowing difficulties, which can further 
hamper energy intake.57-59 Food intake can, therefore, be promoted by a combination of 
feeding assistance and optimal treatment of the motor impairments.14
Olfactory and gustatory disturbances
The sense of smell plays a considerable part in the perception of taste. Olfactory dysfunction, 
due to both structural and functional changes in the brain, has been reported in different 
neurodegenerative disorders.60 It can occur early in the course of the disease in AD, PD, and 
HD.60 A reduced ability to taste and smell may contribute to weight loss in these disorders. 
Therefore, it is particularly important to strive to maximize the smell and taste of food, for 
example by using aroma and flavour enhancers.61
Medication
The side effects of medication can interfere with energy balance on a number of different 
levels (Table 2).32 In particular, commonly used drugs can cause many symptoms which 
could limit energy intake. Acetylcholinesterase inhibitors, which are the first option for 
treating cognitive symptoms in AD, have several potential adverse effects. These include 
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nausea, vomiting and anorexia, which can limit the intake and absorption of nutrients.62-63 
In addition, galantamine, an acetylcholinesterase inhibitor, has been associated with an 
increased incidence of weight loss.64 Nausea and anorexia are also notable side effects of  the 
dopaminergic medication that is widely used in the treatment of PD patients. Moreover, long-
term dopaminergic therapy may increase lipolysis, as a consequence of increased growth 
hormone secretion65, contributing to the loss of fat tissue reported in PD patients.66-67 However, 
pramipexole, a dopamine receptor agonist, has been associated with weight gain in PD, 
presumably through a direct effect on the limbic D3 receptors involved in feeding.
68 The use of 
neuroleptics is, generally, also associated with weight gain, although serious adverse effects 
limit their application (see above in the paragraph ‘Psychiatric disturbances’). In HD patients, 
the effects on body weight of tetrabenazine, an antichoreic drug that selectively depletes 
central monoamines by reversibly binding to the type 2 vesicular monoamine transporter, are 
not well studied, although one study failed to find significant differences in weight change 
between patients on tetrabenazine and those on placebo.69 On the other hand, a small-scale 
open-label study showed that HD patients taking creatine did not lose weight over two years 
of follow-up, suggesting that creatine supplementation may be effective for the treatment 
of weight loss in HD.70 Thus, while some drugs, such as pramipexole in PD, and creatine in 
HD, appear promising for the treatment of weight loss in these disorders, large-scale clinical 
trials are needed to provide convincing evidence of their efficacy. Therefore, currently, no 
pharmacological interventions can be recommended for the treatment of weight loss in 
neurodegenerative disorders. Meanwhile, physicians and caregivers should be aware that 
patients with cognitive impairment may not be able to voice symptoms attributable to the 
side effects of commonly used drugs, such as nausea and anorexia.32 In addition, patients 
who have a low body weight are at an increased risk of receiving higher cumulative doses 
of medication, with a proportional disruption of energy homeostasis attributable to side 
effects.71 Therefore, in case of weight loss or low weight, all medication used should be 
checked and, if necessary, adjusted.
Nutritional supplements
Different studies have demonstrated that oral nutritional supplements can boost total daily 
energy intake, and stabilize or even increase body weight.5,21,72-74 Therefore, energy-rich oral 
nutritional supplements can be applied in case of an increased risk of malnutrition. Daily energy 
requirements can be gauged based on estimates of physical activity level and resting energy 
expenditure, using predictive formulas like the Harris-Benedict and Schofield equations.75 
However, these equations have not been validated in patients with neurodegenerative disease, 
and should only be used as a guide, particularly because requirements are greater in people 
who are underweight.76 As patients who need feeding assistance, and the elderly in general, 
are at an increased risk of developing micronutrient deficiencies, the routine use of vitamin 
and mineral supplements should also be considered.32,77 The implementation of artificial 
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2feeding is highly controversial.5 Enteral feeding (nasogastric/gastrostomy feeding tubes) does not improve the prognosis in terms of survival, functional capacity, and susceptibility to pressure ulcers and infections.5 However, transient artificial feeding should be considered for mildly affected patients in whom oral feeding is not possible in the short term.5
Defects in systemic energy homeostasis
In several neurodegenerative disorders, weight loss may occur despite adequate or even 
increased food intake. This suggests the involvement of other factors that may adversely affect 
systemic energy homeostasis, such as malabsorption, defects in energy homeostatic centres in 
the brain (particularly the hypothalamus and autonomic centres), and peripheral biochemical 
abnormalities, such as mitochondrial dysfunction.58,78-84 Indeed, various components of 
systemic energy homeostasis in neurodegenerative disorders may be defective. For example, 
abnormalities have been described in gastrointestinal function, in peripheral tissues, such as 
muscle and fat, and in the different parts of the brain which are involved in the regulation 
of energy balance. 4,58,78-84 However, most of these findings stem from fundamental research 
of which the clinical relevance is still unclear. Further physiological studies on the relation 
between defects in the various components of systemic energy homeostasis and clinical 
symptoms are, therefore, warranted. Based on these studies, more effective therapeutic 
interventions could then be designed to target basal pathophysiological mechanisms.
Conclusion
Unintended weight loss frequently complicates the course of many neurodegenerative 
disorders. It is a clinically relevant problem since weight loss can contribute substantially to 
both morbidity and mortality. Timely recognition, and a multidisciplinary approach, could 
result in (cost)effective intervention, and prevent a variety of complications (e.g. infections), 
thereby eventually resulting in considerable improvements in the quality of life.85 However, 
further studies on the (cost)effectiveness of the various types of intervention are necessary.
Search strategy and selection criteria
References for this review were identified by searches of PubMed from 1966 to February 2008. 
Two searches were performed, the first with the MeSH terms “weight loss” and ”neurodegen-
erative diseases”, and the second with the terms ”weight loss” in combination with ”Alzheimer 
disease”, ”Parkinson disease” or ”Huntington disease”. Articles were also identified through 
searches of the authors’ own files. 
Acknowledgements
NAA was supported by the Netherlands Organisation for Scientific Research (grant 
#017.003.098). MAvdM was supported by ‘Stichting Porticus’ and ‘Stichting Nuts-Ohra’. 
36
References
1. Evans DA, Smith LA, Scherr PA, Albert MS, Funkenstein HH, Hebert LE. Risk of death from Alzheimer’s disease in 
a community population of older persons. American journal of epidemiology. 1991;134(4):403-12.
2. Guyonnet S, Nourhashemi F, Ousset PJ, Micas M, Ghisolfi A, Vellas B, Albarede JL. Factors associated with weight 
loss in Alzheimer’s disease. J Nutr Health Aging. 1998;2(2):107-9.
3. Craft S. Insulin resistance syndrome and Alzheimer’s disease: age- and obesity-related effects on memory, 
amyloid, and inflammation. Neurobiol Aging. 2005;26 Suppl 1:65-9.
4. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 
2004;3(3):169-78.
5. Gillette Guyonnet S, Abellan Van Kan G, Alix E, Andrieu S, Belmin J, Berrut G, Bonnefoy M, Brocker P, Constans 
T, Ferry M, Ghisolfi-Marque A, Girard L, Gonthier R, Guerin O, Hervy MP, Jouanny P, Laurain MC, Lechowski L, 
Nourhashemi F, Raynaud-Simon A, Ritz P, Roche J, Rolland Y, Salva T, Vellas B, International Academy on N, Aging 
Expert G. IANA (International Academy on Nutrition and Aging) Expert Group: weight loss and Alzheimer’s 
disease. J Nutr Health Aging. 2007;11(1):38-48.
6. Tamura BK, Masaki KH, Blanchette P. Weight loss in patients with Alzheimer’s disease. J Nutr Elder. 2007;26(3-
4):21-38.
7. Gillette-Guyonnet S, Nourhashemi F, Andrieu S, de Glisezinski I, Ousset PJ, Riviere D, Albarede JL, Vellas B. 
Weight loss in Alzheimer disease. Am J Clin Nutr. 2000;71(2):637S-42S.
8. Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA. Change in body mass index and risk of 
incident Alzheimer disease. Neurology. 2005;65(6):892-7.
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: 
report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services 
Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939-44.
10. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, Jr., Yaffe K. Obesity in middle age and future risk 
of dementia: a 27 year longitudinal population based study. Bmj. 2005;330(7504):1360.
11. Luchsinger JA, Patel B, Tang M-X, Schupf N, Mayeux R. Measures of adiposity and dementia risk in elderly 
persons. Arch Neurol-Chicago. 2007;64(3):392-8.
12. Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson’s disease. N Engl J Med. 
2005;353(10):1021-7.
13. Chaudhuri KR, Healy DG, Schapira AHV, National Institute for Clinical E. Non-motor symptoms of Parkinson’s 
disease: diagnosis and management. Lancet Neurol. 2006;5(3):235-45.
14. Bachmann CG, Trenkwalder C. Body weight in patients with Parkinson’s disease. Mov Disord. 2006;21(11):1824-
30.
15. Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A. Weight loss in Parkinson’s disease. Ann Neurol. 
2003;53(5):676-9.
16. Abbott RD, Ross GW, White LR, Nelson JS, Masaki KH, Tanner CM, Curb JD, Blanchette PL, Popper JS, Petrovitch 
H. Midlife adiposity and the future risk of Parkinson’s disease. Neurology. 2002;59(7):1051-7.
17. Bates G, Harper PS., Jones L. Huntington’s disease. Third edition ed. Press OU, editor2002.
18. Kremer HP, Roos RA. Weight loss in Huntington’s disease. Arch Neurol-Chicago. 1992;49(4):349.
19. Morales LM, Estevez J, Suarez H, Villalobos R, Chacin de Bonilla L, Bonilla E. Nutritional evaluation of Huntington 
disease patients. Am J Clin Nutr. 1989;50(1):145-50.
20. Djousse L, Knowlton B, Cupples LA, Marder K, Shoulson I, Myers RH. Weight loss in early stage of Huntington’s 
disease. Neurology. 2002;59(9):1325-30.
21. Trejo A, Boll M-C, Alonso ME, Ochoa A, Velasquez L. Use of oral nutritional supplements in patients with 
Huntington’s disease. Nutrition. 2005;21(9):889-94.
22. Kremer H. The lateral hypothalamus in Huntington’s, Alzheimer’s and Parkinson’s disease1992.
23. Farrer LA, Meaney FJ. An anthropometric assessment of Huntington’s disease patients and families. Am J Phys 
Anthropol. 1985;67(3):185-94.
24. Farrer LA, Yu PL. Anthropometric discrimination among affected, at-risk, and not-at-risk individuals in families 
with Huntington disease. Am J Med Genet. 1985;21(2):307-16.
25. Trejo A, Tarrats RM, Alonso ME, Boll M-C, Ochoa A, Velasquez L. Assessment of the nutrition status of patients 
with Huntington’s disease. Nutrition. 2004;20(2):192-6.
37
W
eight loss in neurodegenerative disorders
226. Pratley RE, Salbe AD, Ravussin E, Caviness JN. Higher sedentary energy expenditure in patients with Huntington’s disease. Ann Neurol. 2000;47(1):64-70.27. Lanska DJ, Lanska MJ, Lavine L, Schoenberg BS. Conditions associated with Huntington’s disease at death. A case-control study. Arch Neurol-Chicago. 1988;45(8):878-80.28. Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, Pettengill FK, Bird ED. Factors associated with slow progression in Huntington’s disease. Arch Neurol-Chicago. 1991;48(8):800-4.
29. National Collaborating Centre for Acute Care. Nutrition support in adults: Oral nutrition support, enteral tube 
feeding and parenteral nutrition. London2006.
30. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake 
and body weight. Nature. 2006;443(7109):289-95.
31. Sandoval D, Cota D, Seeley RJ. The integrative role of CNS fuel-sensing mechanisms in energy balance and 
glucose regulation. Annu Rev Physiol. 2008;70:513-35.
32. White HK. Nutrition in advanced Alzheimer’s disease. N C Med J. 2005;66(4):307-12.
33. Van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR, Hayden MR. Body weight is modulated 
by levels of full-length huntingtin. Human molecular genetics. 2006;15(9):1513-23.
34. Hickson M. Malnutrition and ageing. Postgrad Med J. 2006;82(963):2-8.
35. Thomas DR, Ashmen W, Morley JE, Evans WJ. Nutritional management in long-term care: development 
of a clinical guideline. Council for Nutritional Strategies in Long-Term Care. J Gerontol A Biol Sci Med Sci. 
2000;55(12):M725-34.
36. Malnutrition Universal Screening Tool. Available from: http://www.bapen.org.uk/must_tool.html.
37. Mini Nutritional Assessment. Available from: http://www.nestle-nutrition.com/tools/mna.aspx.
38. Stratton RJ, King CL, Stroud MA, Jackson AA, Elia M. ‘Malnutrition Universal Screening Tool’ predicts mortality 
and length of hospital stay in acutely ill elderly. Br J Nutr. 2006;95(2):325-30.
39. Guigoz Y. The Mini Nutritional Assessment (MNA) review of the literature--What does it tell us? J Nutr Health 
Aging. 2006;10(6):466-85.
40. Volkert D, Berner YN, Berry E, Cederholm T, Bertrand PC, Milne A, Palmblad J, Schneider S, Sobotka L, Stanga 
Z, Lenzen-Grossimlinghaus R, Krys U, Pirlich M, Herbst B, Schutz T, Schroer W, Weinrebe W, Ockenga J, Lochs H. 
ESPEN guidelines on enteral nutrition: Geriatrics. Clinical Nutrition. 2006;25(2):330-60.
41. Finley B. Nutritional needs of the person with Alzheimer’s disease: practical approaches to quality care. J Am 
Diet Assoc. 1997;97(10 Suppl 2):S177-80.
42. Ragneskog H, Brane G, Karlsson I, Kihlgren M. Influence of dinner music on food intake and symptoms common 
in dementia. Scand J Caring Sci. 1996;10(1):11-7.
43. Nijs KAND, de Graaf C, Kok FJ, van Staveren WA. Effect of family style mealtimes on quality of life, 
physical performance, and body weight of nursing home residents: cluster randomised controlled trial. 
2006;332(7551):1180-4.
44. Poehlman ET, Dvorak RV. Energy expenditure, energy intake, and weight loss in Alzheimer disease. Am J Clin 
Nutr. 2000;71(2):650S-5S.
45. Kishi T, Elmquist JK. Body weight is regulated by the brain: a link between feeding and emotion. Mol Psychiatry. 
2005;10(2):132-46.
46. Rigler SK, Webb MJ, Redford L, Brown EF, Zhou J, Wallace D. Weight outcomes among antidepressant users in 
nursing facilities. J Am Geriatr Soc. 2001;49(1):49-55.
47. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, 
nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002;14(3):175-82.
48. Deberdt WG, Dysken MW, Rappaport SA, Feldman PD, Young CA, Hay DP, Lehman DL, Dossenbach M, 
Degenhardt EK, Breier A. Comparison of olanzapine and risperidone in the treatment of psychosis and 
associated behavioral disturbances in patients with dementia. The American journal of geriatric psychiatry : 
official journal of the American Association for Geriatric Psychiatry. 2005;13(8):722-30.
49. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup 
TS, Sultzer DL, Weintraub D, Lieberman JA, Group C-AS. Effectiveness of atypical antipsychotic drugs in patients 
with Alzheimer’s disease. N Engl J Med. 2006;355(15):1525-38.
50. White HK, McConnell ES, Bales CW, Kuchibhatla M. A 6-month observational study of the relationship between 
weight loss and behavioral symptoms in institutionalized Alzheimer’s disease subjects. Journal of the American 
Medical Directors Association. 2004;5(2):89-97.
51. Levi S, Cox M, Lugon M, Hodkinson M, Tomkins A. Increased energy expenditure in Parkinson’s disease. 
1990;301(6763):1256-7.
38
52. Markus HS, Cox M, Tomkins AM. Raised resting energy expenditure in Parkinson’s disease and its relationship to 
muscle rigidity. Clin Sci (Lond). 1992;83(2):199-204.
53. Montaurier C, Morio B, Bannier S, Derost P, Arnaud P, Brandolini-Bunlon M, Giraudet C, Boirie Y, Durif F. 
Mechanisms of body weight gain in patients with Parkinson’s disease after subthalamic stimulation. Brain. 
2007;130(Pt 7):1808-18.
54. Gaba AM, Zhang K, Marder K, Moskowitz CB, Werner P, Boozer CN. Energy balance in early-stage Huntington 
disease. Am J Clin Nutr. 2005;81(6):1335-41.
55. Toth MJ, Fishman PS, Poehlman ET. Free-living daily energy expenditure in patients with Parkinson’s disease. 
Neurology. 1997;48(1):88-91.
56. Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin L, Le Bouc Y, Gervais C, Carcelain G, Vassault A, 
Feingold J, Rabier D, Durr A. Early energy deficit in Huntington disease: identification of a plasma biomarker 
traceable during disease progression. PLoS One. 2007;2(7):e647.
57. Chouinard J. Dysphagia in Alzheimer disease: a review. J Nutr Health Aging. 2000;4(4):214-7.
58. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2003;2(2):107-16.
59. Kagel MC, Leopold NA. Dysphagia in Huntington’s disease: a 16-year retrospective. Dysphagia. 1992;7(2):106-
14.
60. Hawkes C. Olfaction in neurodegenerative disorder. Adv Otorhinolaryngol. 2006;63:133-51.
61. Mathey MF, Siebelink E, de Graaf C, Van Staveren WA. Flavor enhancement of food improves dietary intake and 
nutritional status of elderly nursing home residents. J Gerontol A Biol Sci Med Sci. 2001;56(4):M200-5.
62. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of 
donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology. 1998;50(1):136-45.
63. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M. Efficacy 
and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. Bmj. 
1999;318(7184):633-8.
64. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial 
with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000;54(12):2261-8.
65. Vardi J, Oberman Z, Rabey I, Streifler M, Ayalon D, Herzberg M. Weight loss in patients treated long-term with 
levodopa. Metabolic aspects. J Neurol Sci. 1976;30(1):33-40.
66. Beyer PL, Palarino MY, Michalek D, Busenbark K, Koller WC. Weight change and body composition in patients 
with Parkinson’s disease. J Am Diet Assoc. 1995;95(9):979-83.
67. Palhagen S, Lorefalt B, Carlsson M, Ganowiak W, Toss G, Unosson M, Granerus AK. Does L-dopa treatment 
contribute to reduction in body weight in elderly patients with Parkinson’s disease? Acta Neurol Scand. 
2005;111(1):12-20.
68. Kumru H, Santamaria J, Valldeoriola F, Marti MJ, Tolosa E. Increase in body weight after pramipexole treatment 
in Parkinson’s disease. Mov Disord. 2006;21(11):1972-4.
69. Huntington Study G. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. 
Neurology. 2006;66(3):366-72.
70. Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AHV, Warner TT. High-dose creatine 
therapy for Huntington disease: a 2-year clinical and MRS study. Neurology. 2005;64(9):1655-6.
71. Arabia G, Zappia M, Bosco D, Crescibene L, Bagala A, Bastone L, Caracciolo M, Scornaienghi M, Quattrone A. 
Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson’s disease. Neurological sciences : official 
journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2002;23 Suppl 
2:S53-4.
72. Gil Gregorio P, Ramirez Diaz SP, Ribera Casado JM, group D. Dementia and Nutrition. Intervention study in 
institutionalized patients with Alzheimer disease. J Nutr Health Aging. 2003;7(5):304-8.
73. Lauque S, Arnaud-Battandier F, Gillette S, Plaze J-M, Andrieu S, Cantet C, Vellas B. Improvement of weight and 
fat-free mass with oral nutritional supplementation in patients with Alzheimer’s disease at risk of malnutrition: 
a prospective randomized study. J Am Geriatr Soc. 2004;52(10):1702-7.
74. Salas-Salvado J, Torres M, Planas M, Altimir S, Pagan C, Gonzalez ME, Johnston S, Puiggros C, Bonada A, Garcia-
Lorda P. Effect of oral administration of a whole formula diet on nutritional and cognitive status in patients with 
Alzheimer’s disease. Clin Nutr. 2005;24(3):390-7.
75. World Health Organisation. Human energy requirements: Report of a joint FAO/WHO/UNU expert consultation. 
FAO FOOD AND NUTRITION TECHNICAL REPORT SERIES 1. Rome2004.
76. Gaillard C, Alix E, Salle A, Berrut G, Ritz P. Energy requirements in frail elderly people: a review of the literature. 
Clin Nutr. 2007;26(1):16-24.
39
W
eight loss in neurodegenerative disorders
277. de Groot CP, van den Broek T, van Staveren W. Energy intake and micronutrient intake in elderly Europeans: seeking the minimum requirement in the SENECA study. Age Ageing. 1999;28(5):469-74.78. Aziz NA, Swaab DF, Pijl H, Roos RAC. Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington’s disease: clinical consequences and therapeutic implications. Rev Neurosci. 2007;18(3-4):223-51.79. Swaab D. The human hyopthalamus: basic and clinical aspects, part II: neuropathology of the human hypothalamus and adjacent structures. Amsterdam, The Netherlands, Elsevier, 2004.
80. Thannickal TC, Lai Y-Y, Siegel JM. Hypocretin (orexin) cell loss in Parkinson’s disease. Brain. 2007;130(Pt 6):1586-
95.
81. Fronczek R, Overeem S, Lee SYY, Hegeman IM, van Pelt J, van Duinen SG, Lammers GJ, Swaab DF. Hypocretin 
(orexin) loss in Parkinson’s disease. Brain. 2007;130(Pt 6):1577-85.
82. Kunig G, Leenders KL, Martin-Solch C, Missimer J, Magyar S, Schultz W. Reduced reward processing in the brains 
of Parkinsonian patients. Neuroreport. 2000;11(17):3681-7.
83. Grundman M, Corey-Bloom J, Jernigan T, Archibald S, Thal LJ. Low body weight in Alzheimer’s disease is 
associated with mesial temporal cortex atrophy. Neurology. 1996;46(6):1585-91.
84. Aziz A, Fronczek R, Maat-Schieman M, Unmehopa U, Roelandse F, Overeem S, van Duinen S, Lammers G-J, 
Swaab D, Roos R. Hypocretin and melanin-concentrating hormone in patients with Huntington disease. Brain 
Pathol. 2008;18(4):474-83.
85. Rypkema G, Adang E, Dicke H, Naber T, de Swart B, Disselhorst L, Goluke-Willemse G, OldeRikkert M. Cost-
effectiveness of an interdisciplinary intervention in geriatric inpatients to prevent malnutrition. J Nutr Health 
Aging. 2004;8(2):122-7.
86. Hamilton JM, Wolfson T, Peavy GM, Jacobson MW, Corey-Bloom J, Huntington Study G. Rate and correlates of 
weight change in Huntington’s disease. J Neurol Neurosurg Psychiatry. 2004;75(2):209-12.
87. Gonzalez De Aguilar J-L, Rene F, Dupuis L, Loeffler J-P. Neuroendocrinology of neurodegenerative diseases. 
Insights from transgenic mouse models. Neuroendocrinology. 2003;78(5):244-52.
88. Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Bjorkqvist M, Petersen A, Jackson GS, Isaacs JD, Kristiansen M, 
Bates GP, Leavitt BR, Keir G, Ward M, Tabrizi SJ. Proteomic profiling of plasma in Huntington’s disease reveals 
neuroinflammatory activation and biomarker candidates. J Proteome Res. 2007;6(7):2833-40.
89. Dobbs RJ, Dobbs SM, Weller C, Bjarnason IT, Bjarnason IT, Oxlade NL, Charlett A, Al-Janabi MA, Kerwin RW, 
Mahler RF, Price AB. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology 
and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic 
parkinsonism. Helicobacter. 2005;10(4):267-75.
90. Mahieux F, Couderc R, Fenelon G, Maachi M. [Relationships between weight loss and circulating cytokines in 
patients with Alzheimer’s disease].  
Amaigrissement et cytokines circulantes chez des patients souffrant d’une maladie d’Alzheimer. Psychol 
Neuropsychiatr Vieil. 2006;4(4):281-6.
91. Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I. Twenty-four hour cortisol release profiles in 
patients with Alzheimer’s and Parkinson’s disease compared to normal controls: ultradian secretory pulsatility 
and diurnal variation. Neurobiol Aging. 1997;18(3):285-9.
92. Okun MS, DeLong MR, Hanfelt J, Gearing M, Levey A. Plasma testosterone levels in Alzheimer and Parkinson 
diseases. Neurology. 2004;62(3):411-3.
93. Markianos M, Panas M, Kalfakis N, Vassilopoulos D. Plasma testosterone in male patients with Huntington’s 
disease: relations to severity of illness and dementia. Ann Neurol. 2005;57(4):520-5.
94. Fain JN, Del Mar NA, Meade CA, Reiner A, Goldowitz D. Abnormalities in the functioning of adipocytes 
from R6/2 mice that are transgenic for the Huntington’s disease mutation. Human molecular genetics. 
2001;10(2):145-52.
95. Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ, Warner TT. Abnormal in vivo skeletal 
muscle energy metabolism in Huntington’s disease and dentatorubropallidoluysian atrophy. Ann Neurol. 
2000;48(1):72-6.
96. Saft C, Zange J, Andrich J, Muller K, Lindenberg K, Landwehrmeyer B, Vorgerd M, Kraus PH, Przuntek H, Schols 
L. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington’s disease. Mov 
Disord. 2005;20(6):674-9.
97. Vanhanen M, Kivipelto M, Koivisto K, Kuusisto J, Mykkanen L, Helkala EL, Hanninen T, Kervinen K, Kesaniemi 
YA, Laakso MP, Soininen H, Laakso M. APOE-epsilon4 is associated with weight loss in women with AD: a 
population-based study. Neurology. 2001;56(5):655-9.
40 3
Body Mass Index In ParkInson’s dIsease: a Meta-analysIs
Marjolein A. van der Marck, Heleen C. Dicke, Ergun Y Uc, Zippora H.A. Kentin, George F. Borm, 
Bastiaan R. Bloem, Sebastiaan Overeem, and Marten Munneke. 
Parkinsonism and Related Disorders 2012; 18(3):263-267.
Body Mass Index In ParkInson’s dIsease: a Meta-analysIs
Marjolein A. van der Marck, Heleen C. Dicke, Ergun Y Uc, Zippora H.A. Kentin, George F. Borm, 
Bastiaan R. Bloem, Sebastiaan Overeem, and Marten Munneke. 
Parkinso ism d Related Disorders 2012; 18(3):263-267.
41
Body M
ass Index in Parkinson’s disease: a m
eta-analysis
3
Chapter 3
Body Mass Index in Parkinson’s disease:  
a meta-analysis
Marjolein A. van der Marck,  Heleen C. Dicke, Ergun Y Uc, 
Zippora H.A. Kentin, George F. Borm,  Bastiaan R. Bloem, 
Sebastiaan Overeem, Marten Munneke. 
Parkinsonism and Related Disorders 2012; 18(3):263-267.3
Body Mass Index In ParkInson’s dIsease: a Meta-analysIs
Marjolein A. van der Marck, Heleen C. Dicke, Ergun Y Uc, Zippora H.A. Kentin, George F. Borm, 
Bastiaan R. Bloem, Sebastiaan Overeem, and Marten Munneke. 
Parkinsonism and Related Disorders 2012; 18(3):263-267.http://www.prd-journal.com/article/S1353-8020%2811%2900370-1/abstract
doi:10.1016/j.parkreldis.2011.10.016
Body Mass Index In ParkInson’s dIsease: a Meta-analysIs
Marjolein A. van der Marck, Heleen C. Dicke, Ergun Y Uc, Zippora H.A. Kentin, George F. Borm, 
Bastiaan R. Bloem, Sebastiaan Overeem, and Marten Munneke. 
Parkinso ism d Related Disorders 2012; 18(3):263-267.
42
Abstract
Prior work suggested that patients with Parkinson’s disease (PD) have a lower Body Mass Index 
(BMI) than controls, but evidence is inconclusive. We therefore conducted a meta-analysis on 
BMI in PD. We searched MEDLINE, EMBASE, Cinahl and Scopus to identify cohort studies on 
BMI in PD, published before February 2011. Studies that reported mean BMI for PD patients 
and healthy controls were eligible. Twelve studies were included, with a total of 871 patients 
and 736 controls (in three studies controls consisted of subjects from other published stud-
ies). Our primary aim was to assess differences in BMI between patients and controls; this 
was analyzed with random effects meta-analysis. Our secondary aim was to evaluate the rela-
tion with disease severity (Hoehn and Yahr stage) and disease duration, using random effects 
meta-regression. PD patients had a significantly lower BMI than controls (overall effect 1.73, 
95% CI 1.11 – 2.35, P<0.001). Pooled data of seven studies showed that patients with Hoehn 
and Yahr stage 3 had a lower BMI than patients with stage 2 (3.9, 95% CI 0.1 – 7.7, P<0.05). 
Disease duration was not associated with BMI. Because a low body weight is associated with 
negative health effects and a poorer prognosis, monitoring weight and nutritional status 
should be part of PD management. 
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3IntroductionParkinson’s disease (PD) was initially known mainly as a motor disorder, with tremor, brady-kinesia and rigidity as dominant features. Later work underscored the importance of a wide range of non-motor symptoms, including neuropsychiatric, autonomic and gastrointestinal 
symptoms.1-2  Both motor and non-motor symptoms may influence the energy balance.3 
Several studies suggested that PD patients have a lower Body Mass Index (BMI) compared to 
controls. This could have clinical implications, because a low body weight is associated with 
negative health outcomes.4-5 However, differences between patients and controls were not 
statistically significant in all studies.6-11 In fact, one uncontrolled study suggested that over-
weight or obesity may also be common in PD.12 Our primary aim was to conduct a meta- 
analysis to examine whether BMI differs between PD patients and healthy controls. A second-
ary aim was to search for possible determinants of weight loss in PD.
Methods
A literature search was conducted to identify original studies that assessed BMI in PD patients 
in Medline (from 1948), EMBASE (from 1980), Cinahl (from 1982) and Scopus (from 2000). The 
search period ended in February 2011. The search strategy included a range of search terms 
for PD, body weight and body composition, which were entered both as thesaurus and as 
free text word (esupplement). Titles and abstracts were then reviewed to assess eligibility. 
In addition, reference lists of relevant articles were screened. Results were restricted to stud-
ies comparing PD patients with controls free of PD or atypical parkinsonism, meeting the 
following criteria: (a) patients diagnosed with PD; (b) mean BMI of PD patients and controls 
was presented or could be calculated; (c) body weight was actually measured and not just 
self-reported; (d) published as a full article (i.e. abstracts were excluded); and (e) published in 
English. 
The study objective, study sample and mean BMI of patients and controls were extracted 
from all included studies. Possible determinants were very inconsistently reported, and only 
disease duration and disease severity were reported commonly enough to be extracted. 
Disease severity was expressed as Hoehn and Yahr stage (HY) 13 as this was the most widely 
reported scale.
Statistics
The primary outcome was the difference in BMI between PD patients and healthy controls. 
Random effects meta-analysis was used to compare these differences. For two14-15  of the three 
studies 11,14-15 with an external control group obtained from existing  population studies, the 
number of controls entered in the analysis were the same as the number of included patients 
in these studies. As secondary outcomes, the relationship between BMI and disease severity 
(expressed as HY stage) and disease duration was analyzed in a random effects meta-regres-
sion.
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Table 1 Aim and definition of the study population of studies that reported the Body Mass 
Index (BMI) of patients with Parkinson’s disease and healthy controls
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3Results Search resultsOur search strategy identified 2886 references, of which 14 met the selection criteria.6-11,14-21 One study reported unusually high BMI values for patients and controls compared to other 
studies, which could have disproportionally influenced the results.21  Therefore, this study 
was excluded from the analyses, but is addressed separately in the Discussion. Two articles 
reported the same population.9,19  Hence, data from 12 studies were included. The objec-
tives and definitions of patients and controls of these studies are specified in Table 1. In three 
studies, control data were obtained from studies in the elderly.11,14-15 The other nine studies 
included their own control group. Objectives of the included studies varied widely, ranging 
from examining weight changes and body composition to studying risk factors for hip frac-
ture (Table 1). Baseline characteristics and BMI are summarized in Table 2.
Cross-sectional data
Differences in BMI between patients and controls from the 12 included studies are presented 
in Figure 1. The studies reported the BMI of 871 patients and 736 controls (for those studies 
with their own control group). In all studies, the average BMI of PD patients was lower 
Figure 1 Forest plot demonstrating the difference in Body Mass Index (BMI) between patients with Parkinson’s disease and 
healthy controls, with the 95% confidence intervals of 12 studies. The magnitude of the circle size represents the sample size. 
Because of the large sample size of Ragonese et al., the circle size is adjusted and the original circle is indicated with a thin line. 
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compared to controls. Differences in BMI varied between -0.2 and -4. For the primary outcome, 
pooled data showed a significant difference of 1.73 in BMI between patients and controls 
(95% CI 1.11 – 2.35, P<0.001). Separate analysis of studies with their own control group again 
yielded a lower BMI for patients (1.0, 95%CI 0.37 – 1.63, P<0.01).
Longitudinal analyses 
Two longitudinal studies on body weight in PD were included.9-11 One study showed that 
after one year follow-up, body weight significantly decreased in patients (mean loss 1.8±SD 
3.1 kilogram).9 The other study examined changes in body weight before and up to on aver-
age 13 years after the clinical diagnosis in 49 patients. Body weight and BMI of patients were 
not changed in the pre-diagnostic phase, but significantly decreased after the diagnosis was 
made, with a mean change in BMI of 2.13 (with standard deviation 0.45).11
Determinants
Disease severity was reported in seven studies. The mean HY stage of individual studies 
covered only a small range, as the overwhelming majority of patients had HY stage 2, 2.5 or 
3.7,11,14-15,17-18,20 Pooled data showed that patients with HY stage 3 had a lower BMI than patients 
with HY stage 2 (3.9, 95% CI 0.1 – 7.7, P<0.05) (Figure 2). Disease duration was reported in ten 
studies. 6-8,10-11,14,17-20 There was no association between disease duration and BMI (0.02, 95% CI 
-0.44 – 0.48, n.s.). 
Figure 2 Association between disease severity (Hoehn and Yahr stages) and Body Mass Index (BMI) (3.9, 95%CI 0.1 – 7.7, P < 
0,05)
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3DiscussionThe main finding of this meta-analysis (which included 12 studies and a total of 871 patients) is that patients with PD have a lower BMI than controls. Only few potential determinants (disease duration and disease severity) were reported consistently enough to allow for further 
evaluation, and this analysis showed that a low body weight was more pronounced in patients 
with greater disease severity (HY stage 3 more than HY stage 2). 
This is the first meta-analysis examining BMI in patients with PD. Several previous publications 
also suggested that patients have a lower body weight, but the results were inconsistent. By 
pooling the data of 12 studies, we now clearly show that patients have a lower BMI compared 
to healthy controls. One study 21 was excluded from the analysis because BMI in both patients 
and controls was unusually high, perhaps because of short stature in the test population, and 
this could have caused marked skewing of the data. However, this study was also consistent 
with the pattern seen in our meta-analysis, showing a lower BMI in patients compared to 
controls.21 Converging evidence that body weight is reduced in PD also comes from studies 
that did not meet our inclusion criteria 22-25, e.g., those that did not specify how weight was 
measured or studies that merely relied upon self-report. Generally, these studies also found 
that BMI in PD patients was lower compared to controls. We found a pooled BMI reduction of 
-1.73 in PD patients, but the clinical relevance of this difference remains to be established. In 
the elderly, a reduction in BMI is generally associated with frailty, greater morbidity and higher 
mortality.26-28 Whether this also applies to PD is currently unclear.
Our meta-analysis shows that BMI is on average lower in a PD population, but this does not 
imply that all individual patients are underweight. Clinicians should be aware that overweight 
may also occur in PD patients.12  Additionally, it must be noted that a good BMI does not per 
se correspond with a good nutritional status. Even when weight is normal, patients may still 
be at risk for malnutrition.29 Ideally, we would have liked to perform an additional analysis on 
the proportion of individual patients who are truly underweight. However, data were insuf-
ficiently reported to allow for such an analysis.
We also studied possible determinants of low BMI, but only few were reported sufficiently 
consistent to allow for a meta-analysis. Disease severity was reported in seven out of the 12 
included studies. Pooled data showed that BMI decreased with greater disease severity (i.e. 
BMI was lower in HY stage 3 compared to HY stage 2), although the range of disease sever-
ity among patients included in this meta-analysis was fairly limited (most were between HY 
stages 2 and 3). Only one longitudinal study in our meta-analysis investigated this association, 
and showed that weight loss was more prominent and appeared to accelerate in advanced 
disease stages.11  Weight changes have also been longitudinally examined in a large, prospec-
tive trial among 468 patients with PD.30 This study showed that weight loss appears to be a 
50
continuous process, that starts several years before the clinical diagnosis and persists there-
after. However, data on possible determinants of this weight loss were not assessed.30 Other 
determinants than disease duration and disease severity were not consistently reported in the 
included studies. Ideally, we would have liked to assess the relative importance of well-known 
risk factors, such as dyskinesias14, dysphagia8 and hyposmia. Examining determinants that 
potentially contribute to weight loss could be a target for future research. In addition, causal 
relationships need further investigation. Disease progression is characterized by weight loss31 
and worsening of PD symptoms has been proposed as an independent predictor for this 
weight loss.11  Alternatively, weight loss itself could be an important predictor of worsening of 
parkinsonism. Although the associations between pesticide exposures and the development 
of PD is still debated, increased plasma concentrations  of organocholorine after weight loss 
have been suggested to contribute to worsening of symptoms.32
This meta-analysis was not without shortcomings. First, we have not assessed the quality of 
the individual studies included in our meta-analysis. A key source of potential bias in a meta-
analysis is bias by limitations in the original studies, including the methodological quality of 
individual studies and the quality of reporting.33 Currently, there is however no agreed ‘gold 
standard’ tool to evaluate the quality of observational epidemiological studies, which were 
included in our meta-analysis.33 There is a need to agree on critical elements to assess qual-
ity and to develop appropriate evaluation tools33, especially as different scales may reach 
different conclusions and influence the interpretation of meta-analytic studies.34 Secondly, 
another potential limitation is the heterogeneity of patients and controls within the original 
studies. Nevertheless, despite this variety, the results of the individual studies consistently 
showed that BMI of PD patients was lower than BMI of controls. 
What are the potential clinical implications of our findings? We would recommend to 
routinely record body weight and nutritional status as part of the management of PD.  Previ-
ous research has shown that a substantial part of PD patients is at risk of malnutrition.29,35 
Hence, PD patients should be screened for under-nutrition and the Malnutrition Universal 
Screening Tool (MUST)  may be considered as a useful early screening tool.35 Dieticians might 
be considered as team member of the multidisciplinary Parkinson team, in order to moni-
tor these patients and to provide nutritional interventions.  In addition, much more work is 
needed to study the clinical implications of the observed weight differences. First, the clinical 
relevance of a low BMI in PD must be determined, and which magnitude of BMI reduction is 
associated with health risks. Second, it is necessary to examine possible predictors of weight 
changes and their relative importance. At present, there is no specific diet for patients with 
PD, and it is unknown whether dietary interventions (e.g. supplements, energy-dense prod-
ucts and protein redistribution) can influence the disease course and prognosis.31,36 As a start, 
longitudinal studies now need to be performed to address these issues.
51
Body M
ass Index in Parkinson’s disease: a m
eta-analysis
3AcknowledgementsThis research was supported by research grants of NutsOhra Foundation, Stichting Porticus and the National Parkinson Foundation (NPF). Professor Bastiaan R. Bloem was supported by a research grant of The Netherlands Organisation for Health Research and Development (VIDI 
research grant #016.076.352). We thank Wim Lemmens for his support in preparing the figures 
for this paper. 
52
References
1. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and 
management. Lancet Neurol. 2006;5(3):235-45.
2. Poewe W, Mahlknecht P. The clinical progression of Parkinson’s disease. Parkinsonism Relat Disord. 2009;15 
Suppl 4:S28-S32.
3. Aziz NA, van der Marck MA, Pijl H, OldeRikkert MG, Bloem BR, Roos RA. Weight loss in neurodegenerative 
disorders. J Neurol. 2008;255(12):1872-80.
4. Reife CM. Involuntary weight loss. Med Clin North Am. 1995;79(2):299-313.
5. Harrington M, Gibson S, Cottrell RC. A review and meta-analysis of the effect of weight loss on all-cause 
mortality risk. Nutr Res Rev. 2009;22(1):93-108.
6. Ragonese P, D’Amelio M, Callari G, Di BN, Palmeri B, Mazzola MA, Terruso V, Salemi G, Savettieri G, Aridon P. Body 
mass index does not change before Parkinson’s disease onset. Eur J Neurol. 2008;15(9):965-8.
7. Revilla M. Body composition in Parkinson’s disease: A study with dual-energy X-ray absorptiometry. 
Parkinsonism Relat Disord. 1998;4(3):137-42.
8. Coates C, Bakheit AM. Dysphagia in Parkinson’s disease. Eur Neurol. 1997;38(1):49-52.
9. Lorefalt B, Ganowiak W, Palhagen S, Toss G, Unosson M, Granerus AK. Factors of importance for weight loss in 
elderly patients with Parkinson’s disease. Acta Neurol Scand. 2004;110(3):180-7.
10. Marczewska A, De Notaris R, Sieri S, Barichella M, Fusconi E, Pezzoli G. Protein intake in Parkinsonian patients 
using the EPIC food frequency questionnaire. Mov Disord. 2006;21(8):1229-31.
11. Uc EY, Struck LK, Rodnitzky RL, Zimmerman B, Dobson J, Evans WJ. Predictors of weight loss in Parkinson’s 
disease. Mov Disord. 2006;21(7):930-6.
12. Barichella M, Marczewska A, Vairo A, Canesi M, Pezzoli G. Is underweightness still a major problem in Parkinson’s 
disease patients? Eur J Clin Nutr. 2003;57(4):543-7.
13. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427-42.
14. Markus HS, Tomkins AM, Stern GM. Increased prevalence of undernutrition in Parkinson’s disease and its 
relationship to clinical disease parameters. J Neural Transm Park Dis Dement Sect. 1993;5(2):117-25.
15. Yapa RSS, Playfer JR, Lye M. Anthropometric and Nutritional Assessment of Elderly Patients with Parkinsons-
Disease. J Clin Exp Gerontology. 1989;11(3-4):155-64.
16. Abbott RA, Cox M, Markus H, Tomkins A. Diet, body size and micronutrient status in Parkinson’s disease. Eur J 
Clin Nutr. 1992;46(12):879-84.
17. Beyer PL, Palarino MY, Michalek D, Busenbark K, Koller WC. Weight change and body composition in patients 
with Parkinson’s disease. J Am Diet Assoc. 1995;95(9):979-83.
18. Fernandez MC, Parisi MS, Diaz SP, Mastaglia SR, Deferrari JM, Seijo M, Bagur A, Micheli F, Oliveri B. A pilot study 
on the impact of body composition on bone and mineral metabolism in Parkinson’s disease. Parkinsonism Relat 
Disord. 2007;13(6):355-8.
19. Lorefalt B, Ganowiak W, Wissing U, Granerus AK, Unosson M. Food habits and intake of nutrients in elderly 
patients with Parkinson’s disease. Gerontology. 2006;52(3):160-8.
20. Sato Y, Kaji M, Tsuru T, Oizumi K. Risk factors for hip fracture among elderly patients with Parkinson’s disease. J 
Neurol Sci. 2001;182(2):89-93.
21. Andreadou E, Nikolaou C, Gournaras F, Rentzos M, Boufidou F, Tsoutsou A, Zournas C, Zissimopoulos V, 
Vassilopoulos D. Serum uric acid levels in patients with Parkinson’s disease: their relationship to treatment and 
disease duration. Clin Neurol Neurosurg. 2009;111(9):724-8.
22. Annanmaki T, Muuronen A, Murros K. Low plasma uric acid level in Parkinson’s disease. Mov Disord. 
2007;22(8):1133-7.
23. Diederich NJ, Vaillant M, Leischen M, Mancuso G, Golinval S, Nati R, Schlesser M. Sleep apnea syndrome in 
Parkinson’s disease. A case-control study in 49 patients. Mov Disord. 2005;20(11):1413-8.
24. Markus HS, Cox M, Tomkins AM. Raised resting energy expenditure in Parkinson’s disease and its relationship to 
muscle rigidity. ClinSci(Lond). 1992;83(2):199-204.
25. Durrieu G, Llau ME, Rascol O, Senard JM, Rascol A, Montastruc JL. Parkinson’s disease and weight loss: a study 
with anthropometric and nutritional assessment. Clin Auton Res. 1992;2(3):153-7.
26. Landi F, Zuccala G, Gambassi G, Incalzi RA, Manigrasso L, Pagano F, Carbonin P, Bernabei R. Body mass index and 
mortality among older people living in the community. J Am Geriatr Soc. 1999;47(9):1072-6.
53
Body M
ass Index in Parkinson’s disease: a m
eta-analysis
327. Newman AB, Yanez D, Harris T, Duxbury A, Enright PL, Fried LP. Weight change in old age and its association with mortality. J Am Geriatr Soc. 2001;49(10):1309-18.28. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA. Frailty in older adults: evidence for a phenotype. JGerontolA BiolSciMedSci. 2001;56(3):M146-M56.29. Barichella M, Villa MC, Massarotto A, Cordara SE, Marczewska A, Vairo A, Baldo C, Mauri A, Savardi C, Pezzoli 
G. Mini Nutritional Assessment in patients with Parkinson’s disease: correlation between worsening of the 
malnutrition and increasing number of disease-years. Nutr Neurosci. 2008;11(3):128-34.
30. Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A. Weight loss in Parkinson’s disease. AnnNeurol. 
2003;53(5):676-9.
31. Barichella M, Cereda E, Pezzoli G. Major Nutritional Issues in the Management of Parkinson’s Disease. Mov 
Disord. 2009;24(13):1881-92.
32. Teasdale N, Hue O, Simoneau M, Tremblay A, Marceau P, Marceau S. Predictors of weight loss in Parkinson’s 
disease: is weight loss the chicken or the egg? Mov Disord. 2007;22(3):436-7.
33. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in 
epidemiology: a systematic review and annotated bibliography. Int J Epidemiol. 2007;36(3):666-76.
34. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 
1999;282(11):1054-60.
35. Jaafar AF, Gray WK, Porter B, Turnbull EJ, Walker RW. A cross-sectional study of the nutritional status of 
community-dwelling people with idiopathic Parkinson’s disease. BMC Neurol. 2010;10:124.
36. Cushing ML, Traviss KA, Calne SM. Parkinson’s disease: implications for nutritional care. Can J Diet Pract Res. 
2002;63(2):81-7.
54 4
consensus-Based clInIcal PractIce recoMMendatIons for the exaMInatIon 
and ManageMent of falls In PatIents WIth ParkInson’s dIsease
Based on
Marjolein A. van der Marck, Margit Ph.C. Klok, Michael S. Okun, Nir Giladi, Marten Munneke 
and Bastiaan R. Bloem, on behalf of the NPF Falls Task Force. 
Parkinsonism and Related Disorders (Accepted). 
consensus-Based clInIcal PractIce recoMMendatIons for the exaMInatIon 
and ManageMent of falls In PatIents WIth ParkInson’s dIsease
Based on
Marjolei  A. van der Marck, Margit Ph.C. Klok, Michael S. Okun, Nir Giladi, Marten Munneke 
and Bastiaan R. Bloem, on behalf of the NPF Falls Task Force. 
Parkinsonism and Related Disorders (Accepted). 
55
Consensus-based clinical practice recom
m
endations for falls in Parkinson’s disease
44
consensus-Based clInIcal PractIce recoMMendatIons for the exaMInatIon 
and ManageMent of falls In PatIents WIth ParkInson’s dIsease
Based on
Marjolein A. van der Marck, Margit Ph.C. Klok, Michael S. Okun, Nir Giladi, Marten Munneke 
and Bastiaan R. Bloem, on behalf of the NPF Falls Task Force. 
Parkinsonism and Related Disorders (Accepted). 
Chapter 4
Consensus-basedclinical practice 
recommendations for falls in 
Parkinson’s disease
Marjolein A. van der Marck, Margit Ph.C. Klok, Michael S. Okun, 
Nir Giladi, Marten Munneke and Bastiaan R. Bloem, on behalf of 
the NPF Falls Task Force. 
Parkinsonism and Related Disorders, 2013.
consensus-Based clInIcal PractIce recoMMendatIons for the exaMInatIon 
and ManageMent of falls In PatIents WIth ParkInson’s dIsease
Based on
Marjolei  A. van der Marck, Margit Ph.C. Klok, Michael S. Okun, Nir Giladi, Marten Munneke 
and Bastiaan R. Bloem, on behalf of the NPF Falls Task Force. 
Parkinsonism and Related Disorders (Accepted). http://www.prd-journal.com/article/S1353-8020%2813%2900447-1/abstract 
doi:10.1016/j.parkreldis.2013.10.030 
56
Abstract
Falls in Parkinson’s disease (PD) are common and frequently devastating. Falls prevention is 
an urgent priority, but there is no accepted program that specifically addresses the risk profile 
in PD. Therefore, we aimed to provide consensus-based clinical practice recommendations 
that systematically address potential fall risk factors in PD. We developed an overview of both 
generic (age-related) and PD-specific factors. For each factor, we specified: best method of 
ascertainment; disciplines that should be involved in assessment and treatment; and which 
interventions could be engaged. Using a web-based tool, we asked 27 clinically active 
professionals from multiple relevant disciplines to evaluate this overview. The revised version 
was subsequently reviewed by 12 experts. Risk factors and their associated interventions were 
included in the final set of recommendations when at least 66% of reviewing experts agreed. 
These recommendations included 31 risk factors. Nearly all  required a multidisciplinary 
team approach, usually involving a neurologist and PD-nurse specialist. Finally, the expert 
panel proposed to first identify the specific fall type and to tailor screening and treatment 
accordingly. A routine evaluation of all risk factors remains reserved for high-risk patients 
without prior falls, or for patients with seemingly unexplained falls. In conclusion, this project 
produced a set of consensus-based clinical practice recommendations for the examination 
and management of falls in PD. These may be used in two ways: for pragmatic use in current 
clinical practice, pending further evidence; and as the active intervention in clinical trials, 
aiming to evaluate the effectiveness and cost-effectiveness of large scale implementation.
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4IntroductionFalls in patients with Parkinson’s disease (PD) are common and often devastating. Prospective surveys have revealed high rates of falls that exceed those of the community-dwelling elderly. A meta-analysis concluded that the risk of sustaining a fall was considerably increased in 
moderately affected patients with PD as compared with healthy age-matched peers. Almost 
50% of patients fell during a brief follow-up of only 3 months.1
Falls in PD are associated with a poor prognosis. Injuries are common, and patients with 
PD with hip fractures face high morbidity and mortality.2 Minor injuries such as bruises 
or lacerations are even more common.3 Moreover, the disease appears to become more 
severe and difficult to treat once falls are present, usually because of fall-related injuries and 
cognitive dysfunction, and overall survival of fallers is reduced.4 Falls also commonly induce a 
fear of renewed falls,3 which can lead to secondary immobilization and a reduction in general 
fitness, thereby increasing the risk of cardiovascular disease.5 Lack of physical activity is also 
associated with constipation, pressure sores, insomnia and osteoporosis (which further 
increases fracture risk).6 Immobility also deprives patients of their independence and social 
interactions. Not surprisingly, falls and mobility problems have been associated with poorer 
quality of life.7-9 In addition, the economic burden of falls in PD is substantial, due to the 
relatively high cost of treatment of injuries and nursing home admissions.10
These potentially serious implications make the prevention of falls a high priority in the 
management of patients with PD. However, there is no accepted falls prevention program 
tailored specifically to the problems encountered in individual patients with PD. We therefore 
developed  falls prevention recommendations specifically for PD, based on consensus among 
various health professionals and a smaller panel of experts on falls in PD. The starting point 
was based on the premise that falls in PD are typically multifactorial, resulting not only 
from various disease-specific mechanisms (e.g. freezing of gait),11 but also from generic 
age-related risk factors.12 Indeed, older patients with PD are not exempt from age-related 
processes or problems common to any geriatric population, such as complex co-morbidity 
or polypharmacy. Experience with the elderly suggests that optimal falls prevention requires 
a careful assessment of all potentially contributing risk factors, and this analysis should serve 
as a basis for subsequent interventions tailored to each of the identified risk factors.12-14 We 
hypothesized that a similar multifaceted approach would be required for patients with PD. 
Here, we describe the development of the consensus-based clinical practice recommendations 
for the examination and reduction of falls, tailored to both generic and disease-specific risk 
factors in PD.
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Methods
Development of  concept recommendations  
We first developed concept recommendations based on a literature search in PubMed using 
the following search terms: ((Parkinson’s disease) OR (Parkinson disease)) AND risk factors AND 
((accidental falls) OR (fall) OR (falling) AND ((fear of falling) OR (injuries) OR (fracture) OR (hip 
fracture) OR (fear of falling)) AND (fall prevention), supplemented with additional references 
by the panel members, generic guidelines,15 PD-specific guidelines 16-17 and expert opinion. 
The resultant included 31 risk factors for falling, both generic (age-related) and PD-specific 
(Table 1). For each risk factor we outlined the following elements: background; method of 
ascertainment (i.e. how to verify the presence and severity of each risk factor); which disci-
plines should be involved in the assessment and treatment; the primarily responsible disci-
pline; and suggestions for therapeutic interventions to reduce or eliminate the risk factor.
Multidisciplinary evaluation of the concept recommendations
The concept recommendations were presented via a web-based tool to a group of 27 
professionals from multiple disciplines that were recruited from National Parkinson 
Foundation (NPF) centers (Figure 1). 
Figure 1 Multidisciplinary evaluation of the falls prevention recommendations
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4These professionals evaluated the recommendations, gave additional suggestions, and rated their level of expertise with each risk factor. If they rated their expertise as ‘none’ in any category, their scores were not considered. Subsequently, the revised recommendations were reviewed by 12 international experts from multiple relevant disciplines (Falls Task 
Force group; Figure 1). These experts were selected for their specialization and research 
experience in balance, gait and falls in PD. For each item, agreement between at least 
two-thirds of these experts was considered as consensus. Therapeutic interventions were 
scored on a 6-point scale, ranging from 0 (totally unimportant) to 5 (extremely important). 
Interventions with a mean evaluation score of >2 were included as final recommendations. 
Implementation of the protocol in clinical practice
Two possible ways to implement the recommendations  in clinical practice were offered to 
the panel of 12 experts. Option A was a ‘One size fits all approach’ where all patients should be 
reviewed for all risk factors, and be treated accordingly. This approach is comprehensive and 
ascertains that all risk factors will be addressed, but might lead to “over-care” in a subset of 
patients. Option B was the ‘Fall type approach’ where the first diagnostic step is to identify the 
specific fall type for each patient (e.g., falls that are always caused by freezing of gait, or falls 
that are consistently preceded by syncope). For those patients with a clear and identifiable 
fall pattern, the diagnostic and therapeutic approach could be limited to those specific 
risk factors and no unnecessary disciplines will be addressed. This provides a specialized 
approach, but carries the risk of under-treatment and missing of unidentified additional and 
possibly relevant risk factors. Each of the 12 experts of the Falls Task Force was given a choice 
between these two approaches, while underscoring the equipoise of the options.
Results
We identified 16 generic risk factors and 15 PD-specific risk factors (Table 1). All of these risk 
factors were recommended to be managed by a multidisciplinary team, except for visual 
impairment. Generic risk factors for falls in PD were recommended to be managed by the 
general practitioner, geriatrician, neurologist and PD nurse specialist. The neurologist, PD nurse 
specialist and physiotherapist were considered as the main disciplines to address PD-specific 
risk factors.18-20 Caregivers were thought to have an important role in falls prevention, e.g. by 
assisting with implementing the recommended interventions. It is also necessary to consider 
the effect of falls on caregiver burden. The Falls Task Force unanimously preferred the ‘Fall type 
approach’ over the ‘One size fits all approach’.
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Table 1 Overview of generic and disease-specific risk factors for falls in Parkinson’s disease
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Consensus-based clinical practice recom
m
endations for falls in Parkinson’s disease
4Table 1 Overview of generic and disease-specific risk factors for falls in Parkinson’s disease
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Discussion 
Our project yielded a comprehensive set of recommendations for the examination and possi-
ble reduction of falls for patients with PD, tailored to a combination of generic risk factors 
for older adults and PD-specific risk factors. These recommendations were based on a liter-
ature review plus consensus among both clinically active professionals (round 1) and an 
international expert panel (round 2), involving all relevant disciplines (medical, allied health 
and nursing). It should be seen as a clinical practice protocol based on expert opinion that 
supplements the existing formal guidelines. The recommendations offered here can be used 
to guide management decisions in current clinical practice. Furthermore, these recommenda-
tions can serve as active treatment in future intervention studies to determine the cost-effec-
tiveness and feasibility of this approach. Finally, the present set of recommendations may 
serve to counter the common belief among older adults that falls cannot be prevented.21 We 
will now discuss our findings, and briefly address several issues related to practical implemen-
tation of the current set of recommendations created to clinical practice.
Falls prevention is an important element of quality of care for elderly in general, as well as 
in PD management.22-23 Recently, the American Academy of Neurology provided a core set 
of quality measures to guide treatment of PD. One of these quality measures includes the 
recommendation to query falls as part of diagnosis review and other regular visits.22 The falls 
prevention recommendations included 31 risk factors, which underscores the complexity of 
falling problems in PD. Each risk factor alone can increase the risk of falls, but the fall risk mark-
edly increases when multiple risk factors are present in a single individual.15 For example, in 
older populations, the relative risk of falling increases from 8% when no risk factors are pres-
ent, to 78% with four or more risk factors.24 The complexity of falling problems in PD under-
score the need for a multidisciplinary team approach, with a combined involvement of medi-
cal disciplines, allied health personnel and specialized nurses, each with specific roles. It was 
recommended that falls prevention programs in older adults utilize a multidisciplinary team 
approach.25 A similar multidisciplinary team approach is widely felt to be optimal for patients 
with PD as well,26 but to date there is no good evidence to support this recommendation, 
and further work remains necessary to demonstrate the merits of a multifaceted approach. 
Also, more research is needed on the effectiveness of the isolated elements to establish what 
specific part of the intervention package is effective. For instance, cueing strategies may have 
an indirect effect on falls via known influences on gait and mobility27-29, but this is merely 
based on theory than direct evidence. Also, a recent Cochrane Review concluded that physio-
therapy interventions had no effect on falls.30 Additionally, although we included 31 potential 
factors, we concede that there may be other yet to be identified factors.
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4We concentrated on risk factors that were potentially modifiable. The best predictor of falls in PD is the presence of prior falls, but this is a risk factor that can no longer be reversed. A possi-bly modifiable marker of future falls is fear of falling,1 although there are currently no estab-lished methods to reduce fear of falling in PD. In contrast, specific treatments are available for 
other risk factors. We will illustrate this for freezing of gait, which is increasingly recognized 
as an important cause of falls in PD.11,31 Freezing of gait can be treated using adjustments in 
pharmacotherapy (usually an increase in dopaminergic medication),10 delivery of individually 
tailored cueing strategies, according to evidence-based guidelines, and use of therapy and 
assistive devices.27 
What group should receive the falls prevention recommendations? Pending further evidence, 
the Falls Task Force recommended a time-efficient strategy adjusted to specific individual risk 
profiles for those patients who report prior falls. For example, an important step in prior fall-
ers is to ascertain whether or not falls were preceded by transient loss of consciousness.32 A 
consistent pattern of falls caused by orthostatic syncope could obviate the need for a detailed 
assessment of all 31 risk factors. This strategy is defendable in terms of its short-term effi-
ciency, and perhaps also optimizes compliance because interventions are linked to actually 
perceived problems. However, further work remains to determine the long-term outcome, 
as more falls may be prevented when all patients are consistently screened (and treated) for 
all risk factors. This certainly applies to patients without a clear fall pattern, who should be 
screened according to the entire protocol. It is important to note that even patients reporting 
no falls in the previous year should be eligible to receive the complete protocol, because the 
risk of falling is substantial in this population.1 This suggestion also applies to older patients, 
and those with complex co-morbidity or polypharmacy. It is not possible to pinpoint patients 
with PD with a particular disease severity as being most likely to sustain falls, although fall 
risks appear highest in the ‘intermediate’ disease stages (Hoehn and Yahr stage 2.5 and 3) 
when patients develop gait disability and postural instability, but remain sufficiently active to 
be at risk of falling.1,5
Another issue is how frequently the protocol should be reviewed. PD is a progressive disease, 
and new risk factors will inevitably emerge over time. An annual review may be reasonable, 
though feasibility may be difficult as may be agreement on the viability of potential new 
factors.
We believe that optimal fall prevention also involves caregivers, although they are not specifi-
cally mentioned in the protocol. Caregivers can play a key role, e.g. by assisting patients in 
adopting recommendations and optimizing adherence to the falls prevention program. This 
could be important particularly for patients with cognitive decline. For example, caregivers 
can assist cognitively impaired patients in using external cues or applying cognitive move-
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ment strategies.33 In the elderly, a multifactorial falls prevention program with a patient-care-
giver dyad was successful in a subgroup of patients with lower MMSE scores (27 or less), and 
living with a partner seemed to mediate this positive finding.34 Additionally, it is necessary to 
consider the effect of falls on caregiver burden.35
This falls prevention protocol should serve to counter the common belief among older 
adults that falls cannot be prevented.21 In older populations, active participation of patients 
and their caregivers is essential, but this recommendation is extra challenging for complex, 
multifactorial interventions as proposed here.36 Implementation of fall prevention strategies 
should therefore be embedded within a positive approach, including emphasis on a positive 
self-identity (e.g., increased independence, better confidence, more active role)21 and a focus 
on health and independence, rather than falls.37 In addition, theories of health behavior, like 
the health belief model or self-efficacy theories, could be used. Recommendations are best 
tailored to the individual lifestyle, and patients should have an active role in implementing 
the fall prevention program.21 Follow-up is also needed to ascertain that patients actually 
adhere to the recommendations.
A word of caution regarding the development process is necessary. We selected two 
sequential panels to offer feedback on a concept procedure of recommendations that was 
drafted based upon an extensive literature review. Participation in either of the two panels 
was by invitation and this could have introduced a bias. However, it should be pointed out 
that we succeeded in generating two multidisciplinary panels with representatives of all 
relevant disciplines, although some professionals were more heavily represented than others. 
The two panels were complementary, the first being pragmatically oriented, the second being 
driven by experts with state-of-the-art knowledge. The literature search was comprehensive 
and included generic and PD-specific guidelines. 15-17,23,38-41 We acknowledge that the division 
into generic versus disease-specific risk factors was to some extent arbitrary for some of 
these factors, as these commonly occur in both PD and with ageing (an example is cognitive 
impairment). Indeed, our sole motivation for making this distinction was to ascertain that the 
set of recommendations would be comprehensive, and that generic factors would not be 
overseen in this population with its own specific risk factors. As such, our recommendations 
underscore just how many different risk factors can be involved, and how complex it is to 
prevent falls in patients with PD.
Although not infallible, we believe that the present fall prevention recommendations are an 
adequate reflection of the current evidence and expert opinion in the field. We acknowledge 
that these recommendations are based largely on expert opinion and smaller research 
studies (partially done in elderly populations without PD), and that it is not yet based on large 
randomized controlled trials in PD, fueling the need for further research. The recommendations 
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4can be considered for use in current clinical practice in three different ways: as a ‘one size fits all’ strategy to postpone or perhaps even prevent the very first fall in prior non-fallers; as a ‘one size fits all’ strategy to diminish the risk of further falls in patients with unclear fall patterns; and as a dedicated falls prevention strategy in patients with a consistent and specific fall pattern. 
Further research is now needed to test the effectiveness of the individual components and 
also the cost-effectiveness and feasibility of this falls strategy approach. 
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Abstract 
Objectives To evaluate the reliability and user experiences of an automated telephone system 
to monitor falls during a prolonged period of time. 
Design Prospective cohort study.
Setting Four neurological outpatient clinics in The Netherlands.
Participants We included 119 community-dwelling, non-demented patients with Parkinson’s 
disease, because falls are common in this population.
Measurements We obtained clinical and demographic data. The Falls Telephone is a comput-
erized telephone system, through which subjects can enter the number of falls during a previ-
ous period. During a follow-up period of one to forty weekly calls, 2465 calls were made. In 
total, 173 “no-fall” entries and 115 “fall” entries were verified by personal telephone interviews. 
User experiences were evaluated in 90 of the 119 participating patients, using structured tele-
phone interviews.
Results All “no-fall” entries and 78% of “fall” entries were confirmed to be correct. Sensi- 
tivity to detect falls was 100% and specificity was 87%. Users regarded the Falls Telephone as 
a convenient tool to monitor falls. 
Conclusion The Falls Telephone is a convenient and reliable instrument to monitor falls. The 
automated system has a high specificity, obviating the need for time-consuming personal 
follow-up calls in the majority of non-fallers. As such, the Falls Telephone lends itself well for 
data collection in large trials with prolonged follow-up in patients with Parkinson’s disease.
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5IntroductionFalls are common in the elderly. The morbidity of falls is considerable because of fall-related injuries and loss of independence. Moreover, mortality rates are increased among fallers.1 There is a pressing need for development of tools that can reliably detect falls over long 
periods, for example to evaluate the effect of fall prevention strategies.2 Frequently used 
outcomes include the number of fallers and fall rates.3 There are several approaches to obtain 
these data, e.g. via personal or telephone interviews, questionnaires, or diaries. However, 
these methods are resource-intensive, especially within large and long-lasting trials. To 
address this, we have developed an automated system to monitor falls by telephone. This 
“Falls Telephone” is comparable with automated telephone systems used previously for 
other purposes, e.g. for management of diabetes care4-5, health promotion6 or as a reminder 
for medication intake.7 The Falls Telephone automatically makes periodic phone calls at an 
investigator-defined interval, allowing participants to enter the number of falls experienced 
in the preceding period.
Here, we describe our first evaluation of the Falls Telephone. We piloted the system in patients 
with Parkinson’s disease (PD) because of their high fall rates.8 A meta-analysis showed that, 
even during a brief follow-up of three months, 46% of PD patients fell at least once.9 These 
fall rates make people with PD a good test population, with a substantial proportion of both 
fallers and non-fallers, allowing for tests of specificity and sensitivity.
Methods
Participants
Patients were part of a trial on the cost-effectiveness of multidisciplinary care for PD patients 
(ClinicalTrials.gov identifier NCT00518791). Main inclusion criteria were idiopathic PD, Hoehn 
and Yahr stage10 ≤4, Mini-Mental State Examination11 ≥24 and living independently in the 
community. We included 119 non-demented PD patients (77 men, 65%;  mean age 67.6 years 
(range 43.4 – 81.1); mean disease duration 6.3 years (range 0.8  – 21); mean Unified Parkinson’s 
Disease Rating Scale motor score (Part III)12 of 23.6 (SD 10.6). 
Falls Telephone 
The Falls Telephone is a computerized system that automatically contacts patients by tele-
phone using pre-recorded messages. The system was developed by a software company 
specialized in communication (ASK Community Systems, Rotterdam, The Netherlands). 
First, the system has to be activated via a website. After logging on, name and telephone 
number of the patient are entered as well as the day of the week on which the Falls Telephone 
starts calling. Then, the Falls Telephone automatically calls at the pre-specified day and time. 
Patients are asked to start the procedure and confirm that they are the requested person by 
dialing ‘1’. Every call then starts with a brief explanatory introduction. Patients then need to 
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enter the number of falls via the touch-tone keypad. They are asked to enter this number 
twice as a verification step. When the entry is correct, the system calls again at the next sched-
uled day and time. Otherwise, the system will call again on the same day or on the subsequent 
day, until the telephone call has been completed successfully. The outline of the telephone 
call is shown in Table 1. The frequency of the calls is adjustable, according to the needs of the 
investigator. Other parameters which can be tailored include the day and time of calling, as 
well as the frequency of a repeated call on a single day (in case of no response).The software 
company provides the automated telephone calls. The system requires that the patient has 
a telephone device with dual-tone multi-frequency (DTMF) signals. Both home telephones 
(analogue telephony, ISDN and VOIP) and cell phones can be used. Entered data are auto-
matically stored within a MySQL database, which is accessible through the internet using a 
standard web browser. After logging on, data can easily be exported by the researcher on any 
computer at any time. 
Table 1 The digitally recorded introduction and instructions that were asked by the Falls 
Telephone during weekly telephone calls (translated from Dutch). 
Start Good day. You’re being called because a healthcare professional requires 
information from you. Please press 1 to continue.   
“1”→Introduction
“Other number“ → Replay message (maximum 3 times, otherwise disconnect)  
“No number“ → Disconnected
Introduction You are called by the Falls Telephone of the IMPACT study from the Radboud 
University Nijmegen Medical Centre in cooperation with your own hospital. You 
are a participant of this study and therefore we would like to ask you a question.  
Please indicate how many times you have fallen in the past week. To overcome 
mistakes, you are asked to indicate the number of falls twice. You can now dial the 
number of falls in the previous week. 
“Number dialed”’ → Verification
“No number dialed“ → Introduction
Verification Please dial the number of falls in the past week once more. 
 “Same number dialed“ → Closure 
“Different number dialed“→ (maximum 3 times, otherwise disconnect) The 
entered number differs from your previous entry, please try again. 
You can now dial the number of falls in the previous week. 
“Number dialed“ → Verification
“No number dialed“ → Introduction
Disconnected You were called by request of a healthcare professional. We could not reach you 
and will try again at a later time. Disconnected; patient will be called again.
Closure Thank you for your participation. The telephone connection will now be 
disconnected. 
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5For this study, the Falls Telephone called weekly on workdays, between 11 a.m. and 8 p.m. with time intervals of three hours, until the telephone call had been completed successfully. Patients were asked to enter the number of falls sustained in the preceding week. At the outset of the study, all patients received a letter with instructions about the Falls Telephone, as 
well a definition of a fall. A fall was defined as “an unexpected event in which the participants 
come to rest on the ground, floor, or lower level”.2  In addition, the procedure was explained in 
person by a research-assistant. 
Evaluation 
All 119 patients used the Falls Telephone for a given period (varying per patient from one to 
forty weeks). Entries were verified through personal telephone interviews, within two weeks 
after the week in which the entry was made. During these interviews, patients were asked 
to confirm the entry and to confirm whether the reported number of falls represented their 
actual number of falls in the previous week. 
Personal telephone interviews took place at several time points. First, all 119 patients were 
contacted when they had been using the Falls Telephone for several weeks. We then evalu-
ated if the system was working properly (e.g. no technical problems) and verified their latest 
entry. Second, 90 patients were interviewed for user experiences with the system (see below). 
During these interviews we also evaluated their entries in the preceding week. Third, all “fall” 
entries were, whenever possible, evaluated by personal telephone interviews. This approach 
yielded a total of 288 entries that were verified, including 173 “no-fall” entries given by 109 
patients, and 115 “fall“ entries given by 46 patients. Hence, some patients were interviewed to 
confirm a “no-fall” entry as well as a “fall” entry. 
To evaluate user experiences, a sample of 90 patients was randomly selected from our study 
population and interviewed by telephone. These interviews included questions on clarity of 
the instructions and the feasibility of the system. Patients were also asked for any encoun-
tered problems, suggestions for possible improvements, and their overall satisfaction on a 10 
point-scale (1: very poor; 10: excellent). We also discussed several alternative ascertainment 
methods, such as a falls calendar, fortnightly postcards and a falls hotline (i.e. patients call the 
hotline themselves when a fall has occurred), in light of their current experience with the Falls 
Telephone. For each of the different ascertainment methods, patients were asked if they were 
willing to use that particular system to monitor their falls for prolonged periods of time. 
Costs
We estimated the expenses needed to weekly monitor falls using (1) the Falls Telephone, (2) 
fall diaries and (3) personal telephone interviews. Personnel costs were based on an hourly 
salary of $27, and on the following amounts of time needed: Falls Telephone, 10 minutes 
once-only to activate the system for each patient and to export individual data at the end of 
the study, 10 minutes to verify each “fall” entry and 10 minutes weekly to export data from 
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all patients; Diaries, 20 minutes per diary to send, check for response, telephone follow-ups 
when diaries are not returned and entering the data in the database; Interviews, 25 minutes 
per week per patient for the interview, repeated attempts to contact patients and data entry. 
Operational costs were based on the following estimations. Falls Telephone: $5360 to set 
up the system and $51 per patient per year, including telephone costs for weekly calls. Fall 
diaries: $1.17 per fall diary.  
 
Statistical analysis
Descriptive statistics were used for patient characteristics. Means were calculated for contin-
uous variables and percentages were used for categorical variables. In order to take into 
account that some telephone calls were made by the same patients, a random effects model 
was used to estimate sensitivity and specificity, with patient as random factor.
Ethical Considerations 
The trial from which patients were selected was approved by the Medical Ethical Committee. 
Use of the Falls Telephone was an integral part of this trial. All patients gave informed consent 
for participation.
Results
A total of 2465 telephone calls were completed successfully. On 2332 occasions patients indi-
cated that they had not fallen in the preceding week. Fall incidents were reported during 133 
calls by 49 patients (41.2%). These calls concerned 105 “single fall events”, 11 times “two falls 
events” and 17 times “three or more falls”, with a maximum number of 12 falls in the preced-
ing week. The mean number of successfully completed telephone calls was 20.7 per patient 
(range 1 – 40).
Reliability
All ”no-fall” entries (n=173) were confirmed as non-falls. Among the “fall” entries, 115 were 
verified and 90 (78%) were confirmed as actual falls. An overview of the fall and no-fall entries 
and the verification data is shown in Figure 1. Explanations for misclassification (n=25) were 
dialing the incorrect number (n=12) and scoring a ‘near fall’ as an actual fall (n=2). Incorrect 
entry was not confirmed in nine cases, as patients said they had dialed a different number 
than the number stored in the database. Data entry was not remembered in two cases.
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Frequent falls (more than one fall per week, verified in 25 calls) had been entered reliably in 
24 calls. In one case the reported value was underestimated (three falls had been entered, 
instead of the actual five fall incidents). The other incorrect “fall” entries (n=24) were all 
single fall events. The comparison of fall data obtained via the Falls Telephone and personal 
telephone interviews is presented in Table 2. The sensitivity of the Falls Telephone to detect a 
fall was 100% (CI 96% - 100%), and the specificity was 87% (CI 82% - 92%). 
Falls Telephone
Personal telephone interviews 
Fall No-fall Total
Recorded as fall 90 25 115
Recorded as no-fall 0 173 173
Total 90 198 288
Table 2 Comparison of fall data obtained using the Falls Telephone and personal telephone inter-
views
Figure 1 Overview of total number of calls made by the Falls Telephone, indicated falls and non-falls and 
the reliability of the verified data.
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User experiences  
The clarity of the instructions was rated positively by almost all patients (99%, n=89). The 
majority of patients (94%, n=85) did not experience the weekly calls as a burden. The Falls 
Telephone was perceived as an attractive system to record falls by 96% (n=86) of the patients. 
The use of alternative methods was less often scored as an attractive system: a fall calendar 
by 50% (n=45), postcards by 31% (n=28) and a falls “hotline” by 30% (n=27). Overall, patients 
were pleased with the Falls Telephone and the mean overall rating was 8.3 (range 6-10). Issues 
raised were that the Falls Telephone could not be used due to technical restrictions of the 
phone (n=2) and the system did not ring long enough for patients to answer the telephone 
on time (n=1). Four patients experienced problems while using the Falls Telephone, two of 
them mainly when they started using the system. One patient did not trust the system and 
therefore did not answer the telephone calls. The following improvements were suggested 
(all mentioned once): dialing the number of falls just once (instead of twice), shorten the 
introduction, exclude holidays and Sundays, call monthly instead of weekly, allow more time 
to dial the number, and to use a telephone hotline in the beginning of the disease (because 
falls are very rare in this stage), with a switch to the Falls Telephone in later disease stages 
when falling becomes more prevalent. One patient indicated that the voice could be more 
cheerful.
Costs
Costs were estimated for a fictive trial with 50 participants and one-year follow-up. Based 
on approximately 5% of the Falls Telephone entries as “fall” entry (which needs to be verified 
by telephone), this would amount to the following costs estimations, for various methods. 
Falls Telephone: $8,954 (operational costs $7,910, personnel costs $1,044), fall diaries: $26,442 
(operational costs $3,042, personnel costs $23,400) and personal telephone interviews: 
$29,250 (personnel costs). 
Discussion 
Several methods are available to monitor falls, both prospectively and retrospectively.3 
Comparisons between calendars, postcards, interviews or questionnaires show varying 
percentages of sensitivity (31%-97%) and specificity (91%-99%).13-14 However, comparisons of 
these sensitivity and specificity levels across techniques is difficult because of methodological 
differences (e.g. duration of the recall intervals over which falls were assessed). Prospective 
data collection has been recommended to avoid recall bias2, but the optimal way to monitor 
falls remains unknown.13 Our Falls Telephone is sensitive (100%), but less specific (87%). The 
great strength of the Falls Telephone is that persons can reliably indicate when they have not 
fallen, so this obviates the need for a time-consuming and labor-intensive personal follow-up 
in the large majority of non-fallers. Conversely, patients who indicate having fallen need to 
85
Evaluation of the ‘Falls Telephone’: an autom
ated system
 for enduring assessm
ent of falls 
5be called by the researcher to verify if the reported fall represents an actual fall event. For the current study, this implied that a relatively small proportion of all telephone calls (133 out of 2465 calls) needed to be verified to reliably estimate fall rates. In addition, this verification call can be used to obtain more details about the fall events, such as specific circumstances or the 
consequences of the fall. 
The Falls Telephone is likely to save costs. Estimations based on a fictive trial (involving 50 
patients with weekly fall monitoring and one year follow-up) showed that the Falls Tele-
phone will save about $17,500 compared to falls diaries, and even more when compared to 
personal interviews. Once the application has been installed, the system automatically runs 
at relatively low costs. Personnel expenses are much less for the Falls Telephone because most 
patients (i.e. those who have not fallen) do not have to be called. The cost savings in favor of 
the Falls Telephone will become increasingly larger with more participants, or with prolonged 
follow-up.
Our study demonstrates a good agreement between the automated Falls Telephone and a 
structured interview. We acknowledge that a structured interview (regarded in this study as 
the gold standard) is not infallible, as patients may have forgotten some of their falls by the 
time of the personal interview. However, simultaneously using alternative monitoring tools 
such as calendars or fall cards was not possible because this could have resulted in response 
enhancement for both methods.
The system scored high on patient satisfaction. Most patients regarded the Falls Telephone as 
an attractive system to monitor falls for prolonged periods of time. Alternative methods, such 
as calendars, postcards or a falls hotline, were found to be less appealing. Only a few patients 
were disturbed by the use of the Falls Telephone, while the majority of patients were not 
burdened by the weekly calls. Although most telephone devices meet the requirements of 
the Falls Telephone system, some patients may experience problems due to technical restric-
tions of their phone. For those patients who are unable or unwilling to use the Falls Telephone, 
alternative methods can be used to collect falls data.  
Another technical restriction was the fact that the Falls Telephone did not provide information 
about unsuccessful calls for the investigators. In a new release of the Falls Telephone, the call 
history information will be made visible for a regular user of the system.
Another future improvement of the Falls Telephone is to include a reminder of the fall defi-
nition. When patients started using the Falls Telephone, they received a letter with instruc-
tions (how to use the system, and a definition of falls). In the present study, subjects were not 
reminded of this fall definition during the automated telephone calls. Providing a reminder 
of this definition in the pre-recorded message can simply be implemented by adding just a 
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single sentence. One advantage is that fewer patients will mistake a ‘near fall’ as a fall incident. 
If desired by the investigators, a definition of near falls can also be added, so these can be 
recorded as well. Such reminders would be particularly helpful in trials with a long follow-up. 
Additionally, future studies should evaluate whether automated calls must be made weekly, 
or whether less frequent calls would be sufficient to obtain a reliable estimate of falls. 
We evaluated the Falls Telephone in a group of PD patients, because of their high fall rates.9 
We suspect that the Falls Telephone also holds promise for other populations with a high risk 
of falling, but this needs to be demonstrated in future work. A particular challenge will be to 
test this new approach in patients with cognitive impairment: they have a clearly increased 
risk of falling15, but may have more difficulty remembering the instructions and recalling their 
number of falls. On the other hand, all other methods of ascertainment are also threatened 
by cognitive decline in the study population, and the Falls Telephone may represent a good 
alternative for spouses or other carers, allowing them to enter the fall rates. Our present study 
population only included non-demented patients with PD, so additional studies need to 
address the feasibility and reliability of the Falls Telephone in elderly populations with varying 
degrees of cognitive impairment.
Conclusion 
The Falls Telephone is a convenient instrument to monitor falls, not only for patients but 
also for researchers. Combined with personal interviews to verify the accuracy and details of 
reported falls, the system is a useful and reliable tool to collect fall rates, especially in large 
and long-lasting trials. 
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Abstract
Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder with a 
complex phenotype, featuring a wide variety of both motor and non-motor symptoms. Current 
medical management is usually monodisciplinary, with an emphasis on drug treatment, 
sometimes supplemented with deep brain surgery. Despite optimal medical management, 
most patients become progressively disabled. Allied health care may provide complementary 
benefits to PD patients, even for symptoms that are resistant to pharmacotherapy or surgery. 
This notion is increasingly supported by scientific evidence. In addition, the role of allied 
health care is now documented in recent clinical practice guidelines that are available for 
physiotherapy, occupational therapy and speech-language therapy. Unfortunately, adequate 
delivery of allied health care is threatened by the insufficient expertise among most therapists, 
and the generally low patient volumes for each individual therapist. Moreover, most allied 
health interventions are used in isolation, with insufficient collaboration and communication 
with other disciplines involved in the care for PD patients. Clinical experience suggests 
that optimal management requires a multidisciplinary approach, with multifactorial health 
plans tailored to the needs of each individual patient. Although the merits of specific allied 
health care interventions have been scientifically proven for other chronic disorders, only 
few studies have tried to provide a scientific basis for a multidisciplinary care approach in 
PD. The few studies published so far  were not yet convincing.  We conclude by providing 
recommendations for current multidisciplinary care in PD, while highlighting the need for 
future clinical trials to evaluate the cost-effectiveness of a multidisciplinary team approach.
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6IntroductionParkinson’s disease is a chronic and progressive neurodegenerative disorder with a complex and diverse phenotype. Clinically discernable motor features include varied combinations of resting tremor, akinesia, rigidity, gait impairment and postural instability. In addition, most 
patients also experience a wide variety of non-motor symptoms, including neuropsychiatric 
complaints (depression, anxiety or cognitive decline), sleep disorders, autonomic dysfunction 
and sensory problems. These non-motor symptoms have a major impact on the quality of life 
and are an important source of disability.
Current medical management
The current therapeutic approach of PD is often ‘monodisciplinary’, i.e. only one medical 
discipline is involved in the care for patients. In most cases this is the medical specialist 
(neurologist or geriatrician) who focuses on minimising motor symptoms and reducing 
disease severity. Therapy is based primarily on symptomatic treatment with dopaminergic 
medication, and this is usually effective in reducing the classical motor features. However, 
there are drawbacks to current pharmacotherapy in PD. First, even levodopa is unable to 
sufficiently alleviate all motor symptoms. For example, ON-period freezing, falling and 
postural instability are usually not very responsive to dopaminergic treatment. Second, only 
few non-motor symptoms are responsive to dopaminergic treatment. Some non-motor 
symptoms may actually worsen due to dopaminergic therapy, including e.g. orthostatic 
hypotension or hallucinations in PD. Third, long-term use of dopaminergic treatment is 
complicated by development of dose-limiting response fluctuations, including sometimes 
disabling dyskinesias. Deep brain surgery can be considered when motor symptoms can no 
longer be controlled satisfactorily with drug treatment. These surgical procedures are suitable 
for only a selected group of patients, and the symptomatic effects do not exceed those 
obtained with dopaminergic therapy. Hence, pharmacotherapy and neurosurgery alone are 
insufficient to meet the entire symptom complex of PD.
Allied health care
Allied health care may complement these standard medical treatments, both in terms of 
focus, treatment goals and working mechanisms (Table 1). 
Allied health care includes physiotherapy (PT), occupational therapy (OT) and speech-
language therapy (SLT), as well as treatment by dieticians, social workers or sexologists. While 
the neurologist determines disease severity and optimizes medical treatment to reduce 
symptoms, allied health therapists aim to minimize the impact of the disease process s and 
improve the patient’s participation in everyday activities. The underlying working mechanism 
is also different. Both pharmacotherapy and neurosurgery aim to correct nigrostriatal 
dysfunction in PD. In contrast, allied health therapists try to bypass the defective basal ganglia 
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by engaging alternative neural circuitries that are still intact (cortical pathways and sensory 
systems). This generic principle can be applied to support a broad variety of motor functions, 
such as increasing the stride length while walking, or phonating louder when talking. There 
are three motor strategies that are specific for patients with hypokinetic-rigid features and 
that can be applied for both PT, OT and SLT: (a) avoiding multitasking during daily activities, 
by instructing patients to focus on the primary task at hand; (b) using cues to initiate and 
maintain movements during activities; and (c) dividing complex movements into a series of 
simpler components of the overall task, such that each component now needs to be executed 
independently and sequentially.1
Support for the possible merits of allied health care long came from mere clinical experience. 
Here we will discuss how allied health care is increasingly developing into an evidence-based 
profession.
Physiotherapy 
The therapeutic arsenal of physiotherapy in PD is outlined in an evidence-based guideline 
for clinical practice.1 This guideline has been adopted by the Association of Physiotherapists 
in Parkinson’s Disease Europe (APDDE) and is available online (http://www.appde.eu ). The 
guideline incorporates all available scientific evidence, and is supplemented with expert 
opinion. Among the 39 recommendations for clinical practice, there were several strong 
recommendations (i.e. based on randomized trials of good methodological quality): 
application of cueing strategies to improve gait, application of cognitive movement strategies 
to improve transfers (e.g. turning around in bed, and rising from a chair), and exercise therapy 
to improve balance (mainly strength and balance training).
Medical management Allied health care
Focus Disease process Impact of disease process on daily 
functioning
Treatment goals Reduce symptoms 
Minimise disease severity
Reduce disability due to motor and 
non-motor symptoms
Improve participation in roles and 
activities in daily life
Improve level of activities
Working mechanism Correct nigrostriatal dysfunction Support compensatory (movement) 
strategies
Scientific evidence Moderate to strong Limited (occupational therapy) to 
moderate or strong (physiotherapy, 
speech therapy) 
Table 1 Differences between medical management (pharmacotherapy and deep brain surgery) 
and allied health care
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6An update of the guideline appeared in 2008.2 New findings included the notion that cueing strategies improved not only undisturbed gait, but also gait while performing a secondary motor task. In addition, cues were found to be helpful for improving posture, transfers (performance of sit to stand), and the confidence to carry out functional activities without 
falling. Another relevant finding was that cueing strategies, although effective in the short 
term, had no long-term effects (as determined at 6-weeks of follow-up). 3 However, cueing 
strategies may be more effective under real life circumstances when cues are needed 
most. There was also new evidence for exercise therapy: high-force eccentric resistance 
training of the lower extremities improved physical capacity, as reflected by improvements 
in stair descent, walking distance and muscle volume.4 A meta-analysis provided a strong 
recommendation that exercise therapy can improve physical capacity (strength, balance), gait 
speed and health-related quality of life.5 Two treadmill training studies provided supporting 
evidence that exercise therapy can improve gait parameters, lower extremity tasks and well-
being.6-7 Finally, one hour of Tango classes improved both balance (Berg Balance Score) and 
gait (backward stride length).8 This ‘Tango study’ also illustrates the challenge to scientifically 
identify the most effective component of such mixed and complex interventions: the music 
can act as an auditory cue, the consecutive steps of the dance can act as a movement strategy, 
and the activity itself can act as an exercise.
Occupational therapy
PT and OT are closely related, but the treatment goals are different. PT aims to improve daily 
functioning by enhancing basic skills such as gait or transfers. In contrast, OT focuses on 
being able to use these skills, enabling patients to engage in meaningful roles and activities 
in the domains of self care, productivity and leisure activities. OT interventions can focus on 
changing person-related factors, on adopting the actual activities themselves, and on tackling 
the environment where the activities are being performed.
In 2008, an evidence-based guideline for OT in PD was published in the Netherlands 
(translation into English is underway).9 A total of 31 recommendations were made, covering 
referral, assessment techniques and treatment. Good scientific evidence for the effectiveness 
of OT in PD is lacking, hence recommendations were made based on indirect evidence 
obtained from PT. Specifically, the assumption was made that PD-specific compensatory 
strategies (shown previously to enhance basic skills) are also effective in optimizing activity 
performance. Additional indirect evidence was obtained from published experience with 
effective OT interventions for other chronic conditions (e.g. dementia and multiple sclerosis), 
whenever these interventions were felt to be relevant for PD.
Important elements of the guidelines are the focus on encouraging self-management skills 
and addressing the needs of caregivers on issues related to activities and participation. 
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Another recommended OT intervention is coaching the patient in carefully planning daily and 
weekly routines, while considering factors such as energy level, medication effects and speed 
of task performance. A daily or weekly activity plan may also provide a structure for patients 
with problems in initiating or planning activities. To optimize the use of motor or cognitive 
strategies and activity performance, the occupational therapist can advise the patient and 
caregiver about alternative equipment or changes to the physical environment.
The guideline also highlighted the need for well-designed intervention trials. No large scale 
OT intervention trials have been published since appearance of the guideline, but some 
relevant articles have been published. These articles concern the possible contribution of 
OT in self-management in PD10, the use of assistive devices and mobility aids in PD11, and 
approaches to optimize hand function in PD.12 A pilot RCT in the UK supports the feasibility of 
evaluating OT in a randomised clinical trial.13 In the Netherlands, an RCT has started this year 
to evaluate the impact of a 10-week OT intervention according to clinical practice guidelines.
Speech and language therapy
In 2008, an evidence-based guideline for SLT in PD was published in the Netherlands.9 This 
guideline provides 60 recommendations that can assist speech-language therapists in clinical 
decision making, during both assessment and treatment. The treatment goals can be bundled 
into three main domains: speech impairment (hypokinetic dysarthria), swallowing disorders, 
and drooling. The recommendations are graded from strong (n=2), moderately strong (n=41) 
to weak (remainder). The two strong recommendations were made in the domain of speech. 
One recommendation is to limit dysarthria assessment in PD to establishing whether or not 
patients are indicated for specific intensive treatment (Lee Silverman Voice Treatment –LSVT- 
or Pitch Limiting Voice Treatment - PLVT).14-15 The other strong recommendation is to treat 
patients with an indication with PLVT or LSVT at least three times a week for at least four 
weeks14, the highest treatment intensity that is currently realistic, at least for Dutch SLTs. 
Patients with severe hypokinetic dysarthria or mixed dysarthria (resulting from atypical 
parkinsonism) can profit from the same approach, but results are obviously limited.
Other work showed that videophone-delivered speech therapy can be cost-effective.16 In 
the field of drooling there is new evidence that botulinum toxin injections can trim down 
saliva production, without improving swallowing physiology.17 In the field of dysphagia, a 
small pilot study demonstrated that the daily use of effortful swallowing (assisted with 
biofeedback) for two weeks was helpful in reducing dysphagia in PD.18 Another small study 
showed that expiratory muscle strength training can reduce aspiration while swallowing in 
PD.19 Although evidence is still limited, it seems that high-energy treatments are not only 
effective in improving voice quality and intelligibility in PD20, but also in improving swallowing 
and maybe also saliva control.
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6Drawbacks to current allied health careAllied health care as it is currently used is not without shortcomings. More good quality randomized trials are needed to demonstrate the effectiveness of allied health care interven-tions. Furthermore, more work is needed to show if allied health approaches can be applied 
universally in all patients, or whether certain subgroups are less suitable for receiving these 
treatments. For example, the presence of cognitive impairment can interfere with the afore-
mentioned treatment strategies, because patients may be unable to understand the recom-
mendations or fail to memorise their new movement strategies. Patients with cognitive 
impairment may also fail to appreciate the risks of walking disturbances or dysphagia. Hence, 
therapy should also focus on safety aspects. The caregivers should be involved whenever 
possible, because they can support the patient by applying the newly acquired strategies 
while performing daily activities.
Another problem is that allied health care interventions are typically used in isolation, despite 
partially overlapping treatment strategies and partially complementary goals. In current clini-
cal practice, most health professionals are unfamiliar with the potential treatment options 
offered by other professionals.21 For example, LSVT is such an intensive training that less 
emphasis on other treatments during those four weeks is highly advisable.
Multidisciplinary treatment of PD
Given the complexity of PD, a multidisciplinary approach would appear to be preferable. 
Indeed, allied health care interventions are effective for only part of the complex symptom 
spectrum in PD. A multidisciplinary team approach, combining pharmacological and non-
pharmacological therapies, thus seems necessary to obtain optimal therapeutic efficacy. For 
this reason (and also increasingly driven by patient foundations), specialized PD centres have 
begun to implement integrated and multidisciplinary health care programs within their clini-
cal practice. The UK-based NICE guideline also recommends regular access to a broad range 
of medical and allied health professionals. An obvious question is: who should be part of the 
team? There is no evidence whatsoever that has addressed this question, and our impression 
(based on discussions with colleagues) is that a considerable variation exists in team constitu-
tion across different treatment centres, depending on issues such as availability of expertise 
and funding. It is not known which clinical structure or team involvement is most effective, 
and the NICE guidelines give no recommendations as to how to organize the multidisciplinary 
care.
Theoretically speaking, multidisciplinary care teams for PD patients could include a wide 
range of different professionals, including medical specialists (neurologist, neurosurgeon, 
psychiatrist, geriatrician, urologist), specialised PD nurse specialists and allied health 
professionals (at least PT, OT and SLT). In addition, dieticians, social workers, sexologists 
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and clinical neuropsychologists can be included in the team. Important elements of inter-
professional team work are, among others, shared goal setting and shared contribution to 
treatment plans, effective communication and appropriate referrals to other team members. 
These aspects should all be incorporated when organizing multidisciplinary care for PD 
patients. Professionals should work according to evidence-based guidelines, when these are 
available. The goals should be defined not only around disease severity and symptoms, but 
should also consider mobility, independence and relationships. Importantly, the treatment 
plan should address the individual needs of each patient. In our Parkinson Centre Nijmegen, 
we routinely invite our patients to prioritize their own ‘top five’ complaints, and we have been 
struck by the wide variety in priorities set by different patients. Because this prioritization is 
done before the actual visit to our centre, we can adjust the team constellation according 
the unique needs of each patient. This client-centered approach improves the quality of care, 
while reducing the amount of redundant attention to issues that are less relevant for patients.
The treatment plan is incomplete without engaging the immediate caregiver, family and 
friends. Many caregivers have a crucial role in assisting more severely affected patients in 
using cues or cognitive movement strategies. Caregivers may also benefit from OT, by improv-
ving their ability to cope with complex situations and to gain more competence in supporting 
the patient. Moreover, an optimal multidisciplinary approach also addresses the needs of the 
caregivers. When the caregiver collapses, patients may lose their independence, and must 
resort to much more expensive assisted care.
Evidence for multidisciplinary care in PD (and beyond)  
Multidisciplinary care is used increasingly, but the question arises how well founded this 
approach is. Scientific evidence on the effectiveness of multidisciplinary care in PD is limited. 
Positive effects on health, disability, quality of life and well-being have been reported in 
several uncontrolled studies that used a pre-test versus post-test design.22-25 Only few 
studies used a controlled design to evaluate the effectiveness of multidisciplinary care in 
PD.26-27 One crossover RCT evaluated a multidisciplinary intervention that featured individu-
alised PT, OT, SLT, specialized nursing, access to a social services care manager, and group 
educational support.27-28 Improvements for patients and their caregivers were found directly 
after the program (using a pre-post test design), but these had disappeared after six months 
of follow-up. A recent RCT evaluated the effect of group education combined with personal 
rehabilitation delivered by a multidisciplinary team, including a specialized movement disor-
der neurologist, PT, OT, dietician, psychologist and a nurse.29 Positive effects were found for 
quality of life, activities of daily living (UPDRS II) and motor scores (UPDRSIII) at eight weeks 
after the intervention.
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6Given this limited availability of good quality research, we resorted to published evidence that supported the merits of multidisciplinary care for other chronic neurological or even non-neurological disorders. Generally speaking, some trends have been found towards posi-tive effects of integrated care programs in the chronically ill.30 In addition to positive effects for 
patients, team work may also improve process outcomes, such as compliance and adherence 
to guidelines, and lead to a higher degree of work satisfaction.
Future trials
Although sound scientific evidence is available for certain allied health care interventions, 
the evidence for an integrated multidisciplinary approach is still limited. Clearly, more work 
is needed to substantiate the general feeling that multidisciplinary care improves the quality 
of care and leads to a better outcome for patients. Research is needed to provide a more 
thorough basis for multidisciplinary care in PD (in case of positive findings), or to a critical 
reappraisal of this costly and time-consuming intervention (in case of negative findings). There 
is also a need to determine which specific elements should be part of the multidisciplinary 
approach, and whether a ‘one size fits all’ treatment is as good as an individually tailored 
approach. Even positive findings need to be weighed against the undoubtedly higher costs 
associated with multidisciplinary care: how much is the society willing to spend on quality 
of life for PD patients and their families? In the Netherlands, we are currently performing a 
large cluster controlled trial (the IMPACT study) to evaluate the effectiveness and costs of 
integrated, multidisciplinary care in PD, as compared to usual - i.e. largely monodisciplinary - 
care. Hopefully, the results of this trial and other studies will contribute to a better quality of 
care for PD patients and their families. 
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7.1  The Parkinson’s disease 
  multidisciplinary package
By Christopher G. Goetz, MD, Rush University Medical Center, 
Chicago, Illinois, USA 
Published as: 
The Parkinson’s disease multidisciplinary package, 
Movement  Disorders 2013;28(5):565.
The final publication is available at Wiley Online Library via 
http://onlinelibrary.wiley.com/doi/10.1002/mds.25414/abstract
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7Physicians caring for patients with Parkinson’s disease (PD) often use many therapies simultane-ously, including medications, dietary recommendations, physical therapy, social support strate-gies, and for some patients, surgery. In most cases, the implementation of this multifaceted care involves a team of experts, including movement disorder specialists, trained nurses, and social 
workers. Whereas this type of approach may be available in movement disorder specialty centers, 
the same integrated care is less feasible for general neurologists. Randomized clinical trials focus 
on the study of individual components of this overall care model, but the overall “package” of inte-
grated multidisciplinary care has not been previously evaluated.
In this issue of Movement Disorders, van der Marck and colleagues conducted a randomized 
clinical trial to study the impact on quality of life and other functional measures in PD patients 
receiving multidisciplinary specialty care or general neurological care.1 (Chapter 7.2) The results 
favor the multidisciplinary approach, with improvements in quality of life and UPDRS, depres-
sion, and psychosocial functional scores. In a brief discussion of effect size, the authors argue that 
the observed differences have clinical pertinence. There is no health economic analysis to provide 
readers with a measure of societal cost for the relative difference. A substantive cost difference 
can be inferred, however, in that no patient in the general neurologist care group accessed a 
social worker or a PD specialty nurse, whereas in the multidisciplinary group, 69% consulted with 
social workers and 86% accessed a specialty nurse, with 59% receiving care from both. Because 
the movement disorder specialist was only part of the multidisciplinary team, the specific impor-
tance of the higher level of PD expertise cannot be dissected. Further, it is clear that those in the 
multidisciplinary group received more attention and time focused on them, so it not possible to 
attribute the favorable outcomes specifically to better expertise. Had neighbors or friends phoned 
the patients or visited them at the same level as the professionals, would the patients have done 
equally well?
The article, even with these limitations, is an important contribution because scientists and clini-
cians increasingly recognize that PD is a disease composed of motor and nonmotor impairments. 
In fact, the latter components often become the predominant issues as the disease advances. 
Having this article as a starting point offers a first entry into the evidence base of comprehensive 
health models and presents international colleagues with a number of ideas for future protocols 
and studies.
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1.  van der Marck MA, Bloem BR, Borm GF, Overeem S, Munneke, M, Guttman M. Effectiveness of multidisciplinary 
care for Parkinson’s disease: a randomized, controlled trial. Mov Disord 2013;28(5):605–611.
106
107
Effectiveness of m
ultidisciplinary care in Parkinson’s disease
7
7.2  Effectiveness of multidisciplinary care 
  for Parkinson’s disease: a randomized 
  controlled trial
Marjolein A. van der Marck, Bastiaan R. Bloem, George F. 
Borm, Sebastiaan Overeem, Marten Munneke, Mark Guttman. 
Movement Disorders 2013; 28(5):605-611. 
The final publication is available at Wiley Online Library via 
http://onlinelibrary.wiley.com/doi/10.1002/mds.25194/abstract 
DOI: 10.1002/mds.25194
108
Abstract 
Background 
Multidisciplinary care is considered an optimal model to manage Parkinson’s disease (PD), 
but supporting evidence is limited. We performed a randomized controlled trial to establish 
whether a multidisciplinary/specialist team offers better outcomes compared to stand-alone 
care from a general neurologist. 
Methods
Patients with PD were randomly allocated to an intervention group (care from a movement 
disorders specialist, PD nurses and social worker) or a control group (care from general 
neurologists). Both interventions lasted 8 months. Clinicians and researchers were blinded for 
group allocation. The primary outcome was the change in quality of life (Parkinson’s Disease 
Questionnaire, PDQ-39) from baseline to 8 months. Other outcomes were Unified Parkinson’s 
Disease Rating Scale (UPDRS), depression (Montgomery-Asberg Depression Scale, MADRS), 
psychosocial functioning (Scales for Outcomes in Parkinson’s disease-Psychosocial, SCOPA-
PS) and caregiver strain (Caregiver Strain Index, CSI). Group differences were analyzed using 
analysis of covariance adjusted for baseline values and presence of response fluctuations. 
Results 
122 patients were randomized and 100 completed the study (intervention n=51, control 
n=49). Compared to controls, the intervention group improved significantly on PDQ-39 
(difference 3.4, 95%CI 0.5 – 6.2) and UPDRS motor scores (4.1, 95%CI 0.8 – 7.3). UPDRS total 
score (5.6, 95%CI 0.9 – 10.3), MADRS (3.7, 95%CI 1.4 – 5.9) and SCOPA-PS (2.1, 95%CI 0.5 – 3.7) 
also improved significantly. 
Conclusions 
This randomized controlled trial gives credence to a multidisciplinary/specialist team 
approach. We interpret these positive findings cautiously due to the limitations in study 
design. Further research is required to assess teams involving additional disciplines, and to 
evaluate cost-effectiveness of integrated approaches.
109
Effectiveness of m
ultidisciplinary care in Parkinson’s disease
7IntroductionParkinson’s disease (PD) is a progressive and disabling disorder.1-2 A multidisciplinary team approach is widely felt to offer better control of PD than pharmacotherapy alone.3-5 However, evidence supporting this approach remains limited, and previous randomized controlled 
trials (RCTs) did not show robust and sustained findings.6-9 Here, we report the results of an 
RCT to establish whether a multidisciplinary/specialist team approach (involving a move-
ment disorders specialist, PD nurses and PD social worker) offers better outcomes compared 
to stand-alone care by a general neurologist.  
Methods
The study was designed as a single-blind RCT comparing two arms: an intervention group 
(IG), with care delivered by a multidisciplinary/specialist team (movement disorders special-
ist, PD nurses and social worker) and a control group (CG), with care delivered by a general 
neurologist. The trial was conducted between June 2002 and January 2005 and was approved 
by the Markham Stouffville Hospital Research Ethics Committee. Written informed consent 
was obtained from all participants. 
Participants
Patients were referred to the Centre for Movement Disorders (Markham, Ontario) for multi-
disciplinary management of their PD.  The reason for referral varied widely and did not neces-
sarily involve complex or advanced patients. Due to limitations in the number of movement 
disorders specialists in Ontario, it is common for PD patients to be seen initially by a general 
neurologist and then referred to a sub-specialist. The intervention Centre had a single move-
ment disorder neurologist (MG) during the study. No other neurologists worked in the Centre. 
The general neurologist continued to be involved until the first visit by the movement disor-
der neurologist.
Administrative staff at the Centre, not involved in the study, booked the initial assessment 
appointment with the patient with a wait time of approximately eight months as part of the 
standard processing of new patients. This wait time was typical for new patients referred to 
the Centre at the time of this study.  After accepting their initial appointment, consecutive 
patients were contacted by telephone by research assistants and screened to discuss their 
potential involvement. A screening assessment was offered to patients who passed the initial 
telephone screen. This screening assessment was conducted by movement disorders fellows 
who were part of the research staff for this study and did not participate in the clinical care of 
any recruited patient. At the screening assessment, inclusion criteria were evaluated, includ-
ing a clinical diagnosis of PD according to the UK Brain Bank criteria,10 ability to complete the 
study questionnaires, written informed consent and presence of a caregiver who also partici-
pated in the study. Exclusion criteria included dementia (Mini-Mental State Examination <24) 
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and current treatment by a movement disorders specialist. We also determined the presence 
of response fluctuations (wearing-off or dyskinesias, assessed with the Unified Parkinson’s 
Disease Rating Scale (UPDRS)). 
Randomization, blinding and study design
Patients meeting the inclusion criteria were randomly assigned to the IG or CG. Randomiza-
tion allocation was computer generated. There was a 1:1 randomization to the intervention 
or control group, stratified by presence of response fluctuations. Research assistants with-
out clinical or research involvement in the trial assigned patients with sealed envelopes and 
organized visits and data-entry. The research staff who performed the screening, baseline and 
follow-up assessments were unaware of group identity. The clinical team providing care were 
not aware if patients participated in the study.
After randomization, patients in the IG were rescheduled for a clinical neurological 
examination by the movement disorders specialist within three weeks from the screening 
visit, rather than waiting for their original appointment (typically 8 months later). Patients 
in the CG received usual care from general neurologists who did not have nursing or social 
work staff.  Usual care was determined by the general neurologist; there was no standard 
approach to the frequency of visits or other interventions. The general neurologists were 
not aware of patients’ participation. Patients in both groups were asked to not share their 
study involvement with any treating clinician. No formal power calculation was made, but 
we strived to include 100 patients. Patients who unblinded their participation were dropped 
from the study and replaced randomly to reach the target of 100 patients who completed the 
study. This occurred only sporadically (one IG patient).
Intervention
The intervention is described in detail in the Addendum. This included ongoing individually 
tailored care from the movement disorders specialist, supported by PD nurse and social 
worker within the same physical location. Visits to the movement disorders neurologist were 
scheduled at baseline, 4 months and 8 months. Additionally, patients were offered to see the 
social worker for psychosocial issues and homecare issues, and the PD nurse for changes in 
symptoms, medication issues or other PD-related questions. Control patients were followed 
by the general neurologist outside the Centre who was associated with their care before 
referral. Intervention patients saw the movement disorders neurologist at the Centre. 
Outcomes
Baseline and follow-up assessments were performed by trained movement disorders fellows 
and physiotherapists who were not involved in patient care and who were unaware of group 
allocation. The primary outcome was change from baseline to 8 months in quality of life, 
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7assessed with the Parkinson’s Disease Questionnaire (PDQ-39).11-12 The secondary outcome was change from baseline to 8 months in the UPDRS part III (motor section). Motor ratings were not performed in a pre-specified time with respect to the patient’s medication response. Tertiary outcomes included UPDRS total score, depression (Montgomery-Asberg Depression 
Scale, MADRS), psychosocial functioning (Scales for Outcomes in Parkinson’s disease-
Psychosocial, SCOPA-PS) and caregiver strain (Caregiver Strain Index, CSI). Daily medication 
use was converted to levodopa equivalent dose.13 Outcomes were assessed at baseline, 4 
months and 8 months. 
Statistical analyses 
Changes from baseline to 8 months were analyzed for all outcome measures. Differences in 
changes between groups were examined with analysis of covariance (ANCOVA), with baseline 
value of the variable and presence of response fluctuations as covariates. In a secondary 
analysis, the possible impact of disease duration and age were evaluated by including 
these variables in the analyses. Results with P<0.05 (two-sided) were considered statistically 
significant.
Results
Study population
159 patients were screened, 122 were eligible to participate and were randomly assigned to IG 
or CG (Figure 1). Twenty-two patients dropped out due to withdrawal of consent, unblinding 
of the clinical team, incorrect diagnosis or having received the clinical neurology assessment 
before baseline assessment. In total, 100 patients completed the study, including 51 patients 
in IG and 49 in CG (Table 1). Baseline characteristics and baseline scores for the outcomes were 
comparable between the groups, except for higher CSI scores in IG.   
Figure 1 Enrollment and patient flow. 
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Intervention
All IG patients visited the movement disorders specialist three times. PD nurses were engaged 
by 86% of patients, the social worker by 69% of patients, and both professionals by 59% of 
patients. PD nurses were mainly contacted by telephone (84% of 160 contacts), whereas the 
majority of social worker contacts was an office visit (72% of 46 contacts). In contrast, no CG 
patient visited a PD nurse or social worker during the study period.
Efficacy
The PDQ-39 improved from 22.2±14.4 at baseline to 19.7±14.2 at eight months for IG, but 
worsened from 19.1±12.4 at baseline to 20.2±13.4 at eight months for CG (Table 2). 
Variable Intervention group
Mean (SD)
(n=51)
Control group
Mean (SD)
(n= 49)
Age (yrs) 65.9 (8.5) 68.1 (8.8)
Men (%) 59 57
Disease duration (yrs) 4.6 (3.9) 3.7 (3.5)
Patients with response fluctuations (%) 27.4 28.6
PDQ-39 index score 22.2 (14.4) 19.1 (12.4)
   Mobility 26.6 (25.0) 23.4 (21.8)
   Activities of daily living 26.6 (21.0) 22.2 (19.4)
   Emotional well-being 25.7 (18.4) 21.4 (17.0)
   Stigma 18.8 (19.8) 15.1 (15.2)
   Social support 8.2 (12.3) 6.5 (14.7)
   Cognition 20.2 (17.0) 21.7 (16.4)
   Communication 21.1 (21.2) 15.3 (15.7)
   Pain 30.9 (22.0) 27.2 (20.3)
UPDRS III 22.6 (14.4) 21.7 (11.3)
UPDRS total 39.0 (23.1) 36.0 (18.1)
MADRS 10.1 (7.5) 8.2 (6.7)
SCOPA-PS 10.6 (7.0) 9.2 (6.6)
CSI 18.3 (12.3) 14.1 (10.6)
Daily levodopa equivalent dose (mg) 413 (247) 431 (289)
Medication, used by (%)
   Levodopa
   Dopamine agonist 
   COMT inhibitor
   MAO B blocker
   Anticholinergic
   Amantadine
67%
24%
6%
2%
10%
10%
71%
29%
2%
0%
0%
8%
COMT catechol -O-methyl transferase; CSI Caregiver Strain Index; MADRS Montgomery-Asberg Depression Scale; 
MAO B monoamine oxidase beta;  PDQ-39 Parkinson’s Disease Questionnaire; SCOPA-PS Scales for Outcomes in Parkin-
son’s disease-Psychosocial; SD standard deviation; UPDRS Unified Parkinson’s Disease Rating Scale (III, motor part).
Table 1 Participants characteristics at baseline
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These changes differed significantly between IG and CG (3.4, 95% CI 0.5–6.2). Separate analy-
sis for the eight PDQ-39 domains showed that IG patients significantly improved on mobility 
scores (7.1, 95% CI 1.9–12.3) and emotional well-being scores (5.4, 95% CI 0.7–9.9) compared 
to CG patients. There were no group differences on the other domains (Table 2). The second-
ary outcome (UPDRS III) improved from baseline to eight months in the IG, but deteriorated 
in the CG. These changes differed significantly between both groups (4.1, 95% CI 0.8-7.3). 
Tertiary outcomes that improved significantly in the IG included UPDRS total scores (5.6, 95% 
CI 0.9 – 10.3), SCOPA-PS (2.1, 95% CI 0.5 – 3.7) and MADRS (3.7, 95% CI 1.4 – 5.9) (Table 2). CSI 
scores did not differ between IG and CG (1.5, 95% CI -1.2 – 4.2). Additional analyses with age 
and disease duration incorporated as covariates did not change the results. 
Levodopa equivalent dose
During follow-up, the levodopa equivalent dose increased more in CG compared to IG (differ-
ence 18.5%, 95% CI -1% – 41%). Additional adjustment for levodopa equivalent dose did not 
change the greater improvement in PDQ-39 scores for the IG compared to the CG (estimated 
difference in improvement 3.7, 95% CI 0.2 – 7.3). 
Intervention Group
Mean (SD)
Control Group
Mean (SD)
Estimated difference 
(95%CI)
Primary outcome
PDQ-39 index score (n=98) -2.5 (5.8) 1.4 (8.6) 3.4  (0.5 to 6.2)
   Mobility
   Activities of daily living
   Emotional well-being
   Stigma
   Social support
   Cognition
   Communication
   Bodily discomfort
-3.8 (9.4)
-2.9 (14.0)
-4.7 (11.2)
-2.0 (13.9)
0.0 (11.5)
-0.4 (12.5)
-3.8 (10.3)
-2.6 (18.4)
3.8 (16.2)
3.3 (14.2)
2.0 (13.8)
1.1 (14.4)
2.1 (11.7)
1.9 (13.7)
0.0 (13.2)
1.1 (18.8)
7.1  (1.9 to 12.3)
5.1  (-0.5 to 10.6)
5.4  (0.7 to 9.9)
1.8  (-3.4 to 6.9)
1.6  (-2.7 to 5.9)
-1.1 (-6.1 to 3.9)
2.2  (-2.3 to 6.7)
1.9  (-4.8 to 8.5)
Secondary outcome
UPDRS III (n=100) -2.7 (8.7) 1.6 (9.3) 4.1 (0.8 to 7.3)
Tertiary outcome
UPDRS total (n=100) -4.4 (13.4) 2.0 (12.4) 5.6 (0.9 to 10.3)
SCOPA-PS (n=100) -1.8 (4.4) 0.7 (4.7) 2.1 (0.5 to 3.7)
MADRS (n=99) -4.1 (6.6) 0.4 (6.6) 3.7 (1.4 to 5.9)
CSI (n=97) -0.7 (7.7) 1.4 (5.1) 1.5 (-1.2 to 4.2)
Daily levodopa equivalent 
dose (mg)
42.1 (158.4) 95.4 (208.7) 18.5% (-1% to 41%)
Table 2 Health outcomes change (8 months – baseline) and differences between groups
CI Confidence interval; CSI Caregiver Strain Index; MADRS Montgomery-Asberg Depression Scale;  PDQ-39 Parkinson’s 
Disease Questionnaire; SCOPA-PS Scales for Outcomes in Parkinson’s disease-Psychosocial; SD Standard deviation UPDRS 
Unified Parkinson’s Disease Rating Scale (III, motor part).
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Discussion
These results show that an individually tailored multidisciplinary/specialist team intervention, 
with involvement of a movement disorders specialist, PD nurses and social worker, improved 
both primary (PDQ-39) and secondary (UPDRS-III) outcome measures, as compared to 
management by a general neurologist alone. Several tertiary outcomes (UPDRS total, SCOPA-
PS, MADRS) also improved during the 8-month intervention period. As such, this is one of the 
first RCTs that gives credence to a multidisciplinary/specialist team approach. However, we 
will interpret these positive findings cautiously, given the complexity of the intervention, and 
in light of several methodological imperfections.
Effect size
Did the effects of this multidisciplinary/specialist team intervention have any clinical rele-
vance? For quality of life (primary outcome), our results showed an improvement of 3.4 points 
on the PDQ-39 summary index for the team approach. Such an improvement will be clinically 
meaningful to patients.14 By comparison, the effect of deep brain stimulation on quality of life 
compared to optimal medication is about 7.0 points, based on four trials.15 Comparison with 
our trial is difficult, e.g. because stimulation is given to more severely affected patients, and 
because quality of life at baseline is lower. However, this comparison suggests that a multidis-
ciplinary team approach may offer a fairly substantial effect, compared with an invasive and 
highly effective intervention like deep brain stimulation.
We also found greater improvement in motor functioning for the team approach, as assessed 
with UPDRS part III (4 points difference in favor of IG). This improvement falls within the range 
of effect sizes reported in several clinical trials of dopaminergic medication.16 Although direct 
comparisons with drug trials are difficult, the observed change in motor functioning appears 
clinically relevant for patients.17 Although the motor assessments were not performed in a 
pre-specified “on” or “off” time, it is unlikely that this altered our findings since only 28% of 
patients in both groups had response fluctuations. 
With respect to the IG, we do not know other studies that evaluated a similar group of patients 
in a prospective controlled study with a similar type of intervention that could act as compari-
son. Our CG essentially reflected usual care and natural disease progression. Compared to 
natural disease progression studies and to the control arms in open label studies, our CG 
globally behaved the way we expected them to18-22, suggesting we included representative 
patients.
In general, integrated care programmes for the chronically ill seem to have a positive effect 
on quality of care, but comparisons are difficult due to the heterogeneity of interventions 
and outcomes used.23 Thus far, the evidence on multidisciplinary rehabilitation in PD remains 
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7limited and failed to reveal consistent benefits.3,5 The literature to support multidiscipli-nary involvement in other chronic neurological disorders is also variable. For example, the evidence to support multidisciplinary inpatient stroke units is robust, showing beneficial effects on survival and independence.24-25 For dementia, collaborative primary care involv-
ing an advanced practice nurse working together with families with dementia has shown 
improvements in behavioural and psychological symptoms.26 However, other studies showed 
that coordinated care in memory clinics had no positive effects on health outcomes in demen-
tia patients.27-29 
Components of the multifactorial intervention
Compared to single interventions like drugs, evaluation of multidisciplinary care poses scientific 
challenges due to the complex nature of the intervention, with several interconnecting 
components.30 Here, we evaluated the merits of a team intervention as the sum of its parts. 
Our study was not designed to evaluate the contributions of the different members of the 
multidisciplinary/specialist team. However, it is important to consider which component of our 
multifactorial intervention might have contributed to the observed benefits. One important 
element was the movement disorders specialist who treated all IG patients, whereas all CG 
patients were treated by general neurologists. Because the multidisciplinary team included a 
movement disorders specialist, we cannot be certain if the group difference in outcome was 
due to the “team” aspect or the “specialist” aspect of the intervention. A retrospective analysis 
of Medicare claims in the United States suggested that neurologist’s care of PD patients is 
associated with better clinical outcomes (fewer hip fractures) and greater survival, compared 
to primary care without neurologist, although a causal relationship could not be proven.31 In 
our study, patients in both arms received neurologist care, but for the IG the neurologist was a 
specialist in movement disorders who perhaps offered better care than a general neurologist. 
Interviews and surveys have clarified that patients greatly value the dedicated expertise of a 
movement disorders specialist,32-33 so patient expectations may have played a role. Moreover, 
PD experts may yield better outcomes because of improved diagnosis, better counseling, and 
dedicated treatment for specific complications of PD. 
The team intervention also included access to PD nurses and a social worker. PD nurses are 
closely involved in several aspects of care, including counseling, coping with PD and social 
concerns. However, evidence for the effectiveness of nursing care alone for PD patients 
remains limited and inconclusive.34 Perhaps nursing care is more effective when delivered 
as part of an integrated team approach. The treatment goals of social workers aim at 
psychosocial issues, helping patients to link to community services that are not offered to 
patients on site. The nature of these services of PD nurses and social workers corresponds 
with the improvements observed on the tertiary outcome measures relating to emotional 
and psychosocial functioning. Finally, the multidisciplinary/specialist team that we evaluated 
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could also have included additional disciplines, such as physiotherapy or speech-language 
therapy, which are increasingly becoming evidence-based treatments for PD.35-37 Future work 
should investigate their possible added value to the multidisciplinary team approach. 
Recently, the American Academy of Neurology provided a core set of quality measures to 
guide clinicians in their management of PD.38 These quality measures recommend focusing 
on 10 topics as part of the clinical assessment, and most measures focus on non-motor 
symptoms. This emphasizes the need for a team-oriented approach to manage the broad 
range of PD-related symptoms, as these cannot easily by managed by one discipline.
Shortcomings and future perspectives
This study was not without shortcomings. First, we were unable to perform an intention-
to-treat analysis, because we acquired no data in dropouts. Hence, we were restricted to 
perform a case-controlled analysis with only subjects who completed the study. Future work 
needs to take this into account. Second, it is possible that the observed differences were 
caused by more neurological services being provided to the IG compared to the CG. It was 
not possible to determine the number of neurological services received in the CG, and this 
should be addressed in future studies. In addition, the exact nature of the intervention should 
be addressed further. Data on the number of visits and telephone contacts with the team 
members were reported, but we did not report the topics that were addressed. Third, the 
study results cannot automatically be generalized due to a possible selection bias in referrals 
to the participating centre. The reason for referral to a movement disorder specialist varies 
widely and does not necessarily involve complex patients or advanced patients. Nevertheless, 
it is conceivable that referrals were for more complex patients, or for patients that were 
more interested in specialized care. However, such selective referral to a specialized centre 
reflects everyday clinical practice worldwide, and as such our trial does inform the current 
management of PD in many specialized centers. Fourth, most patients had relatively early 
stage PD, as only 28% had experienced response fluctuations. Therefore, our findings cannot 
be extrapolated to patients with more advanced disease. Fifth, this RCT was conducted as a 
single-blind study. Awareness of treatment allocation among patients might have induced 
a placebo effect in favor of the intervention. In PD drug treatment studies, placebo effects 
commonly taper off during a 3-6 month study, although placebo effects can persist for longer 
periods of time. In our study, the efficacy was present in the primary and secondary outcomes 
throughout the 8-month observation, but a placebo effect cannot be excluded. Double-blind 
RCTs are required to better untangle placebo effects from real effects of the intervention, 
but are difficult to perform with this type of study. Finally, our results were limited to an 
8-month follow-up. More research is needed to establish the potential long-term effects of 
multidisciplinary care, including a cost-effectiveness assessment. A multidisciplinary team 
approach is a far more complex and less homogenous intervention than, for example, a single 
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7dose drug intervention. This is a generic challenge for studies in this new emerging field. To explore the impact of a team, a next step might be to perform an RCT on a general neurologist plus a team versus a general neurologist alone. Studying a movement disorders specialist plus a team versus a movement disorders specialist risks the possibility of a ceiling effect. In view 
of the shortage of movement disorders specialists,33 a solution could be to surround a general 
neurologist with PD nurses and social workers, reserving movement disorders specialists to 
patients beyond the care of such a team. Additionally, more research is needed to refine the 
most effective elements of multidisciplinary interventions. A further challenge is to extend 
the intervention with additional disciplines, e.g., physiotherapists or occupational therapists, 
to establish the relative importance of each discipline within such a team approach, and to 
evaluate their merits in different settings.
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ADDENDUM
Intervention
The intervention included individually tailored care from a single movement disorders 
specialist (MG) supplemented with support, teaching and assistance from Parkinson’s 
disease (PD) nurses and a PD social worker.  Visits to the movement disorders neurologist 
were scheduled at baseline, 4 months and 8 months. Supplementary appointments were 
determined by the patients’ needs. At the initial clinical appointment each patient was 
offered to meet with the social worker. In addition to performing a psychosocial assessment, 
the social worker oriented patients as to the role of the paramedical healthcare professionals 
in the multidisciplinary/specialist team. The patients were given more detailed information 
about the potential for telephone support before the next scheduled visit and were given 
information as to who they should contact for different situations. Patients were instructed 
to contact the social worker for psychosocial issues and if there were issues related to access 
to local government provided services including homecare in addition to educational 
services provided by the local Parkinson’s Society. Patients were also instructed to contact the 
nursing staff if they had a change in their PD symptoms, issues with their PD medications or 
if they had other questions relating to their PD. They were informed that the team members 
would communicate with the neurologist and get back to the patient with a plan to address 
their issues. If they requested an earlier appointment with the neurologist before the next 
scheduled appointment, this was discussed with the neurologist as part of daily meetings 
and a decision of how to manage the issue was then made by the neurologist. In addition 
to telephone support, patients were offered meetings with the paramedical staff during 
their office visits as determined by the movement disorders specialist to enhance their PD 
management. The intervention, both in the frequency of visits and the topics addressed, was 
tailored to the patient’s individual needs. 
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Despite advances in the treatment of Parkinson’s disease, many patients develop serious compli-
cations that are unresponsive to pharmacological and surgical manipulation of dopaminergic 
neurotransmission.1 As a result, several studies have assessed the value of rehabilitation in Parkin-
son’s disease, particularly through a multidisciplinary approach.2-4 Such studies typically suggest 
a slight benefit from this approach, yet they do not satisfy current standards of evidence-based 
practice.5 
In The Lancet Neurology, Marjolein van der Marck and colleagues6 (Chapter 8.2) begin to address 
this gap in the evidence with the Integrated Multidisciplinary care for Parkinson’s disease: a 
Controlled Trial (IMPACT) study by taking the question one step further: how effective is multidis-
ciplinary care within the setting of a modern health-care system? A superficial review of the study 
might conclude that its results are negative: the slight benefits of the treatment on activities of 
daily living and quality of life were wiped out when the analysis was corrected for asymmetries 
in severity between the intervention and control groups. However, the greater importance of this 
study lies in the lessons learned while addressing the challenges of implementing a multidiscipli-
nary care model within a modern health-care system, and of assessing the effectiveness of such 
implementation. 
To answer the question of how to implement multidisciplinary care within a health-care system, 
the IMPACT investigators adopted a hybrid approach, with initial multidisciplinary assessments 
at an expert centre yielding recommendations for therapy that were subsequently outsourced 
to providers participating in ParkinsonNet, a network of community-based collaborating allied 
health professionals with specialised Parkinson’s disease training. The investigators included 
150 patients in the intervention group and used a geographically separate control group of 151 
patients who received standard care as prescribed by their neurologists. One out of three patients 
in the intervention group declined the intervention, and many of the patients who agreed did 
not consistently comply with recommendations. Conversely, more than half of the patients in 
the control group did receive rehabilitative treatments as part of standard care, which, not least 
because of the previous efforts of the investigators of this study,7 is already at a very high level in 
the Netherlands. 
What can be learned from the apparent failure of multidisciplinary care in this implementation 
model? The investigators point out three weak links in their design that might have frustrated 
their efforts to provide high-quality conclusive evidence: the heterogeneous, customised nature of 
the administered treatments; the absence of selection of patients to whom the intervention was 
offered; and the hybrid nature of the multidisciplinary intervention. 
On the basis of assessments, customised treatment recommendations were provided by the multi-
disciplinary team for each patient in the intervention group. The investigators postulate that a 
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8more standardised prescription across patients might be easier to assess, even if it might result in excessive care for some patients. Besides cost concerns, such an approach could erode effect size by not showing an effect in patients for whom an effect was not expected or needed. The custom-ised approach would more likely enhance compliance; after all, multidisciplinary care is under 
investigation, and heterogeneity of treatments is part of its nature.
Apart from some general inclusion and exclusion criteria, allcomers were offered participation to 
the trial, irrespective of the perceived need for intervention. The investigators propose that restrict-
ing multidisciplinary care to those with the highest need might result in better compliance. Nota-
bly, the study population included generally mildly affected individuals (about three-quarters 
of the intervention group were at Hoehn and Yahr stage 2·5 or lower). Conceivably, less severely 
affected individuals are less likely to have a short-term benefit from the intervention, because 
most of their symptoms are responsive to pharmacological treatment; extending this argument, 
a statistical correction for the asymmetry in severity between groups does not take into account 
the possibility that the relation between disease severity and effect size might be non-linear. There-
fore, the same study might have yielded different results in Hoehn and Yahr stages 3 and 4, when 
patients might have more robust short-term benefits. The intervention could even be linked to a 
specific need, and relevant outcome measures could be targeted. 
This approach would increase the heterogeneity of the administered treatments; however, to reit-
erate, the concept of the multidisciplinary care rather than any specific treatment is under inves-
tigation. In implementing the intervention within the health-care system, patients were offered 
assessments and treatment recommendations at the expert centre, whereas administration of the 
treatments was outsourced to the community. The investigators suggest that it might be prefer-
able to complete the recommended treatments at the expert centre, which would preserve and 
ensure the interdisciplinary dimension of the multidisciplinary model. One of the strongest argu-
ments in support of multidisciplinary care is that communication between disciplines has a syner-
gistic positive effect on outcomes.8 Spatial proximity removes barriers that could compromise such 
communication. Conversely, such requirement might adversely affect patient recruitment and 
retention by adding more barriers (eg, distance to travel, need for lodging).
The investigators ought to be applauded for including cost-effectiveness and caregiver burden 
analyses in their study. The absence of an adverse economic effect of multidisciplinary care 
emphasises the need for further study: if outcomes can be improved at no higher cost, this model 
should not be dismissed without further study and high-quality evidence. Future studies of multi-
disciplinary care could examine new short-term outcome measures for assessing effectiveness, 
investigate long-term benefits of this approach and relevant long-term outcome measures (eg, 
falls resulting in injury, admission to an institution, and survival), devise support services to reduce 
caregiver stress, and assess the role of recurrent interventions, among other things. The study 
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by the IMPACT investigators6 has launched the discussion on the place of multidisciplinary care 
within a changing health-care environment. The lessons learned will inform future research of this 
care model, not only in Parkinson’s disease, but also in other chronic progressive diseases.
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Abstract
Background A multidisciplinary approach is thought to be the best way to manage the motor 
and non-motor symptoms of Parkinson’s disease, but how such care should be delivered is 
unknown. To address this gap in knowledge, we assessed the effectiveness of an integrated 
multidisciplinary approach compared with usual care.
Methods We recruited patients for our non-randomised controlled trial from six community 
hospitals in the Netherlands (two in regions where the integrated care intervention was avail-
able and four in control regions that administered usual care). Eligible patients were those with 
Parkinson’s disease, aged 20–80 years, and without severe cognitive impairment or comorbid-
ity. Patients in the intervention group were offered an individually tailored comprehensive 
assessment in an expert tertiary referral centre and subsequent referrals to a regional network 
of allied health professionals specialised in Parkinson’s disease. Primary outcomes were activi-
ties of daily living (Academic Medical Center linear disability score [ALDS]) and quality of life 
(Parkinson’s disease quality of life questionnaire [PDQL]) measured at 4, 6, and 8 months. 
Secondary outcomes included motor functioning (unified Parkinson’s disease rating scale, 
part III [UPDRS III], at 4 months), caregiver burden (belastungsfragebogen Parkinson ange-
hörigen-kurzversion [BELA-A-k] at 4 and 8 months), and costs (during whole study period). 
Primary analysis was by intention to treat and included scores over 4, 6, and 8 months, with 
correction for baseline score. The trial is registered at Clinicaltrials.gov, number NCT00518791.
Findings We recruited 301 patients (150 patients in the intervention group and 151 in the 
control group) between August, 2007, and December, 2009, of whom 285 completed follow-
up (last follow-up was July, 2010). 101 (67%) patients in the intervention group visited the 
expert centre; 49 (33%) opted not to visit the expert centre. The average ALDS score from 
months 4, 6, and 8, with correction for baseline score, was greater in the intervention group 
than in the control group (difference 1·3 points, 95% CI -2·1 to 2·8; corresponding raw logit 
score difference 0·1, 95% CI 0·003 to 0·2) as was the average PDQL score (difference 3·0 points, 
0·4 to 5·6). Secondary analysis with correction for baseline disease severity showed no differ-
ences between groups for ALDS (difference 0·9 points, 95% CI –0·6 to 2·4; corresponding raw 
logit 0·1, –0·02 to 0·3) or PDQL (difference 1·7 points, –1·2 to 4·6). Secondary outcomes did not 
differ between groups (UPDRS III score difference 0·6 points, 95% CI –1·4 to 2·6; BELA-A-k score 
difference 0·8 points, –0·2 to 1·8; cost difference €742, –€489 to €1950).
Interpretation This integrated care approach offered only small benefits to patients with 
Parkinson’s disease, and these disappeared after correction for baseline disease severity. 
These results suggest that different approaches are needed to achieve more substantial 
health benefits.
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8IntroductionParkinson’s disease is increasingly recognised as a multidimensional disorder. In addition to classic motor symptoms, patients have a wide variety of non-motor symptoms that substan-tially affect quality of life but often remain unrecognised and untreated.1 Moreover, most non-
motor features do not respond satisfactorily to dopaminergic drugs, and some might even 
get worse, such as orthostatic hypotension and cognitive function.1 Therefore, the possible 
benefits of non-pharmacological interventions are generating interest. A multidisciplinary 
approach combining pharmacological treatment with non-pharmacological interventions 
to manage a complex disorder such as Parkinson’s disease might be beneficial.2 Despite the 
shortage of evidence for effectiveness,3 guidelines recommend regular access to a broad 
range of medical and allied health-care professionals.4-5 Indeed, many centres deliver inte-
grated and multidisciplinary care for patients with Parkinson’s disease.2,6 However, a standard 
template for multidisciplinary care in Parkinson’s disease does not exist, and guidelines do 
not clarify how a team approach should be organised and structured. We developed an inte-
grated model to organise care for patients with Parkinson’s disease, with two complemen-
tary elements: an individually tailored assessment by a multidisciplinary team that defines 
a comprehensive treatment plan (including advice on drug treatment and recommenda-
tions for non-pharmacological interventions); and subsequent implementation of this plan 
within a network of specifically trained allied health professionals, supervised by the referring 
neurologist.7 To assess the effectiveness of this model, we designed Integrated Multidiscipli-
nary care for Parkinson’s disease: a Controlled Trial (IMPACT) to compare outcomes in patients 
with Parkinson’s disease who had access to this model of care with those in patients receiving 
standard care.
Methods
Study design and participants
We recruited patients for this non-randomised, controlled trial from neurological outpatient 
clinics in six community hospitals in the Netherlands—two in a region where the interven-
tion was available (intervention region), and four in regions where it was not (control regions; 
appendix). The control regions were geographically separated from the intervention region. 
Inclusion criteria were having Parkinson’s disease (diagnosed by a neurologist according to 
UK Brain Bank criteria),8 being aged 20–80 years, living independently in the community, 
being able to complete questionnaires, having no severe cognitive impairment (mini-mental 
state examination ≥24), having no severe comorbidity that interfered with daily functioning, 
and having a planned routine follow-up consultation with the treating neurologist. Exclu-
sion criteria were having atypical parkinsonian syndromes, being wheelchair bound (Hoehn 
and Yahr [HY] stage 5), having other neurological disorders, intending to have a deep brain 
stimulation procedure within the intervention period, and having a previous assessment at 
the expert centre in the intervention region. Signed informed consent from each patient was 
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obtained at the start of the research assessment. The study protocol was submitted for review 
to the medical ethics committee of the Radboud University Nijmegen Medical Centre, but 
they declared that formal judgment was not required. 
Randomisation and masking
The type of intervention did not allow for randomisation, because the integrated organisation 
of care was confined to one specific region were the tertiary expert centre and allied health-
care networks were available. Therefore, we compared patients recruited from hospitals 
within the intervention region (containing the integrated care model) with those recruited 
from the control regions, where this infrastructure of care was absent. Patients and caregiv-
ers were masked to differences in organisation of care between the intervention and control 
regions. The research staff was responsible for all research activities, but had no role in the 
multidisciplinary assessment or treatment of patients. The clinical team was masked to trial 
participation and was not involved in any research activities related to the outcome measures; 
they assessed patients at the centre. Treatment was administered by regional therapists. The 
patients’ own neurologists were aware that patients were invited to participate in the trial and 
of the differences between the regions, but were not told whether patients had accepted or 
declined participation. The Parkinson’s disease nurses in the two community hospitals in the 
intervention region were aware of participation in the trial and of the differences between the 
two regions. The Parkinson’s disease nurses in the control regions were not involved in trial 
activities, but might have been aware that patients had been invited to participate in the trial.
Procedures
In the intervention region, organisation of care was integrated by combining the services of 
an expert tertiary referral centre for Parkinson’s disease (the Parkinson Centre of the Radboud 
University Nijmegen Medical Centre) with those of ParkinsonNet - a regional network of 
health-care providers who specialise in treating and managing patients with Parkinson’s 
disease. A detailed description of the multidisciplinary assessment in the expert centre is 
provided in the appendix. All patients were assessed at baseline, and about two weeks later 
met their own neurologist for a routine follow-up visit. Participants in control regions received 
their usual care. By contrast, after the baseline assessment and visit to the neurologist, patients 
in the intervention group then met the Parkinson’s disease nurse of their local hospital who 
offered them an optional visit to the expert centre. This visit was scheduled immediately for 
participants who consented. Otherwise, usual care was continued. After the multidisciplinary 
assessment in the expert centre, patients were followed up by the same nurse. When patients 
in the intervention group visited the expert centre they received an individually tailored 3-day 
assessment by a multidisciplinary team of medical and allied health-care professionals. These 
consultations were followed by an integrated face-to-face meeting of all team members and 
a treatment plan, created on the basis of consensus building between all of the medical and 
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8allied health-care professionals,  was discussed subsequently with the patient and caregiver. This plan included medical advice for the referring neurologist plus referrals to allied health professionals (physiotherapists, occupational therapists, and speechlanguage therapists) working in the ParkinsonNet network. Key elements included dedicated training of all profes-
sionals, treatment according to evidence-based guidelines, structuring of referral processes, 
and optimisation of communication between specialists.7
The expert centre and ParkinsonNet services were accessible to patients in the interven-
tion region, but not to patients in control regions (Table1). This approach in the intervention 
region fits the conceptual framework of an integrative model of team health-care practice.9 
The organisation of care in control regions was not changed by the investigators; profes-
sionals working in the control regions were free to change their care services as they saw 
fit. In both groups, health professionals could initiate any assessment or treatment that they 
thought to be appropriate. After the initial baseline assessment, all patients were assessed 
at 2, 4, 6, and 8 months (Figure1). Meetings were scheduled with trained research assistants 
at baseline and 4 months. Questionnaires that could be completed by patients were sent to 
the patients’ homes. Participating caregivers completed questionnaires at baseline, 4 months, 
and 8 months. 
The primary outcomes were activities of daily living and quality of life; differences between 
groups over 4, 6, and 8 months were analysed. Activities of daily living were assessed with 
the Academic Medical Centre linear disability score (ALDS).10-14 The ALDS is a generic item 
bank that quantifies functional status by the ability to undertake activities of daily life using 
an item response theory framework. The item bank includes activities hierarchically ordered 
Intervention region Control regions
Expert assessment in tertiary movement 
disorders centre
Yes No
ParkinsonNet network of allied health-care 
professionals who specialise in Parkinson’s 
disease (physiotherapists, occupational 
therapists and speech-language therapists) 
Yes No
Community neurologists Yes Yes
Community-based allied health-care 
professionals without ParkinsonNet training 
Yes Yes
Medical specialists (other than neurologist; see 
table 3)
Yes Yes
Table 1 Similarities and differences in healthcare between the intervention and control regions
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from relatively easy to difficult. Based on item parameters for each of these activities and algo-
rithms, ALDS logits are calculated. These logits are used in the analysis and transformed to 
ALDS scores to make the results easier to interpret. For this study, 30 activities of daily living 
were selected and the maximum ALDS score was 90. Higher scores suggest a better functional 
status. Quality of life was assessed with the Parkinson’s disease quality of life questionnaire 
(PDQL).15-16 This disease-specific assessment contains 37 items allocated to four subscales: 
parkinsonian symptoms (14 items), systemic symptoms (seven items), emotional functioning 
(nine items), and social functioning (seven items). The overall score ranges from 37 to 185, 
with higher scores suggesting a better quality of life. 
Secondary health outcomes were changes in motor functioning - measured by the unified 
Parkinson’s disease rating scale, part III (UPDRS III), a motor assessment scored by trained 
research assistants17 - and caregiver burden - measured by the “bothered by” subscale of 
belastungsfragebogen Parkinson angehörigen - kurzversion (BELA-A-k), a questionnaire for 
measuring caregivers’ psychosocial problems caused by caring for an individual with Parkin-
son’s disease.18 Health-care costs were estimated from a societal perspective with a detailed 
questionnaire completed by patients at baseline, 2, 4, 6, and 8 months, each covering their 
health-care use over the previous 2 months. We then used this data to calculate total costs on 
the basis of microcosting (appendix).19-20 
Tertiary endpoints included changes in generic quality of life (36-item short-form health 
survey, version 2 [SF-36v2]), depression and anxiety (hospital anxiety and depression scale 
Figure 1 Study design. Informed consent was obtained at baseline (0 months). Costs refer to total health-care costs, assessed 
by questionnaires about health-care use completed by  patients. 
ALDS Academic Medical Centre linear disability score; BELA-A-k belastungsfragebogen Parkinson angehörigen-kurzver-
sion; PDQL Parkinson’s disease  quality of life questionnaire; UPDRS III unified Parkinson’s disease rating scale, part III.
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8[HADS]), fear of falling (falls efficacy scale–international [FES-I]), freezing of gait (freezing of gait questionnaire), ability to undertake activities of daily living (self-assessment Parkinson’s disease disability scale [SPDDS]), and overall wellbeing (measured with a 100-point visual analogue scale), all measured at baseline, 4 months, and 8 months; non-motor symptoms 
(non-motor symptoms [NMS] scale), treatment-related motor and non-motor complications 
(UPDRS IV), activity limitations (patientspecific index for physiotherapy in Parkinson’s disease 
[PSI-PD]), balance (single leg stance), turning, and the Parkinson activity scale, measured at 
baseline and 4 months; fall frequency (monitored weekly with the Falls Telephone);21 and a 
questionnaire on quality of care (not standardised) measured at 4 months. For caregivers, 
tertiary health outcomes were depression (HADS) and quality of life (SF-36v2), measured at 
baseline, 4 months, and 8 months, and their view on the patients’ ALDS. Because the entire 
proposed assessment proved too cumbersome and tiring for study participants, the Berg 
balance scale and caregivers’ views on patients’ memory (memory assessment clinic rating 
scale) were assessed at baseline but left out during follow-up assessments.
Statistical analyses
We estimated that a sample size of about 300 patients was needed to detect a difference 
of 2 points in ALDS scores, with 80% power and 5% significance (two-sided), assuming a 
standard deviation of 9 and a correlation of 0·7 between the measurements.14 We assessed 
primary outcomes by a random effects repeated measures analysis whereby ALDS and PDQL 
scores measured at 4, 6, and 8 months were compared between groups. Because the ALDS 
has been developed within the framework of item response theory, the analyses were based 
on the original units of measurements (logits).22 We analysed scores from months 4–8 using 
a linear mixed model, with random factor patient and fixed factors treatment, baseline value, 
assessment time (4, 6, and 8 months), and the interaction of assessment time and treatment. 
We included patients with at least one measure at 4, 6, or 8 months in the analysis of health 
outcomes. Other variables were analysed similarly. We analysed health-care costs over the 8 
months with correction for baseline costs over the 2 months preceding study participation. As 
the costs data were highly skewed, with some outlying values, we used the bootstrap proce-
dure to generate 1000 new samples from the data; we calculated the confidence interval on 
the basis of these samples.The primary analysis was by intention to treat. After completion of 
enrolment we noticed that some baseline characteristics differed between the intervention 
and control groups. Therefore, we did secondary analyses according to UPDRS III score, disease 
duration, HY stage, NMS score, and daily levodopa equivalent dose (mg). Not all patients in 
the intervention group opted for the multidisciplinary assessment in the expert centre. There-
fore, we did a secondary post-hoc  per-protocol analysis for the primary outcomes, comparing 
patients who had actually received the expert multidisciplinary assessment with patients in 
the control group. The trial is registered at Clinicaltrials.gov, number NCT00518791.
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Results
We recruited 301 patients (150 patients in the intervention group and 151 in the control 
group) between August, 2007, and December, 2009, of whom 285 completed follow-up (5% 
dropout rate; figure2). The final follow-up measurement took place in July, 2010. Of the 150 
participants in the intervention group, 101 (67%) received a multidisciplinary assessment. 
49 (33%) patients opted not to visit the expert centre. Reasons to decline included lack of 
perceived benefit or an anticipated burden of having to attend the 3-day assessment. 196 
caregivers participated: 102 in the intervention group (31 [30%] were men, and the mean age 
was 64·0 [SD 9·3] years) and 94 in the control group (32 [34%] men, mean age 65·6 [9·8] years).
At baseline, patients in the intervention group were younger, and had shorter disease dura-
tion and less disease severity (lower UPDRS motor scores) than did patients in the control 
group (Table 2). 
Figure 2 Recruitment and dropout. Burden refers to patients who either found involvement in the study a burden, or whose 
Parkinson’s disease  become too much of a burden for them to continue.
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An overview of consultations during the expert assessment and subsequent referrals is 
presented in the appendix. 90 patients were referred to one or more regional allied health-
care professionals, resulting in 271 referrals. These referrals were not always implemented; 197 
(73%) referrals led to consultations. Seven (8%) of the 90 referred patients had no resultant 
consultations. Referrals that included a recommendation to start a new treatment resulted in 
a consultation in 41 (98%) of 42 patients referred to physiotherapy, 37 (74%) of 50 referred to 
occupational therapy, and 24 (65%) of 37 referred to speech-language therapy. Assessment 
of health-care use showed that patients in both groups were treated by several health profes-
sionals (Table 3), therefore, control patients also received some multidisciplinary care. 
Both primary endpoints showed small improvements in favour of the intervention. At 4–8 
months, average ALDS score was 1·3 points greater (95% CI -2·1 to 2·8; corresponding raw 
logit score difference of 0·1, 0·003 to 0·2) in the intervention group than in the control group 
(p=0·045), and PDQL score was 3·0 points (0·4 to 5·6) greater in the intervention group than in 
the control group (p=0·03; Table 4; appendix). 
UPDRS III and BELA-A-k scores did not differ between groups (Table 4), apart from the partner 
bonding subscale of BELA-A-k, which was significantly greater (indicating a greater burden) 
in the intervention group compared with the control group (appendix). Data for tertiary 
endpoints are presented in the appendix. We noted significant improvements in the interven-
Table 2 Baseline characteristics 
Intervention group
(n=150)
Control group
(n=151)
Age (years) 66·5 (8·2) 69·3 (7·6)
Men 96 (64%) 92 (61%)
Time since diagnosis (years) 5·8 (4·2) 6·8 (4·8)
Modified Hoehn and Yahr stage* 
   HY 1 28 (19%) 33 (22%)
   HY 1.5 6 (4%) 5 (3%)
   HY 2 65 (43%) 38 (25%)
   HY 2.5 22 (15%) 9 (6%)
   HY 3 24 (16%) 60 (40%)
   HY4 2 (1%) 4 (2,6%)
UPDRS III, motor scores (0-108)* 25·6 (11·1) 32·6 (12·1)
Daily levodopa equivalent dose (mg) 494 (402) 580 (305)
Data are mean (SD) or number (%). UPDRS III unified Parkinson’s disease rating scale part III; HY Hoehn and Yahr. 
*Data for HY stage and UPDRS III were not obtained in three patients in the intervention group and two patients in the control 
group because these patients refused to be examined.
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tion group compared with the control group in: anxiety and depression (HADS); activities of 
daily living (SPDDS); non-motor symptoms (total NMS scale score); SF-36 role limitations due 
to physical health, role limitations due to emotional problems, and vitality; and perceived 
general health (visual analogue scale). Quality-of-care scores were better in the intervention 
group, but overall satisfaction was not different from the control group. Changes in levodopa 
equivalent doses during the 8 month follow-up were similar between groups (difference of 
-1%, 95% CI -26 to 32).
Secondary analysis with additional correction for overall disease severity removed the group 
differences for both primary outcomes (Table 4).
The post-hoc per-protocol analysis showed that the difference in the ALDS score at 4-8 
months in the intervention group compared with the control group was the same as that 
in the intention-to-treat analysis (1·3 points, corresponding raw logit score difference of 0·1, 
95% CI -0·01 to 0·3), but the per-protocol analysis showed a greater difference in PDQL score 
between groups (difference 3·6 points, 0·7 to 6·5) than in the intention-to-treat analysis.
The mean average health-care costs per patient during the 8 month follow-up were €4478 
(SD €5544; range €0-37 031) in the intervention group and €5601 (SD €12 260; range €0-135 
357) in the control group. Based on bootstrapping analysis, this difference was not significant 
Table 3 Overview of consultations by medical specialists and allied health professionals during 
the 8-month study period. These numbers are based on self-reported healthcare and include all 
evaluations by healthcare professionals, i.e. both single treatment sessions and prolonged treat-
ments (multiple sessions). 
Health professional Intervention group (n=150)
Control group
(n=151)
Neurologist 142 (95%) 135 (89%)
PD nurse 93 (62%) 43 (28%)
Physiotherapist 120 (80%) 92 (61%)
Occupational therapist 64 (43%) 8 (5%)
Speech-language therapist 49 (33%) 13 (9%)
Psychologist 25 (17%) 3 (2%)
Psychiatrist 13 (9%) 2 (1%)
Social worker 29 (19%) 2 (1%)
Dietician 14 (9%)  9 (6%)
Rehabilitation specialist 11 (7%)  12(8%)
Sexologist 16 (11%) 0 (0%)
Sleep specialist 1 (1%) 0 (0%)
Geriatrician 3 (2%) 1 (1%)
Nursing home specialist 1 (1%) 1 (1%)
Other specialist (e.g. cardiologist, urologist, 
internist) 54 (36%) 62 (41%)
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(mean difference €1123, 95% CI -€844 to €3568). Including baseline costs as covariates did not 
change the significance (mean difference €742, 95% CI -€489 to €1950). Exclusion of outliers 
did not affect the results.
ALDS  Academic Medical Centre linear disability score; PDQL Parkinson’s disease quality of life questionnaire; UPDRS III 
Unified Parkinson’s Disease Rating Scale motor part; BELA-A-k  Belastungsfragebogen Parkinson Angehörigen-kurzver-
sion, Bothered By subscale. 
1 Primary analysis with correction for baseline scores for each outcome. 2 Baseline values of UPDRS III, Hoehn and Yahr stage, 
disease duration, non-motor symptoms score, and daily levodopa use (mg) added as covariates to the primary analysis as an 
overall measure for disease severity. †Corresponding estimated diff erence according to original measurement units (logits) 
were 0•1 (95% CI 0•003 to 0•2) for the primary analysis and 0•1 (-0•02to 0•3) for the secondary analysis. 
Table 4 Primary and secondary outcomes
Intervention 
group Control group
Primary  
analysis1
Secondary  
analysis2 
n
Mean 
(SD) n
Mean 
(SD)
Estimated 
difference
(95%CI)
Estimated 
difference
(95%CI)
Primary outcomes
ALDS
   Baseline 148 79·2 (11·5) 151 79·8 
(10·0)
   Average 4, 6 and 8 months 144 80·8  
(7·7)
145 79·5 
(10·1)
1·3  
(-2·1 to 2·8)†
0·9  
(-0·6 to 2·4)†
PDQL
   Baseline 148 139·0 
(23·2)
150 141·3 
(23·8)
   Average 4, 6 and 8 months 144 142·2 
(23·6)
145 140·7 
(25·5)
3·0  
(0·4 to 5·6)
1·7  
(-1·2 to 4·6)
Secondary outcomes
UPDRS III
   Baseline 147 25·6 (11·1) 149 32·6  
(12·1)
   4 months 135 28·4 (11·6) 140 32·9  
(11·5)
0·6 
(-1·4 to 2·6)
0·3  
(-1·8 to 2·4)
BELA-A-k (Bothered by)
   Baseline 101 7·0  
(7·3)
94 5·7  
(7·5)
   Average 4, 6 and 8 months 94 6·8  
(7·0)
90 5·2 
(5·6)
0·8 
(-0·2 to 1·8)
1·2 
(0·04 to 0·2)
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Discussion
Parkinson’s disease is increasingly acknowledged as a multidimensional disorder, with 
disabling symptoms in physical, emotional, and cognitive domains.1,4,23 Because of this 
complexity, many specialised Parkinson’s disease clinics worldwide use a multidisciplinary 
team approach, because this approach is felt to offer the best management of Parkinson’s 
disease.2,6,24-25 However, this assumption is supported by only a small amount of  inconclusive 
scientific evidence.3,26 Here, we assessed one specific integrative multidisciplinary approach 
with two complementary components: expert review in a tertiary movement disorders clinic 
and subsequent health-care delivery within a regional professional network. Compared with 
usual care, this approach offered significant improvements for the primary outcomes (activi-
ties of daily living and quality of life), but the effect sizes were small and unlikely to be clini-
cally relevant. Moreover, these small effects disappeared after correction for differences in 
baseline disease severity (controls were more severely affected). Better matching for base-
line disease severity could have been achieved with a randomised study design, but this was 
impractical because the integrated organisation of care was confined to one region where 
the expert centre and professional network were available; randomisation within this region 
would have been at risk of contamination, because control patients could have gained access 
to specialised allied health treatment offered by the regional professional network. 
Larger improvements were unlikely to have been missed because of use of  insufficiently 
sensitive outcomes. Large previous trials in Parkinson’s disease also used quality of life and 
activities of daily living as primary outcomes,22,27-30 with some using ALDS and PDQL scores 
to measure outcomes. The intervention that we examined was heterogeneous, including an 
individually tailored multidisciplinary assessment aimed at both motor and non-motor symp-
toms of Parkinson’s disease. This heterogeneity precluded use of a primary outcome that 
reflected the intervention more closely (eg, gait speed for those who received physiotherapy). 
Therefore, we selected activities of daily living and quality of life as overarching outcomes.
We noted no effect on secondary outcomes (motor functioning and overall caregiver 
burden). We were particularly interested in caregiver burden because many patients receive 
support from their family members, and providing this support can be a substantial bur-
den.31-32 Although overall caregiver burden did not differ between groups, our results suggest 
a higher caregiver burden in the intervention group for the partner bonding subscale of 
BELA-A-k. This paradoxical effect needs to be researched further. The tertiary outcomes 
showed improvements in various domains, including anxiety, depression, and total NMS scale 
scores in patients. These non-motor symptoms represent an important target in the manage-
ment of Parkinson’s disease.1,33-34 However, the benefits for these non-motor symptoms were 
small and unlikely to be clinically relevant. 
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8We did an economic evaluation from a societal perspective, providing a comprehensive over-view of direct and indirect health-care costs. These costs in our Dutch study population fell within the range of costs estimates from six different countries.35 Our data are consistent with previously reported cost estimates for a Parkinson’s disease cohort (n=699) in the Nether-
lands that participated in an effectiveness study of physiotherapy.20 The economic evaluation 
showed that, although the integrated multidisciplinary intervention was complex and more 
intensive than the care in the control regions, the average costs during the 8 month follow-up 
were similar in both study groups. 
Several factors might have masked larger benefits for the intervention group. First, usual care 
in the Netherlands often includes a multidisciplinary approach,36 which might have meant 
that the contrast in care between groups was small. Indeed, many control patients received 
some form of allied health care. Moreover, control patients received treatment by a neurolo-
gist working in a community hospital, and neurologist care is an important determinant of 
better clinical outcomes.37 Usual care in the Netherlands might achieve acceptable results 
that improved only incrementally with the more intensive integrated care tested in our study. 
Second, the contrast between both groups was diluted further because the health plan - 
recommended by the expert centre - was not fully implemented by the community profes-
sionals. 
Only 73% of all recommended interventions were delivered to intervention patients, and 
some patients did not receive any follow-up. Delivery of the health plan was left at the discre-
tion of the community neurologist, local Parkinson’s disease nurse, and community thera-
pists and we acknowledge this factor as a shortcoming of our approach. A better alterna-
tive-used by Parkinson’s disease centres in, for example, Tel Aviv (Israel), Toronto (Canada), 
and Melbourne (Australia)38-39-is to incorporate the assessment plus the tailored intervention 
within one centre, supervised by one case manager for each patient. Third, our primary anal-
ysis was based on an intention-to-treat principle. However, only two-thirds of the patients 
in the intervention group visited the expert centre. The improvement in quality of life was 
somewhat larger in the per-protocol analysis-excluding patients who did not have a multi-
disciplinary assessment-suggesting that patients who visited the expert centre benefited 
more. However, this post-hoc analysis should be interpreted cautiously. Finally, we might not 
have included patients who were most likely to benefit. Multidisciplinary rehabilitation seems 
to be most beneficial for patients with higher perceived needs.40 Conceivably, patients with 
advanced disease and many disabilities benefit most from multidisciplinary interventions. 
Yet, in our trial and in previous studies,39,41 severely affected patients were largely underrepre-
sented. For mildly affected patients, a less comprehensive approach might be more appropri-
ate, and cause less stress to caregivers. 
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Only a few previous trials used controlled designs, with inconsistent results.2-3,26 Most 
trials studied the effectiveness of multidisciplinary rehabilitation programmes (Table 5; 
panel).40-41,46-47 One Canadian randomised controlled trial closely resembles our trial, both in 
the study design and the intervention, and both trials assessed ongoing care for 8 months.39 
Specifically, patients received specialised team care by a movement disorders specialist, a 
Parkinson’s disease nurse, and a social worker. This approach positively affected quality of 
life, motor functioning, depression, and psychosocial functioning. This study and ours have 
several key differences, including the team size (small team with only three disciplines in 
the Canadian trial vs a comprehensive approach with up to 13 disciplines in our study), the 
collaboration structure (informal meetings and hierarchal structure vs regular team meetings 
with mutual decision making), and the settings (one expert tertiary  centre vs a tertiary centre 
combined with community treatment). Our study is also larger (n=301) than the Canadian 
trial (n=122). Additionally, usual care in the Canadian trial (where treatment involved only a 
general neurologist) differs substantially from that in the Netherlands (where many patients 
receive allied health interventions). The Canadian study included only patients who had been 
referred to the expert centre because of a perceived need for extra care, whereas we offered 
the intervention to all patients in the entire region. This difference between the studies might 
partly explain the difference in outcome, because about a third of patients in each group 
Panel: Research in context
Systematic review
We searched PubMed until Feb 8, 2013, for trials 
published in English that had the following search 
terms in the title: “Parkinson disease”, “Parkinson’s 
disease”, “Parkinsonian disorders”,  or “parkinsonism” 
combined with “multidisciplinary”, “interdiscipli- 
nary”, “integrated”,  “integrated delivery of health-
care”, “patient care team”, “team approach”, or “reha-
bilitation”.  We identified four reports42-45 on multi-
disciplinary interventions with pre-test–post-test 
designs, without control groups, and four randomised 
controlled trials (RCTs).39-41,46-47
Interpretation
The published work on multidisciplinary and team 
care in Parkinson’s disease is heterogeneous, in terms 
of the types of interventions that have been assessed 
(both the nature and length of the tested interven-
tion), outcomes used, types of interventions (pre-
test–post-test design, crossover studies, randomised 
trials), and duration of follow-up. Our study is unique 
in terms of sample size (to the best of our knowledge, 
the largest study in this specialty thus far), compre-
hensiveness of the team in the expert centre, and 
low dropout rate. Moreover, we have assessed a new 
integrated care approach, consisting of a comprehen-
sive assessment by a multidisciplinary team (part of a 
specialised movement disorders centre), with subse-
quent treatment by specialised health professio- 
nals working in a regional network. Health outcomes 
focused not only on patients but also on care- 
givers. We also included an economic evaluation. Our 
primary outcomes showed benefits in favour of the 
intervention group, but the effects were too small to 
be clinically relevant, and were partly attributable to 
baseline differences. Our study is well timed, in view 
of societal developments towards delivery of more 
multidisciplinary care, despite a shortage of support-
ing evidence. Our results issue caution against over-
zealous implementation of multidisciplinary interven-
tions, pending further evidence. The heterogeneity 
of designs, interventions, outcomes, and follow-up 
complicates a direct comparison with previous stud-
ies. Our trial also confronted us with challenges in 
assessment of this integrated care approach, because 
several interconnecting components had to be tested, 
and it was difficult to keep the control intervention 
stable. Our study offers important lessons about the 
complexity of designing and assessing a multidis-
ciplinary concept. Overall, our findings and those of 
previous studies support further development of well 
designed clinical trials to obtain more knowledge and 
scientific evidence on how to organise team-oriented 
care in Parkinson’s disease.
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8in our trial were in the early stages of Parkinson’s disease (HY stage 1-1·5) and might have been less likely to improve than patients with more advanced Parkinson’s disease. Finally, our patients were masked to treatment assignment, which might also explain why we observed smaller benefits in the intervention group than did the Canadian trial. 
Our trial identified several weak links in the tested intervention, raising suggestions as to how 
to optimise team-based management of Parkinson’s disease. First, care was tailored to each 
patient’s individual needs, but this creates a heterogeneous intervention that is difficult to 
assess. Future studies could test a standard set of interventions for each patient, although this 
approach might lead to excessive care for some. Second, we offered the expert screening to 
all patients in the intervention region because we had no a-priori grounds to restrict the treat-
ment to any specific subgroup. However, a third of eligible patients declined to visit the expert 
centre, partly because they perceived it as having no benefit. This suggests that a multidisci-
plinary intervention should not be offered routinely to all patients, but reserved for patients 
with the highest need. Indeed, the Canadian trial, which focused on patients who had been 
specifically referred to an expert centre, reported greater beneficial effects after multidisci-
plinary treatment.39 A third limitation was that the expert centre offered expert advice but 
responsibility for the actual treatment was outsourced to the community team who were 
left free to modify the treatment plan. Our analysis showed undertreatment in the interven-
tion group, in which not all patients received the recommended treatments from specialised 
community therapists. This finding suggests that expert centres should take responsibility for 
chronic care, either by delivering the actual interventions, or by coordinating community care 
with individual case managers. 
We conclude that the integrated approach assessed in this study offered only a small benefit 
compared with multidisciplinary usual care delivered in the Netherlands. We assessed an inte-
grated intervention that seemed ideal in theory, but we encountered challenges with respect 
to the applicability and feasibility of this model in the healthcare system. As such, our study 
extends beyond the question of effectiveness, because it highlights challenges that come 
with the assessment of a complex multidisciplinary intervention, in the face of the realities of a 
changing healthcare system. Our results fuel the need for development of improved interven-
tions. The evidence supporting the merits of isolated allied healthcare interventions is grow-
ing,48-50 but more work is needed to investigate how these separate interventions are best 
bundled into a multidisciplinary approach. Finally, future studies should assess how patients 
and caregivers could engage in the discussion on how to optimise Parkinson’s disease care, 
because this research will help us to explain why many patients declined the intervention in 
our study, to develop real patient-centred care, and to identify which patients are likely to 
benefit most. 
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8Supplementary AppendixMethodsRecruitment participants and hospitals
Study coordination took place at the Parkinson Centre Nijmegen of the Radboud Univer-
sity Nijmegen Medical Centre. Participants were recruited from the neurological outpatient 
clinic of six hospitals. Two hospitals were selected as the intervention region as they were 
in the direct referral area of the Parkinson Centre Nijmegen and as regional ParkinsonNet 
networks were already  present. The control regions were selected based on the following 
criteria: 1) comparable with intervention hospitals with regard to the number of neurologists 
and number of hospital beds, and 2) absence of a ParkinsonNet network or a comparable 
organisation for comprehensive multidisciplinary care. Healthcare records of all patients 
with PD within the participating hospitals were screened to identify eligible participants. 
Eligible patients received a written invitation to participate. Responders were telephonically 
contacted by the research team to further assess eligibility and schedule the baseline assess-
ment in the two weeks prior to their routine follow-up consultation with their neurologists. 
Intervention
Individually tailored assessment
At the Parkinson Centre Nijmegen, patients received an individually tailored 3-day assessment 
by a team of specifically trained health professionals, including movement disorders special-
ists, PD nurse specialists, social workers, physiotherapists, occupational therapists, speech 
therapists, sleep specialists, dieticians, sexologists, neuropsychologists, neuropsychiatrists, 
rehabilitation specialist, and geriatricians. The team consisted of permanent team members 
and several professionals whose input was tailored to the needs and priorities indicated by 
the patients. Initially, the permanent team included the movement disorders specialist, PD 
nurse specialists and physiotherapist. The social worker  instead of the physiotherapist was 
part of the permanent team for fourteen patients. The needs and priorities of the patients 
were obtained via a comprehensive questionnaire including all possible problem areas in 
PD, which was sent to patients prior to their visit. At the end of the questionnaire, patients 
were asked to indicate which symptoms and disabilities particularly needed clinical atten-
tion. Caregivers were asked to accompany the patient during the assessment. The individual 
assessment took place during two consecutive days that were separated by a week, followed 
by a multidisciplinary meeting at the third day. 
Integrated treatment 
Based on the consultations and a multidisciplinary meeting with all team members involved, 
an integrated treatment advice was written and subsequently discussed with the patient and 
their caregivers. This advice included referrals to health professionals working in the patients’ 
146
direct vicinity, including referrals to allied health therapists within the ParkinsonNet networks. 
Initially, this concept was designed for cooperating physiotherapists.7 At the time of the study, 
the ParkinsonNet networks included community neurologists, physiotherapists, occupational 
therapists and speech-language therapists. These networks were implemented in the inter-
vention region from 200451 and were accessible to all patients in the intervention group, even 
if they were not enrolled in the study or did not receive the multidisciplinary assessment in 
the Parkinson Centre Nijmegen.
Quality of care
Quality of care for Parkinson’s disease was assessed with a self-developed questionnaire. This 
questionnaire included questions on integration of care, the possibility to ask questions and 
satisfaction with obtained answers and information (n=4); questions related to the communi-
cation and referral process between health professionals and their involvement and expertise 
(n=6); attention to PD specific problems including medication, sleep, depression and mood, 
constipation, urinary problems, balance and fall risk, speak and swallowing, driving ability, 
cognition, intimacy and sexuality, and work and leisure time (n=11). Answers were based on a 
5 point Likertscale. Attention to specific PD problems was reported on a 4 point scale with an 
additional option to state that there were no problems with that specific topic. Overall satis-
faction of all healthcare received was reported on a 10 point-scale (1: very poor; 10: excellent). 
All questions related to PD care that was received over the preceding six months. 
Economic evaluation
Data on the patients’ healthcare use were obtained via detailed questionnaires, which also 
allowed for an evaluation on the extent to which the treatment referrals were implemented in 
daily care. These questionnaires were completed by patients at baseline, 2, 4, 6 and 8 months, 
each covering the preceding 8 weeks, and included the following categories of healthcare 
costs: PD medication, consultation of medical professionals and allied health therapists, 
day-hospital rehabilitation, admission to hospital, home-care from paid services, informal 
care, and productivity loss for paid and unpaid labour. Costs were calculated by multiplying 
volumes of resources by standardized cost prices based on the Dutch guidelines for economic 
evaluation in healthcare.19 Costs for medication were valued according to the formal Dutch 
reference for costs of medication52 plus purchase costs.19 Informal care was valued based on 
standardized prices19, with a maximum of 8 hours per day, equalling a workday. Missing data 
were approached as if no costs were made. This analyses was chosen as the most simple and 
realistic approach. Two other imputation methods, namely imputation by series mean and 
multiple imputations, were used. All analyses had similar results. 
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Table 1 Overview of consultations to the different health professionals during the multidisci-
plinary assessment in the expert centre, the number of patients who were referred to community 
health professionals for treatment, and the number of patients who reported an actual consulta-
tion to these health professionals during the 8-month follow-up of the study
* The number of patients referred outnumbers the number of consultations in the expert centre, because the social 
worker also referred patients to the psychiatrist and psychologist. 
N.a. not applicable, patients own neurologist continued treatment
Health professional Consultations in 
expert centre
Number of patients 
referred for treatment
Number of patients 
who received actual 
consultation by a 
community profes-
sional 
Movement Disorders 
specialist
101 n.a. n.a.
Physiotherapist 98 70 69 
Occupational therapist 86 52 39 
Social worker 72 8 4 
Speech therapist 71 38 25 
Parkinson’s disease nurse 
specialist
63 49 35 
Sexologist 25 5 0 
Psychiatrist, psychologist 26 36* 23 
Sleep consultant 11 10 2 
Dietician  11 1 0 
Rehabilitation specialist 1 2 0 
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Table 2 Scores of primary and secondary outcome measures
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8Intervention group Control group Estimated difference(95%CI)n Mean (SD) n Mean (SD)Primary health outcomes
ALDS
   Baseline 148 79·2 (11·5) 151 79·8 (10·0)
   Mean 4 to 8 months 144 80·9 (7·7) 145 79·5 (10·1) 1·3 (-2·1 to 2·8)†*
PDQL
Summary index
   Baseline 148 139·0 (23·2) 150 141·3 (23·8)
   Mean 4 to 8 months 144 142·3 (23·6) 145 140·3 (25·5) 3·0 (0·4 - 5·6)*
Parkinsonian symptoms
   Baseline 148 51·1 (9·5) 150 52·3 (9·3)
   Mean 4 to 8 months 144 52·6 (9·3) 145 52·2 (9·5) 1·0 (-0·1 - 2·1)
Social functioning
   Baseline 148 27·3 (5·5) 151 27·7 (5·8)
   Mean 4 to 8 months 144 27·4 (5·7) 148 27·2 (6·2) 0·31 (-0·4 - 1·0)
Systemic symptoms
   Baseline 148 25·5 (4·7) 151 25·9 (5·2)
   Mean 4 to 8 months 144 26·0 (4·7) 145 25·9 (5·2) 0·31 (-0·3 - 1·0)
Emotional functioning
   Baseline 148 35·1 (6·2) 151 35·4 (6·4)
   Mean 4 to 8 months 144 36·4 (5·9) 145 35·1 (6·7) 1·3 (0·5 - 2·1)*
Secondary health outcomes
UPDRS III
   Baseline 147 25·6 (11·1) 149 32·6 (12·1)
   Mean 4 months 135 28·4 (11·6) 140 32·9 (11·5) 0·6 (-1·4 to 2·6)
BELA-A-k (Bothered By)
   Baseline 101 7·0 (7·3) 94 5·7 (7·5)
   Average 4 to 8 months 94 6·8 (7·0) 90 5·2 (5·6) 0·8 (-0·2 to 1·8)
Achievement capability/ physical symptoms
   Baseline 101 1·8 (2·3) 94 1·4 (2·3)
   Average 4 to 8 months 94 1·7 (2·2) 90 1·3 (1·8) 0·1 (-0·2 to 0·5)
Fear/ emotional symptoms
   Baseline 101 2·6 (2·8) 94 2·1 (2·7)
   Average 4 to 8 months 94 2·4 (2·5) 90 1·9 (2·0) 0·3 (-0·1 to 0·7)
Social functioning
   Baseline 102 1·4 (1·9) 94 1·0 (1·6)
   Average 4 to 8 months 94 1·4 (1·8) 90 1·0 (1·3) 0·1 (-0·2 to 0·4)
Partner-bonding/family
   Baseline 102 1·3 (1·7) 94 1·3 (1·8)
   Average 4 to 8 months 94 1·3 (1·5) 90 1·0 (1·3) 0·3 (0·1 to 0·6)*
Table 3 Primary and secondary health outcomes with summary index and subscale scores
ALDS Academic Medical Centre linear disability score; PDQL  Parkinson’s Disease Quality of Life questionnaire; UPDRS III 
Unified Parkinson’s Disease Rating Scale motor part; BELA-A-k  Belastungsfragebogen Parkinson Angehörigen - kurzver-
sion, Bothered By subscale.
* Statistically significant, p<0.05
† These values correspond with  original measurements units (logits) of  0·1 (95%CI 0·003 to 0·2)
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n 
Intervention group
Mean (SD) n
Control group
Mean (SD)
Estimated difference
(95%CI)
HADS Anxiety 
   Baseline 145 6·1 (4·0) 151 4·9 (3·5)
   Average 4 to 8 months 141 4·9 (3·5) 144 4·9 (3·3) -0·7 (-1·3 to -0·2)*
HADS Depression 
   Baseline 145 5·4 (3·8) 151 4·9 (3·6)
   Average 4 to 8 months 141 4·7 (3·4) 144 5·0 (3·6) -0·5 (-1·0 to -0·1)*
FES-I 
   Baseline 136 25·9 (9·3) 151 25·2 (8·8)
   Average 4 to 8 months 141 25·7 (9·4) 143 26·5 (9·8) -1·2 (-2·4 to 0·1)
FOGQ 
   Baseline 138 6·0 (4·7) 151 6·0 (5·3)
   Average 4 to 8 months 141 5·8 (4·7) 144 6·4 (5·2) -0·3 (-0·9 to 0·2)
SPDDS 
   Baseline 149 38·2 (11·1) 151 36·7 (11·1)
   Average 4 to 8 months 141 37·4 (11·4) 144 38·1 (12·8) -1·5  (-2·9 to -0·1)*
NMS Scale 
   Baseline 146 47·3 (38·7) 145 35·7 (35·6)
   Average 4 to 8 months 138 37·6 (36·5) 140 38·9 (38·5) -9·8 (-15·8 to -3·7)*
Cardiovascular
   Baseline 146 1·5 (3·2) 145 0·9 (2·3)
   Average 4 to 8 months 138 0·6 (1·9) 140 0·8 (2·4) -0·3 (-0·8 to 0·2)
Sleep/fatigue
   Baseline 146 11·1 (11·1) 145 7·2 (9·1)
   Average 4 to 8 months 138 7·8 (9·5) 140 7·6 (9·1) -1·5 (-3·3 to 0·4)
Mood/cognition
   Baseline 146 6·2 (11·3) 145 3·1 (7·6)
   Average 4 to 8 months 138 4·7 (9·3) 140 4·1 (8·9) -1·0 (-2·9 to 0·9)
Perceptual problems
   Baseline 146 0·9 (3·2) 145 1·2 (3·1)
   Average 4 to 8 months 138 1·0 (3·8) 140 1·2 (3·1) 0·08 (-0·5 – 0·6)
Attention/memory
   Baseline 146 5·2 (7·1) 145 4·3 (7·2)
   Average 4 to 8 months 138 4·4 (6·8) 140 4·4 (7·1) -0·3 (-1·6 to 1·0)
Gastrointestinal
   Baseline 146 4·8 (6·7) 145 4·2 (6·3)
   Average 4 to 8 months 138 4·2 (7·1) 140 5·1 (7·3) -1.4 (-2·6 to - 0·1)*
Urinary
   Baseline 146 9·2 (10·9) 145 7·6 (10·1)
   Average 4 to 8 months 138 7·9 (10·5) 140 9·0 (10·1) -2·4 (-4·3 to - 0·6 )*
Sexual function
   Baseline 146 3·3 (6·0) 145 2·0 (4·3)
   Average 4 to 8 months 138 2·4 (5·7) 140 1·5 (2·7) 0·5 (-0·5 to 1·6)
Miscellaneous
   Baseline 146 5·3 (7·8) 145 5·2 (7·3)
   Average 4 to 8 months 138 4·7 (6·7) 140 5·4 (7·7) -0·7 (-2·1 to 0·7)
Table 4 Tertiary health outcomes 
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8n Intervention group Mean (SD) n Control groupMean (SD) Estimated difference(95%CI)UPDRS IV   Baseline 148 2·6 (2·5) 150 2·4 (2·2)
   Average 4 to 8 months 137 2·1 (2·1) 139 2·4 (2·1) 0·4 (- 0·8 to 0·06)
SF-36 
Physical functioning
   Baseline 149 61·6 (24·3) 150 61·7 (25·5)
   Average 4 to 8 months 141 62·7 (24·5) 144 60·8 (25·7) 1·6  (-1·4 to 4·5)
Role physical
   Baseline 148 51·6 (24·3) 150 56·6 (25·9)
   Average 4 to 8 months 141 54·8 (23·9) 144 54·7 (25·2) 4·1 (0·3 to 7·9)*
Role emotional
   Baseline 148 70·6 (27·0) 150 72·6 (26·9)
   Average 4 to 8 months 141 70·6 (23·0) 144 66·7 (24·4) 4·7 (0·7 to 8·6)*
Vitality
   Baseline 149 56·3 (17·8) 150 60·4 (19·2)
   Average 4 to 8 months 141 58·2 (17·4) 144 58·6 (19·2) 2·7 (0·02 to 5·4)*
Mental Health
   Baseline 149 69·8 (17·6) 150 72·4 (16·7)
   Average 4 to 8 months 141 71·1 (16·3) 144 71·8 (17·6) 1·3 (-1·1 to 3·7)
Social functioning
   Baseline 149 73·8 (24·2) 150 77·8 (21·3)
   Average 4 to 8 months 141 74·9 (21·1) 144 75·6 (20·6) 1·8 (-1·7 to 5·4)
Pain
   Baseline 149 70·9 (24·1) 150 72·3 (24·6)
   Average 4 to 8 months 141 71·4 (22·6) 144 72·9 (22·7) -0·9 (-4·7 to 2·8)
General health perception
   Baseline 149 50·2 (16·3) 151 50·7 (18·4)
   Average 4 to 8 months 141 51·6 (16·6) 144 50·4 (18·3) 1·5  (-1·2 to 4·2)
Health transition
   Baseline 149 60·7 (19·6) 151 54·5 (22·4)
   Average 4 to 8 months 141 57·6 (21·2) 144 59·2 (17·4) -3·6 (-7·6 to 0·3)
VAS general health 
   Baseline 149 68·2 (13·9) 150 71·0 (14·5)
   Average 4 to 8 months 141 69·0 (12·4) 144 67·4 (13·9) 3·1 (0·8 to 5·4)*
PSI-PD
   Baseline 138 53·4 (17·9) 136 53·9 (17·3)
   4 months 128 53·8 (18·5) 130 57·2 (18·7) -3·3 (-5·3 to -1·2)
Single leg stance
   Baseline 149 16·1 (11·4) 148 13·0 (11·6)
   4 months 138 16·6 (11·0) 138 13·5 (10·9) 1·5 (-0·7 to 3·6)
PAS
   Baseline 123 50·8 (5·7) 108 47·9 (5·0)
   4 months 123 49·1 (6·5) 108 48·9 (5·4) -1·3 (-2·4 to -0·3)
Turning 3600 (seconds)
Normal speed: left
   Baseline 129 5·4 (5·5) 138 4·8 (1·8)
   4 months 133 4·8 (2·6) 132 4·3 (1·7) 0·3 (-0·15 to 0·73)
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Normal speed: right
   Baseline 129 5·5 (5·7) 137 4·6 (2·0)
   4 months 133 4·8 (3·5) 132 4·3 (1·7) 0·17 (-0·27 to 0·61)
Increased speed: left
   Baseline 129 3·9 (5·1) 137 3·7 (3·9)
   4 months 129 3·5 (3·0) 128 3·1 (1·3) 0·19 (-0·94 to 0·47) 
Increased speed: right
   Baseline 129 4·1 (5·8) 137 3·3 (1·5)
   4 months 129 3·5 (2·8) 128 3·1 (1·2) 0·08 (-0·20 to 0·36)
Quality of care# 
Questionnaire score
   4 months 127 70·7 (13·5) 141 65·6 (13·9) -5·0 ( -8·3 to - 1·7)
Overall satisfaction 
   4 months 126 7·6 (1·0) 138 7·4 (1·3) -0·2 ( -0·5 to 0·1)
Care costs (€)
   Baseline† 150 850 (1174) 151 1347 (2733)
   Over 8 months studyperiod 150 4478 (5546) 151 5601 (12258) 742 (- 489 to 1950)
CAREGIVER HEALTH MEASURES
HADS Anxiety 
   Baseline 102 4·8 (3·6) 94 4·0 (3·2)
   Average 4 to 8 months 94 4·7 (3·3) 90 4·0 (2·7) 0·2 (-0·4 to 0·7)
HADS Depression 
   Baseline 102 2·9 (3·1) 94 2·7 (3·1)
   Average 4 to 8 months 94 3·1 (3·0) 90 2·8 (2·5) 0·1 (-0·3 to 0·6)
SF-36 
Physical functioning
   Baseline 102 82·6 (20·3) 94 80·5 (22·6)
   Average 4 to 8 months 94 81·7 (21·3) 90 81·2 (21·1) -0·3 (-3·4 to 2·9)
Role physical
   Baseline 102 75·7 (26·7) 94 71·5 (25·1)
   Average 4 to 8 months 94 73·4 (21·9) 90 70·3 (24·0) 0·5 (-3·8 to 4·2)
Role emotional
   Baseline 102 78·0 (25·9) 94 81·0 (21·2)
   Average 4 to 8 months 94 79·3 (20·4) 90 79·6 (20·9) 0·9 (-3·7 to 5·5)
Vitality
   Baseline 102 66·1 (16·8) 94 67·9 (16·9)
   Average 4 to 8 months 94 67·0 (14·7) 90 68·1 (15·8) 0·6 (-2·2 to 3·4)
Mental Health
   Baseline 102 73·6 (17·3) 94 78·5 (15·3)
   Average 4 to 8 months 94 74·1 (15·7) 90 79·1 (13·3) -1·6 (-4·3 to 1·1)
Social functioning
   Baseline 102 85·5 (17·9) 94 85·5 (19·1)
   Average 4 to 8 months 94 85·4 (17·8) 90 85·0 (16·5) 0·5 (-3·3 to 4·3)
Pain
   Baseline 102 79·5 (22·8) 94 79·8 (20·5)
   Average 4 to 8 months 94 79·6 (22·4) 90 79·5 (19·5) 0·09 (-3·8 to 4·0)
n 
Intervention group
Mean (SD) n
Control group
Mean (SD)
Estimated difference
(95%CI)
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HADS Hospital Anxiety and Depression Scale; FES-I  Falls Efficacy Scale-International; FOGQ Freezing Of Gait Question-
naire; SPDDS Self-assessment Parkinson’s Disease Disability Scale; NMS Scale  Non-Motor Symptoms Scale; UPDRS IV 
Unified Parkinson’s Disease Rating Scale, Complications of therapy; SF-36 Short-Form 36; VAS Visual Analogue Scale; 
PSI-PD Patient Specific Index for Parkinson’s Disease, ALDS Academic Medical Centre linear disability score. 
* Statistically significant, p<0.05
# Measured at 4 months only; analysed with independent sample t-test
† over 8 weeks for enrolment
§These values correspond with  original measurements units (logits) of  0·10 (95%CI -0·05 to 0·24, p = 0·18)
General health perception
   Baseline 102 65·9 (18·6) 94 66·9 (20·0)
   Average 4 to 8 months 94 65·4 (18·3) 90 66·9 (19·0) 0·5 (-2·7 to 3·7)
Health transition
   Baseline 100 52·5 (15·7) 94 55·6 (15·6)
   Average 4 to 8 months 94 51·1 (15·3) 90 54·2 (10·8) -1·5 (-4·9 to 1·8)
Caregivers view on patients’ ADL
   Baseline 102 78·7 (10·6) 94 78·7 (11·8)
   Average 4 to 8 months 94 79·8 (9·8) 90 78·2 (12·9) 1·2 (-0·4 to 2·8)§
n 
Intervention group
Mean (SD) n
Control group
Mean (SD)
Estimated difference
(95%CI)
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PD is progressive and disabling disorder, which is typically accompanied by a range of 
motor and non-motor features. This broad symptom complex, combined with a highly 
variable individual presentation and progression of the disease, poses a significant 
treatment challenge to medical specialists. This thesis aimed to cover the broad symp-
tom complex in a structured way, covering the spectrum from identification of indi-
vidual symptoms to an integrated treatment approach. The multidimensional nature 
of PD was illustrated by addressing unintentional weight loss and falls. This complexity 
of PD calls for team-based care, but it is unknown how this team approach should be 
organised to offer optimal care for PD patients and their caregivers. Therefore, we also 
addressed the effectiveness of allied health care interventions and two different organ-
isations of team-oriented models in this thesis. 
Weight loss 
Chapter 2 and 3 addressed unintentional weight loss, which is common among PD patients. 
The work described in these chapters showed the complexity of weight loss by summing the 
various causes, and by providing evidence that PD patients have a lower Body Mass Index 
(BMI) when compared to controls. 
In Chapter 2, we reviewed the various potential causes of unintentional weight loss in PD. 
This review showed that various symptoms might lead to different levels in energy balance, 
i.e. reduced energy intake, reduced intestinal energy absorption and increased energy expen-
diture. The factors that are co-responsible for unintentional weight loss in PD include not only 
those that are directly related to neuronal dysfunction and neurodegeneration (like motor 
disturbances, altered olfaction and cognitive problems), but also secondary factors  that are 
not directly attributable to the neurodegenerative processes itself, but which are nevertheless 
common, like nausea and other side effects of medication. Because weight loss and low body 
weight are associated with increased morbidity and mortality, timely detection of weight 
changes is important for adequate intervention. We addressed some therapeutic strategies 
and implications for better patient care, for example to improve food intake by offering food 
more frequently in between meals, and the use of flavour enhancers. Also, changes can be 
made to the medication regime in order to reduce potential adverse effects. Moreover, nutri-
tional supplements may be used to ensure adequate intake. Overall, a team approach seems 
warranted in light of the complexity and multifactorial nature of unintentional weight loss in 
PD. This complexity is not unique for PD, but applies to other neurodegenerative disorders 
as well. This was also illustrated in this chapter by reviewing the pathophysiology underly-
ing three different major neurological disorders (PD, Alzheimer’s disease and Huntington’s 
disease), summing both common (i.e. generic across conditions) and disease-specific features 
for each of these three conditions. 
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9Unintentional weight loss in PD is caused by a complex interplay of multiple contributing factors. For an adequate intervention, timely detection is important, and a multispecialty team will be required to tackle all causative factors. 
A meta-analysis on the literature on body weight in PD patients and controls
Weight loss is frequently described in PD. There is, however, a controversy whether patients 
have a lower body weight than controls since differences described in the literature were 
not always statistically significant. Therefore, we performed a meta-analysis to establish if PD 
patients indeed weighted less compared to controls (Chapter 3). In addition, we looked at 
possible determinants. After a literature search, 12 studies were included that met our inclu-
sion criteria. These combined data showed that patients with PD have a significantly lower 
BMI of 1.73 (95%CI 1.11-2.35) compared to controls. Hoehn & Yahr (HY) stage was reported 
in seven studies and pooled data showed a relation with BMI. Patients with HY stage 3 had 
a significantly lower BMI compared to patients with HY stage 2 (3.9, 95%CI 0.1 - 7.7). Other 
determinants were inconsistently reported, and did not allow further analysis.
Patients with PD weight significantly less than controls. Disease severity appears to be 
one of the determinants of weight loss. 
Falls prevention
The complexity of PD was further illustrated by providing a comprehensive overview of fall 
risk factors. Falls are a common and devastating consequence in PD, fuelling the need for 
falls prevention in this population. Therefore, consensus-based clinical practice recommenda-
tions for prevention of falls in PD was presented in Chapter 4. We developed a set of concept 
recommendations which was evaluated during two rounds. First, it was evaluated by 27 clini-
cally active professionals from multiple specialties, and subsequently by 12 falls experts in 
the field, also from several disciplines. For each risk factor, the following items were evalu-
ated: best method of ascertainment; disciplines that should be involved in the assessment 
and treatment; and which interventions could be engaged. Risk factors and their associated 
interventions were included in the final set of recommendations when at least 66% of the 
reviewing experts agreed. The final overview provided a summary of 31 risk factors to be 
considered by healthcare teams. These included generic risk factors, like age, side-effects of 
medication and postural hypotension, and disease-specific risk factors, such as slow mobility, 
freezing of gait and postural instability. Almost all risk factors required a multispecialty team 
approach for management, with important roles for the neurologist and PD-nurse specialist. 
Finally, the expert panel opted for a tailored approach to first identify the specific fall type and 
to adapt screening and treatment accordingly, over a one-size-fits-all approach including all 
risk factors for each patient. A routine evaluation of all risk factors remains reserved for high-
risk patients without prior falls, or for patients with seemingly unexplained falls.
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We developed clinical practice recommendations for the management of falls in PD. Falls 
prevention in PD is complex, because the risk of falls in this population includes both 
generic, age-related as well as disease-specific risk factors. Therefore, a multispecialty 
team approach is required that should preferably be tailored to each patient’s individual 
risk factors. 
A new system to monitor fall events: the Falls Telephone
When evaluating the prevalence of falls and effectiveness of falls prevention programs, accu-
rate information about the occurrence fall events is needed. In Chapter 5 we described the 
evaluation of an automated telephone system for fall monitoring that could provide a low-
cost method for tracking falls for longitudinal studies. This so called “Falls Telephone” consists 
of a computerized system that automatically makes periodic phone calls (done at an inves-
tigator-defined interval), allowing participants to enter the number of falls experienced in 
the preceding period. We designed an evaluation study to determine the sensitivity, specific-
ity and acceptability of the Falls Telephone, using a set-up where the patients were called 
at weekly intervals. 119 community-dwelling, non-demented PD patients were followed for 
one to 40 weeks (mean 20.7 calls per patient). In total, 2465 calls were made. Of these, 173 
“no- fall” entries and 115 “fall” entries were verified by personal telephone interviews. We veri-
fied whether entries were correctly stored, and whether the reported number of falls repre-
sented their actual number of falls in the previous week. All “no-fall” entries and 78% of “fall” 
entries were confirmed to be correct. Sensitivity to detect falls was 100% and specificity was 
87%. With this high specificity, the Falls Telephone obviates the need for time-consuming and 
costly personal follow-up calls in the majority of non-fallers. Also, user experiences were eval-
uated in a subgroup of 90 patients during telephonically interviews with questions on several 
aspects of the usability. We also discussed several alternative ascertainment methods that are 
frequently used to monitor falls events, such as a falls calendar, fortnightly postcards and a 
falls hotline, in light of their experience with the Falls Telephone. Findings showed that users 
regarded the Falls Telephone as a convenient and attractive tool to monitor falls. In addition, 
cost estimates were provided. Based on a fictive trial of 50 subjects with weekly calls over a 
one year follow-up, the Falls Telephone was estimated to likely save costs, mainly on person-
nel requirements.  
The Falls Telephone offers an effective, convenient and reliable tool way to monitor falls 
in population-based studies in patients with PD, and possibly also for other disorders 
complicated by falls.  
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9Team-based careThe multidimensional nature of PD and the shortcomings of current medical management to adequately control all symptoms call for a broad approach with input from multiple disciplines, as opposed to the single-clinician management which is still the dominant approach for 
many patients. A team-oriented approach is increasingly regarded as the optimal model to 
treat a complex disorder like PD. Yet, there is no standard template on how to organize such 
an approach and there is only limited scientific evidence to support this widespread positive 
perspective of team-oriented models. Chapter 6, 7, and 8 focused on the advantages of 
complementary interventions beyond current medical management. 
The scientific evidence to support the merits of individual allied healthcare interventions 
in PD and multidisciplinary approaches was summarized in Chapter 6. These interventions 
include physiotherapy, occupational therapy, and speech-language therapy. Allied healthcare 
can complement current medical management in terms of focus (impact on daily functioning 
rather than the primary disease process), treatment goal (improve participation in everyday 
activities), and working mechanism (try to bypass the defective basal ganglia by engaging 
alternative neural circuitries that are still intact). Nowadays, there is increasing evidence 
to support the effectiveness of these professions when delivered as a monodisciplinary 
intervention: class II for both physiotherapy and speech-language therapy, and class III for 
occupational therapy.1-3 Despite overlapping treatment goals, allied health carers and medical 
specialists often work isolated from each other. A team approach, in which multiple disciplines 
work together, is widely suggested to represent the optimal treatment approach, in light of 
the broad symptom complex in PD. So far, however, there is only limited scientific evidence to 
support this contention, and only a few controlled trials have thus far evaluated team-based 
interventions in PD.  
The scientific evidence for isolated allied healthcare interventions is growing. Prefera-
bly, these specialists should work together as a team, instead of working parallel to one 
another. Although there is a general feeling that such a multispecialty team approach 
is important and may offer benefits, so far there is only limited research on this topic to 
support this positive perspective of a team-oriented approach. 
A multidisciplinary specialised team approach
In Chapter 7, we described the evaluation of a multidisciplinary team model, defined as 
specialised care by a movement disorders specialist, PD nurse and social worker, whose 
input was tailored to the patients’ individual needs. We studied the effectiveness of 
this multidisciplinary care approach (intervention group, n=51) through a single-blind 
randomized controlled trial (RCT) with a waiting list control group (n=49) that received care 
from a neurologist only. After 8 months, there were improvements in the group randomized 
to the multidisciplinary team. Subjects in the intervention group improved on quality of 
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life (PDQ-39, difference 3.4, 95%CI 0.5 – 6.2) and motor scores (UPDRS III, 4.1, 95%CI 0.8 – 
7.3) compared to the control group. Also, total UPDRS (5.6, 95%CI 0.9 – 10.3), measures of 
depressive symptoms (MADRAS, 3.7, 95%CI 1.4 – 5.9) and psychosocial function (SCOPA-PS, 
2.1, 95%CI 0.5 – 3.7) were improved in the intervention group. Caregiver burden (CSI) was 
not different between groups (1.5, 95%CI -1.2 –  4.2). This is one of the first RCTs that gives 
credence to a multidisciplinary/specialist team approach. 
In a single-blind randomized controlled trial, we offer new evidence that specialised care 
by a multidisciplinary team – consisting of a movement disorders specialist, PD nurse and 
social worker – offers benefits in several health-related domains (quality of life, motor 
scores, depression and psychosocial functioning). This is one of the first RCTs that gives 
credence to a multidisciplinary/specialist team approach.
Towards an integrated model of PD care
Chapter 8 described a large controlled trial aiming to evaluate the effectiveness of an 
integrated organisation of care. This healthcare model included two complementary elements: 
(a) an individualized assessment within an expert centre, resulting in set of treatment advices 
that should next be implemented within (b) regional networks of collaborating allied health 
professionals. Patients were offered a three-day assessment by a comprehensive team, 
whose input was tailored to the patient’s own needs and priorities (identified by patients 
before their actual visit to our center, using a comprehensive screening questionnaire). 
The disciplines included movement disorders specialist, PD nurse specialist, social worker, 
physiotherapist, occupational therapist, speech therapist, sleep specialist, dietician, 
sexologist, neuropsychologist, neuropsychiatrist, rehabilitation specialist, and geriatrician. 
During an integrated meeting (attended by all health professional involved in the assessment 
of a particular patient), treatment advices were developed. This advice could be implemented 
by specialised therapists within the patient’s vicinity, under supervision of the patient’s own 
neurologist. These specialised allied health professionals (physiotherapists, occupational 
therapists, and speech-language therapists) worked within regional ParkinsonNet networks.4-5 
Key elements of these networks included specific training, treatment according to evidence-
based guidelines, structuring of referral process, and optimization of communication and 
collaboration between specialists. 
We designed a controlled trial comparing intervention region (with the integrated care 
model; n=150 PD patients) with control regions (usual care; n=151 patients). Effectiveness 
was evaluated over a 4 to 8 month period after baseline assessment. The primary outcomes, 
activities of daily living and quality of life, were significantly improved (ALDS 1.3, corresponding 
with raw logit 0.1, 95%CI 0.003 – 0.2; PDQL 3.0, 95%CI 0.4 – 5.6). These effects were, however, 
small and disappeared after correction for disease severity at baseline. Secondary outcomes, 
which were motor scores (UPDRS III) and caregiver burden (BELA-A-k), did not change. A 
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9range of tertiary health outcomes, including non-motor symptoms, anxiety and depression and perceived general health, showed consistent but small improvements. Costs data from a societal perspective did not show statistical differences between the groups over the 8 months follow-up (mean difference €742, 95%CI -€489 – €1950). 
In a large controlled trial (the IMPACT study), we showed that an integrated organisation 
of PD care, including an expert centre complemented by regional networks of specialised 
therapists, offered only small benefits. Moreover, these improvements disappeared after 
correction for baseline severity. This trial does not provide evidence that the specific inte-
grative specialised approach tested here offers a more effective model of PD healthcare 
over usual multispecialty care. One possible explanation is that, while we performed the 
trial, usual care gradually changed in the Netherlands and also became more multispe-
cialty, thereby diluting the contrast between the study arms.
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Parkinson’s disease (PD) poses a significant challenge to medical specialists with respect to 
both the diagnosis and treatment, due to the wide variety of motor and non-motor symptoms 
that typically present in patients with PD. Despite this complexity, PD is a treatable disease, 
and there is more to management than solely drugs. This thesis focused on the multifaceted 
nature of PD, describing the road from individual symptoms towards team-oriented care 
approaches. We underscore that such a team approach should also include non-pharmaco-
logical interventions, to control the broad symptom complex. It is evident that PD requires 
expert care delivered by a multispecialty team, and in this thesis, we illustrate this for two 
specific topics: unintentional weight loss; and fall prevention. Indeed, to optimally treat the 
various domains affected by PD, a multidisciplinary approach with access to expert care has 
been recommended by professional guidelines.1-2 Quality indicators of PD care also empha-
size the importance of a broad approach to manage PD.3-4 A recent Task force of the American 
Academy of Neurology has provided a core set of quality measures that should guide clini-
cians in the management of patients with PD, and most of these indicators focus on the non-
motor manifestations.4 
In this thesis, we have described our experience with two types of organisation of team 
healthcare in two different centres. These two approaches have been evaluated in two differ-
ent trials, aiming to identify evidence for their effectiveness on a range of health outcomes. 
Here, we will discuss some of the lessons that we have learned about multifaceted manage-
ment in PD. These will be addressed below by means of the following three themes: (1) the 
organisation of care, (2) clinical effectiveness, and (3) challenges to clinical research on multi-
faceted interventions.     
 
What’s in a name? Multispecialty vs multidisciplinary vs multifaceted
Throughout this thesis different words are used, including multispecialty, multidisciplinary and multifac-
eted. In this discussion, the following definitions are used: by “multispecialty” we mean that multiple health 
professionals from multiple disciplines are involved. “Multidisciplinary” care is commonly used to describe 
such a multispecialty approach. Yet, as we adhere to the terminology of Boon et al.5, we interpret the term 
“multidisciplinary” care as one of the models to organise team collaboration. Although distinctions are 
made between organisations of healthcare, the terminology is often used interchangeably and many 
synonyms are used  to describe team approaches (e.g., multiprofessional, interprofessional and transdisci-
plinary care).6 Moreover, we use “multifaceted” care to indicate the broader approach to manage PD with 
several elements of care, independent of whether this is provided by one or multiple disciplines. 
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10I. Organisation of careAlthough care provided by multiple specialists appears to be the optimal treatment for a complex disorder such as PD, there is no standard template to organise such a team-oriented approach. As a result, the organisation of these team-based approaches differs widely across 
different Parkinson centres worldwide.7 Indeed, the two approaches8-9 that we presented in 
this thesis shared common elements (e.g., multispecialty, PD expertise, tailored care), but also 
differed in many ways regarding the actual implementation of care. Table 1 provides an over-
view of the design of healthcare teams from these two different models. Here, we will discuss 
some of these elements in more detail. 
Guttman trial8
 (Chapter 7)
IMPACT trial9
(Chapter 8)
Disciplines Relatively small team: 
l   movement disorders specialist
l   PD nurse
l   social worker
Comprehensive team: 
l   movement disorders specialist
l   PD nurse specialist
l   social worker
l   physiotherapist  
l   occupational therapist 
l   speech-language  therapist 
l   sleep specialist
l   dietician
l   sexologist
l   neuropsychologist
l   neuropsychiatrist
l   rehabilitation specialist
l   geriatrician
Organisation of 
team work
Multidisciplinary model, 
hierarchically structured with daily 
contact between team members 
Integrative model with two components: 
(1) an expert centre, that used consensus 
and shared decision-making during 
regular integrated team meetings; 
and (2) regional networks facilitating 
collaboration between community 
healthcare providers
Individually 
tailored
Consultation by movement 
disorders specialist, complemented 
with individually tailored input of 
PD nurse and social worker
Individually tailored intervention, 
with movement disorders, PD nurse 
and physiotherapist as standard team 
members supplemented by optional 
input of other team members; Needs 
and priorities ranked by patient
Setting and 
implementation 
of treatment
Expert centre; outpatient clinical 
service. General neurologist no 
longer involved
Expert centre and community networks; 
outpatient clinical service. Treatment 
by community neurologist and local 
healthcare providers outside centre
Usual care 
(Comparator/
control arm)
General neurologist; 
Access to allied health therapists, 
but lack of expertise 
Predominantly the general neurologist, 
sometimes supported by PD nurse; 
Access to allied healthcare, but 
inadequate referrals and lack of 
expertise53  
Table 1 Similarities and differences of the two multispecialty team interventions
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Team formation
No standard template
As described previously, PD comprises a complex set of motor and non-motor symptoms (Box 
2, Chapter 1). Guidelines recommend that patients should be referred and have access to a 
wide range of therapists.1-2 Indeed, over twenty healthcare professionals might be involved 
in PD care to optimally treat this broad symptom complex (Box 4, Chapter 1 Introduction).1 
There is, however, no standard list of disciplines that should be involved in PD care, and it is 
not known which combination of team members is best, nor what the relative contribution of 
each specialist within a team can be. Keeping the heterogeneity of symptoms and individual 
priorities among PD patients in mind, an individually tailored team arrangement seems pref-
erable over a “one size fits all” approach. 
A broad team for a complex disorder 
In the last few years, the non-motor symptoms have increasingly been acknowledged as a 
significant component of the PD phenotype. These non-motor symptoms are very common, 
even in early stages of the disease.10 Nevertheless, despite their high prevalence, these non-
motor symptoms mostly remain unrecognised and untreated.11-12 The NMS (Non Motor Symp-
tom) Questionnaire13 and Scale14 might be helpful instruments for clinicians to better identify 
these non-motor symptoms. and to select the appropriate team members accordingly. Multi-
specialty teams should include a wide range of medical specialists. In general, the neurologist 
and specialised nurse are identified by both professionals and patients as key contributors 
to optimal PD care.1,15-17 These two disciplines were also considered as the most important 
profession that could contribute to fall prevention (Chapter 4). Indeed, regular access to 
neurologists is recommended by clinical guidelines as a part of good PD management, 1-2,15 
and these neurologists should preferably be specialised in movement disorders.15-16,18-19 Also, 
regular access to PD nurse specialists is recommended, and their involvement may offer addi-
tional support to patients and their informal carers.1-2 A range of other health professionals 
can complement medical management, each contributing their own specialty care (see Box 
4 in Chapter 1 for a list of healthcare providers that might be involved in PD care). In fact, 
regular access to physiotherapy, occupational therapy and speech-language therapy is also 
recommended by professional guidelines.2 An even broader approach should be considered 
for patients with needs in several other domains, including depression, sleep problems and 
psychosocial functioning.20-22 A multispecialty assessment is also recommended to manage 
weight and nutritional issues in PD (Box 1), and for fall prevention programmes (Box 2).
Current evidence on ‘monodisciplinary’ interventions
The scientific evidence to support the merits of ‘monodisciplinary’ interventions is increas-
ing and several clinical practice guidelines are currently available (Chapter 6).23 The number 
of trials on the effectiveness of physiotherapy has increased rapidly over the years24 and the 
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efficacy of physiotherapy has been shown in trials with short-term follow-up (i.e. less than 
three months).25 More well-designed trials are needed, focusing especially on the long-
term effectiveness of these physiotherapeutic interventions.25 Although the evidence is also 
increasing for speech-language therapy, there is still insufficient evidence on the efficacy of 
speech-language therapy to conclusively support or refute the efficacy of therapy for speech 
problems in PD.26-27 Good scientific evidence to support occupational therapy in PD is lacking 
so far28, but research is on the way. The effectiveness of occupational therapy based on the 
Dutch guideline is currently being investigated in an RCT (the OTiP study).29 PD nurses are 
closely involved in several aspects of care, including counselling, coping with PD and social 
concerns. However, the evidence for the effectiveness of nursing care alone for PD patients 
also remains limited and inconclusive so far.30 Hence, there is a need for further and more 
intensive scientific research on these and other ‘monodisciplinary’ interventions, given the 
scarcity of high quality evidence to date.1,31 
BOX 1 Monitoring weight and nutritional status
We showed that PD patients weigh less than controls (Chapter 3) and that various nutrition-related symp-
toms are present in PD (Chapter 2). Additionally, it has been shown that malnutrition is frequent in this 
population and that a substantial part of PD patients are at risk for malnutrition, with prevalence exceeding 
numbers seen in the general population.79-81 
Screening
We recommend routinely recording body weight and nutritional status as part of the management of PD. 
It should be noted that PD is characterised by a gradual decline in body weight, which might be missed by 
conventional instruments (e.g. MUST, SNAQ) that are primarily aimed at determining weight changes due 
to acute illness. Dieticians should ideally be included as member of the multispecialty Parkinson team to 
monitor (and treat) these patients. 
Treatment by multispecialty team
Both PD and the treatment result carry the risk of inducing or worsening weight loss and malnutrition. This 
warrants a multispecialty approach by a team of PD specialists.82-84 Obviously, dieticians will have an impor-
tant role, for example by providing nutritional interventions.85 Neurologists should be aware of weight 
changes as daily levodopa dose per kg body weight (rather than the absolute daily intake) has been shown 
to represent a significant factor for dyskinesias.86-87 A range of other specialists, including occupational 
therapists, speech-language therapists, PD nurses, and general practitioners, might be part of the team 
approach to weight loss and malnutrition as well.85
Recommendations for clinical practice 
Recently, a best practice guideline has been developed in the Netherlands for nutritional care in PD.85 
Although a broad range of nutritional risk factors have been identified, the effectiveness of nutritional 
interventions and their influence on the course of PD remains unknown and requires future investiga-
tion.82,88 While awaiting more evidence, the guideline can now be implemented in clinical practice as a 
first step to harmonize treatment and to offer professionals some guidance to shape their intervention. 
As indicated above, all PD patients should be monitored regularly for changes in body weight and nutri-
tional status. Accordingly, energy and nutritional deficiencies should be treated, as well as symptoms and 
side effects that cause these changes. Although residential patients are less often represented or even not 
included in PD nutrition research, this vulnerable population should not be overlooked in clinical care. 
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Patient and their carers as team members
Effective team-based care comes with the recognition that patients as well as their informal 
caregivers should be actively involved as part of the healthcare team.2,7,32 It is important to 
incorporate the experiences and expectations of patients as a meaningful part of the treat-
ment plan. All multidisciplinary team interventions tested so far have largely been driven by 
professionals. However, there is increasing evidence that active involvement of patients helps 
to improve the quality of care and may reduce healthcare costs.33-35 PD patients wish to be 
more actively involved in self-management,36 and evaluating whether and how these patients 
in various disease stages can achieve this is an interesting challenge.
Types of collaboration between members of healthcare teams
There are various ways to implement a team approach (Box 5, Chapter 1 Introduction). These 
range from relatively simple models in which professionals work independently from each 
other. At best, the individual professionals have incidental consultations with colleagues to 
share expert advices at an individual case level. We reasoned that a more formalised and 
complex approach of teamwork would be more efficient and effective. Based on the commu-
BOX 2 Multifactorial fall prevention
Falls are a common and devastating consequence in PD, fuelling the need for fall prevention in this popu-
lation. Based on the literature, guidelines and expert opinion, we developed an overview of recommen-
dations  for the examination and management of falls in patients with Parkinson’s disease including an 
overview of all generic and disease-specific fall risk factors in PD (Chapter 4). 
Screening
Our set of recommendations provides insight into the complex nature of falls in PD, with a wide range of 
generic and PD-specific risk factors. For each risk factor, assessment methods were provided. We recom-
mend to routinely query falls and to screen for fall risk factors as part of everyday PD management.   
Treatment by multispecialty team
In light of the complexity of falls in PD, a multispecialty approach is likely needed to adequately screen for 
falls and to implement fall prevention strategies. Neurologists and PD nurses are the key professions within 
the falls prevention team, together with general practitioners and geriatricians (to tackle the generic risk 
factors) as well as physiotherapists (to address the PD-specific factors). A range of other health specialists 
might also be involved, including rehabilitation specialists, occupational therapists and clinical pharma-
cists.89 
Recommendations for clinical practice
While awaiting further evidence on fall prevention strategies in PD populations, the clinical practice recom-
mendations  can now be implemented as part of PD management. An individually tailored approach is 
preferred to systematically address the many fall risk factors for each patient. Follow-up is needed to ascer-
tain that patients actually adhere to the recommendations. Furthermore, routine monitoring will be neces-
sary to detect changes in risk profile when the disease progresses. Our Falls Telephone (Chapter 5) might 
serve as an easy and reliable tool to monitor fall incidents. This automated system has already been used 
in PD populations (IMPACT trial9, Parkfit study90), and is suitable for monitoring fall incidents among frail 
older persons.91 
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10nication and collaboration between the various team members, three different concepts can be distinguished: multidisciplinary care, interdisciplinary care and integrative care. Multidis-ciplinary care involves multiple health professionals who are each responsible for a specific patient care need. This model can be extended to the interdisciplinary team approach, in 
which team members work collaboratively through regular face-to-face meetings and make 
group decisions. The integrative model of care is characterised by a shared, synergistically 
charged plan of care guided by consensus building in which each health professional contrib-
utes with his or her knowledge and skills and engages patients as team members.5 
The optimal model?
Integrative models are considered to be the most complex, in terms of number of participants 
involved, in terms of number of health determinants that are to be addressed, in terms of an 
increased need for communication and synergy, and in terms of emphasis on the individual 
patient as a whole. However, integrative models do not by definition represent the optimal 
model for organising healthcare. In fact, it is still unclear which type of healthcare delivery 
offers the greatest benefits to PD patients. In the Guttman trial (Chapter 7), we showed that 
a multidisciplinary care approach offered improved outcomes compared to stand-alone care 
from a neurologist. Whether more complex organisations of team healthcare (e.g. interdisci-
plinary or integrated approaches) would result in even better outcomes, remains to be estab-
lished. In fact, we evaluated an integrated model of care in the IMPACT trial (Chapter 8). This 
theoretically represents an optimal organisation to shape team collaboration that extends 
into the community. However, we were unable to show that this approach was a lot more 
effective, as this approach resulted in only minor health benefits over and beyond usual care 
in the Netherlands. We will offer several explanations for this limited effectiveness below.
Integration of health professionals
Based on interviews with patients and carers in the Parkinson Centre Nijmegen we know 
that besides PD expertise, involvement of multiple health providers and collaboration 
between these professionals are the most important elements of our expert centre (unpub-
lished data*). Nevertheless, in current healthcare, patients still identify a lack of collaboration 
between health professionals.36 Indeed, integrated healthcare is complex in terms of coordi-
nation, and it is also often challenging to integrate the priorities of patients and their families 
with the needs of health professionals.32 Collaboration between health professionals is not 
self-evident: connecting professionals does not necessarily entail improved teamwork among 
disciplines.17 Although team-based care is underlined as a core element of the ParkinsonNet 
networks, health professionals are not always aware who participates in the individual patient 
healthcare team. Despite various implementations to encourage communication (e.g. by 
 
 
* Unpublished data from interviews with patients (n=10) and carers (n=9) before the implementation of the expert centre to 
identify needs and desires; and interviews with patients (n=38) and carers (n=35) six months after they visited the expert centre.
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 structured referral, regular meetings, and web-based communities)37  information exchange 
between team members can still be improved significantly.17 Perhaps other initiatives (like 
an online conference table with access for the patient, caregiver and all professionals within 
their individual healthcare team, as is being used in geriatric care) 38 could be implemented to 
overcome this problem and to increase patient-centeredness of care. 
At what stage should team-oriented care be delivered? 
The current therapeutic approach of PD is often ‘monodisciplinary’ with one medical specialist 
(mostly neurologist or geriatrician) who focuses on accurately diagnosing PD and on optimiz-
ing medical treatment.23 The clinical diagnosis of PD is based on the presence of motor symp-
toms.39-40 Nevertheless, it has become evident that some non-motor features, like obstipa-
tion, olfactory dysfunction and sleep disorders, can precede the development of the defining 
motor signs.41-42 Therefore, suggestions have been made to redefine PD, including a ‘premotor’ 
stage to describe these early PD stages, when motor symptoms have not yet appeared.41-44 The 
presence of these non-motor symptoms in the early stages calls for a broader approach than 
just a single specialist defining PD on the motor symptoms. A multispecialty team approach 
from diagnosis onwards should be effected to adequately treat the wide variety of symptoms 
at these early stages. 
Early versus late disease
Overall, a team approach appears preferable throughout all stages of the disease. With 
advanced disease, the number of non-motor symptoms increases45 (although non-motor 
symptoms are remarkably common even in de novo patients)10 and long-term treatment 
complications become prevalent, including response fluctuations and the development of 
dyskinesia.40 The impact of illness also varies among stages: a study comparing early versus 
late PD patients showed that the most prevalent complaints in early stages were slowness, 
tremor, stiffness, pain and loss of smell/taste, whereas patients in the later stages ranked fluc-
tuating response to medications, mood changes and drooling as their top problems.46 
Tailored to individual preferences
The variability in the perception of most troublesome symptoms across individual patients 
highlights the importance of providing interventions tailored to the patients’ individual 
needs and preferences for care. Such a patient-centred approach represents a crucial element 
of quality of care.47 Patient-centeredness comes with the recognition that care is delivered 
with the patient’s needs and preferences in mind. Although this remains a rather new field 
in patient care and research, evidence is accumulating that empowering patients via self-
management support and shared-decision-making results in improved self-efficacy, better 
health-related quality of life, greater treatment compliance and higher patient satisfaction 
(reviewed in reference Van der Marck et al.7).  
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10Targeting the right patientIn most studies, including the two trials described in this thesis, severely affected patients were largely underrepresented.9,48-51 These patients, in particular, might benefit most from a comprehensive assessment because they are faced with an increasing number of disabilities. 
A recent survey in nursing homes has shown that residents in these facilities are faced with 
great disability, caused by severe motor and non-motor handicaps.52 In fact, baseline attrib-
utes have been linked to effectiveness, such that multidisciplinary rehabilitation seemed most 
beneficial for those patients with higher perceived needs.51 However, it remains to be estab-
lished whether patients in the advanced stages of PD might still benefit from a comprehen-
sive team approach. The disabilities that become prevalent in later stages, such as response 
fluctuations to medication, might just obviate the need for specific care in an expert centre. 
For mildly affected patients with a limited number of disabilities, a less comprehensive team 
might be more appropriate. In such cases, access to regional care provided by specialised 
therapists might already be sufficient to alleviate the disease burden for these patients with 
less complex needs. 
Setting 
One expert centre versus networks  
The interventions described in this thesis also differed with respect to the actual implemen-
tation of treatment. In the IMPACT trial (Chapter 8), treatment was provided by outpatient 
services. Here, the actual delivery of healthcare interventions as recommended by the expert 
centre was outsourced to community professionals. Whether or not treatments were actu-
ally delivered and how well this was performed, was outside our control and was left at the 
discretion of the community neurologist, local Parkinson nurse and community therapists. In 
fact, post-hoc analyses showed that only a proportion of all recommended interventions had 
actually been delivered to the intervention patients. Overall, 73% of referrals had resulted in 
an actual treatment visit, but this percentage varied widely between individual disciplines. 
Referrals for some disciplines were hardly or even not implemented (e.g., sleep consultant, 
sexologists) whereas referral to other disciplines showed actual implementation for over 
65% of referrals (this included occupational therapists, speech-language therapists, and PD 
nurses). Treatment compliance was best for physiotherapy, with an almost full implementa-
tion of recommended referrals. Conversely, some patients never received any follow-up, and 
this is worrisome. An alternative and perhaps better approach might be to incorporate the 
tailored evaluation plus the intervention within one centre, similar to the approach described 
in the Guttman trial (Chapter 7). This may offer a more seamless organisation of care because 
assessment and treatment are delivered by the same team. However, such a centred approach 
might not always be feasible, for example due to the high number of patients that have to be 
screened and treated. Additionally, PD patients often experience difficulties in their mobil-
ity that could hamper their travel to healthcare professionals outside their own region. This 
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might be particularly important for intensive treatments that require multiple consulta-
tions (like PLVT training by the speech-language therapist) or regular visits for longer peri-
ods of time (such as weekly physiotherapy visits). The regional networks of the ParkinsonNet 
concept of care were therefore designed to offer patients good care within the vicinity of their 
own home, making specialised healthcare easily accessible without need for much travelling.
The ParkinsonNet concept: specialised regional network care 
The initial idea to develop ParkinsonNet networks was motivated by research showing that 
referrals to allied healthcare were suboptimal (i.e. not all patients with a clear need for treat-
ment were being referred, while others without indication received chronic weekly treat-
ments), combined with lack of PD-specific expertise among health providers.53 This lack of 
expertise was at the time caused in part by the absence of evidence-based treatment guide-
lines, and also by the fact that allied health therapists treated only a small number of patients 
annually (and this precluded development of adequate expertise). Most of these shortcom-
ings have now been tackled. Specifically, PD specific knowledge, adherence to guideline 
recommendations, and patient volume per therapist are increased.53  The quality of care has 
indeed been improved within these professional ParkinsonNet networks.54 However, the 
current concept of hospital-based expert evaluation followed by treatment in the commu-
nity is not infallible. For example, supervision of care by a single case manager or transition 
coach for each patient might have helped to improve the coordination of care between these 
two complementary elements. Lack of coordination and supervision across the entire health-
care chain might explain why many treatment recommendations were never followed. We 
acknowledge that this was a shortcoming of our study design in the IMPACT trial. Also, the 
current extension of the regional networks with other therapists might improve the actual 
uptake of referrals, and we are currently implementing an alternative approach where Parkin-
son nurses assume the role of personal coaches who supervise the entire treatment trajectory.
The number of health professionals included within the ParkinsonNet networks is still 
increasing. Initially, the ParkinsonNet concept started with just physiotherapists, but this has 
meanwhile expanded and over the years multiple other professions have been engaged. 
At the time of the IMPACT trial, the networks also included neurologists, occupational 
therapists and speech-language therapists. Currently, PD nurses, dieticians, psychologists and 
sexologists are also included as regular team members and the networks have reached full 
national coverage in the Netherlands.37 This expansion might facilitate the implementation of 
referrals to specialised allied health therapists.  For example, specialised sexologists were not 
involved at the time of the IMPACT trial, which might be one of the reasons that referrals to 
this discipline did not result in actual consultation after the assessment in the expert centre.  
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10II. EffectivenessBoth trials described in this thesis evaluated the clinical effectiveness of team organisation of care by PD specialists, whose input was tailored to the patients’ individual needs (Table 2 provides an overview of the research designs of our two trials). In the Guttman trial (Chap-
ter 7), movement disorders specialists provided treatment supported by a PD nurse and a 
social worker. This approach was shown to positively affect quality of life, motor functioning, 
depression, and psychosocial functioning. No effects were found on caregiver burden. In the 
IMPACT trial (Chapter 8), the movement disorders specialist collaborated with a broad range 
of disciplines, resulting in consensus-based treatment recommendations for regional thera-
pists. Consistent, but small improvements were found in several domains, including quality 
of life, activities of daily living, non-motor symptoms, depression and anxiety. No effects were 
shown on motor functioning and caregiver burden. 
Interpretation of the results
The results of the Guttman trial give credence to a multidisciplinary specialist care over usual 
stand-alone care from a general neurologist. The improvements on the primary and second-
ary outcomes,  quality of life (assessed by PDQ-39) and motor functioning (assessed by UPDRS 
III), were not only statistically significant, the effect sizes also represented clinically relevant 
improvements for the patients.49 The results of the IMPACT trial also pointed towards effec-
tiveness of the intervention, with statistically significant effects on both primary outcomes 
(activities of daily living, assessed by the ALDS; quality of life, assessed by the PDQL) and a 
range of tertiary outcomes. However, the improvements were only small and unlikely to be 
clinically relevant. Moreover, the effects might have been partly explained by differences 
at baseline, since the differences disappeared after correction for baseline disease severity. 
Taken together, we concluded that usual care was not convincingly outweighed by the more 
intensive integrated care model tested in this IMPACT trial. In both trials, caregiver burden was 
included as one of the outcome measures. The results jointly suggested a higher caregiver 
burden in the intervention groups, and this confirms the experience gained in an earlier trial.48
Possible explanations
The two trials each evaluated a different team in which collaboration was differently organ-
ised, each at a different setting, with a different research design and with partially different 
outcome measures. The results of both trials were in favour of multispecialty expertise care, 
but the Guttman trial showed more robust effects, while only small improvements were 
shown in the IMPACT trial. We will address some perspectives as possible explanations for 
these different results.  
One explanation might be the difference in the number of team members involved and the 
selection of adequate outcome measures that fit the intervention. In the Guttman trial, three 
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disciplines were involved, the movement disorders specialist, PD nurse and social worker. The 
outcome measures (that rated emotional and psychosocial functioning) might have corre-
sponded better with the actual content of delivered healthcare by the PD nurse and social 
worker. Conversely, in the IMPACT trial, we opted for a wide-ranging approach with access to 
a team of 13 health professionals. The input of these disciplines was tailored to each patient’s 
individual needs, resulting in an enormous variety of arrangements of care that complicated 
the choice of more specific outcomes measures. A larger number of disciplines might also 
induce a barrier for collaboration between multiple disciplines.36 
Another difference between the trials was the inclusion process. In the Guttman trial, patients 
were already referred to multidisciplinary/specialist care before they were randomly assigned 
to immediate care or the control group, who visited the centre after the 8-month study period. 
In the IMPACT trial, patients were first included in the study. Subsequently, those patients who 
lived in the intervention region, were referred to the expert centre. It is conceivable that refer-
Table 2 Overview of research design  
Guttman trial8 (Chapter 7) IMPACT trial9 (Chapter 8)
Recruitment Patients were referred to the expert 
centre for a team assessment before 
inclusion in the trial
Patients were offered team 
assessment in the expert centre after 
inclusion in the trial
Design Randomised Controlled Trial: 
randomised after inclusion in the 
trial to immediate intervention or 
usual care/waiting list
Controlled Trial: intervention region 
(integrated model) versus control 
regions (usual care)
Blinded Patients: no
Medical team: yes
Research staff: yes
Patients: yes
Medical team: yes 
Research staff: no
Data analyses No data on drop-outs collected Intention-To-Treat (ITT)
Outcome 
measurements 
Primary: quality of life (PDQ-39)
Secondary: motor and total UPDRS 
scores, depression (MADRS), 
psychosocial functioning (SCOPA-PS) 
Caregiver burden (CSI)
Primary: activities of daily living 
(ALDS) and quality of life (PDQL)
Secondary:  UPDRS motor scores, 
economical evaluation. 
Range of other outcome measures 
including non-motor symptoms (NMS 
Scale), depression (HADS), general 
quality of life (SF-36, VAS)
Caregiver burden (BELA-A-k; SF-36, 
HADS)
Process 
evaluation
Partly: within expert centre Yes
ALDS AMC Linear Disability Score; BELA-A-k Belastungsfragebogen Parkinson Angehörigen-kurzversion; CSI Caregiver 
Strain Index; HADS Hospital and Anxiety Scale;  MADRS Montgomery-Asberg Depression Scale; NMS Scale Non-motor 
symptoms scale; PDQ-39 Parkinson’s Disease Questionnaire; PDQL Parkinson’s Disease Quality of Life questionnaire; 
SCOPA-PS Scales for Outcomes in Parkinson’s disease-Psychosocial; SF-36 Short Form 36; UPDRS Unified Parkinson’s 
Disease Rating Scale; VAS Visual Analogue Scale. 
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10rals in the Guttman trial were made for more complex patients or patients that were more interested in specialised care. Indeed, a sizeable minority of patients (33%) in the IMPACT trial declined to be referred to the expert centre, presumably because they were mildly affected and anticipated only little gain.
Blinding was another factor that differed between the studies. Patients were not blinded to 
group assignment in the Guttman trial, and this might have contributed to a larger influence 
due to a placebo effect. In contrast, patients in the IMPACT trial were not informed about the 
differences between the regions. 
Additionally, it is important to understand the setting in which the research was performed. 
In the Netherlands, usual care already involves multiple healthcare professionals. For exam-
ple, two analyses of usual care in the Netherlands showed that many patients already receive 
some form of multidisciplinary care, including in particular physiotherapy (57% to 62.5% of 
patients), but to a lesser extent also e.g. occupational therapy (8.5% of patients) or speech-
language therapy (14.4% of patients).53,55 Consequently, in the IMPACT trial, we compared 
a formal organisation of team care with a less formally structured collaboration between 
healthcare professionals. The contrast of the intervention in the IMPACT trial over usual care 
was therefore only limited, while this approach might have resulted in larger effects when 
implemented in different settings, for example in countries were allied healthcare therapy is 
not part of usual care. In the Guttman trial, we compared a team approach by PD specialists 
with stand-alone care by a general neurologist who did not have access to support from PD 
nurses or social workers. We would probably not have seen the same results if we had imple-
mented this approach in the Netherlands, as many neurologists in usual Dutch healthcare are 
already supported by PD nurses.  
Interestingly, both models did not decrease caregiver load. In fact, the results even suggested 
a higher caregiver burden, extending earlier experience.48 Many patients receive support from 
their family members throughout daily life. Intensifying the care process by applying new 
treatment strategies and organising extra referrals also impacts on the daily activities of both 
the patient and the caregivers. This can cause a considerable burden for these carers.56-57 The 
results might also have resulted from a lack of attention for the specific problems that these 
carers experience themselves. For this reason, we have recently initiated dedicated consulta-
tions for the spouses or other immediate caregivers, who are offered the opportunity to visit 
our social worker of PD nurse specialist without the patient being present. Specific attention 
to the problems experienced by caregivers is also part of standard care in other PD centres. 
For example, the Tel Aviv Movement Disorders Unit runs a caregivers’ clinic for those who need 
personal counselling on how to take care of their own difficulties to cope with the burden of 
taking care for their family member with PD.7 
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Evidence from previous studies
In PD, positive effects on health, disability, quality of life and well-being of multispecialty team 
interventions have been reported in several uncontrolled studies that used a pre-test versus 
post-test design.58-62 Besides our two trials, only a few trials using controlled designs have 
been published previously, and the results on the effectiveness of team management have 
been inconsistent.23,63-65 A synopsis of the controlled trials published so far (including our two 
trials) is provided in Table 3. Two earlier trials (Guo et al., Trend et al.) showed marked improve-
ments in patients’ outcome following multidisciplinary interventions. 50,62 However, these trials 
only described the immediate effects following short-lived interventions (6 to 8 weeks). One 
of these trials62 was designed as a long-term study (Wade et al.), but the follow-up data after 
six months (i.e., about four months after completion of the six-week treatment) showed no 
sustained effects. In fact, deterioration was noticed for several outcomes compared to base-
line and to controls.48 Another study by Tickle-Degnen et al. also involved a six-month follow-
up. Directly after the intervention and after six months, more patients in the rehabilitation 
group experienced an improved quality of life compared to patients without rehabilitation.51 
However, the group difference declined with time, suggesting that the benefits were short-
lived.51 These findings, as well as the fact that PD is a progressive condition, suggest a need for 
continuing treatment to obtain more sustained benefits. In fact, the trials in this thesis evalu-
ated the effects of prolonged care by a multidisciplinary team for a period of eight months. A 
longer follow-up may still be relevant for health outcomes and cost-effectiveness. Future trials 
should therefore investigate whether the effects found in our trials are also persistent and 
how care can best be reinforced to sustain effects as the disease progresses. 
Heterogeneity in design, intervention and outcomes 
The summary of trials in Table 3 clearly reflects the large variability in research design, nature 
of the multispecialty intervention and choice of outcome measures. This heterogeneity makes 
it difficult to compare studies. Just like our trials, previous studies were also complicated by 
methodological difficulties, including loss of follow-up data, and potential bias due to study 
design, blinding and selection methods.48,50-51 In fact, there are many methodological chal-
lenges when evaluating complex approaches like multispecialty care in PD, which we will 
further address in the following part of this Discussion.  
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10III.  Challenges to clinical research on multifaceted careComplex interventions, like our multispecialty approaches, represent an emerging field that poses significant challenges to the scientific evaluation. In addition to the practical and meth-odological difficulties that all studies have to overcome, these interventions are increasingly 
challenging due to multiple active and interacting components.66-67 We also faced methodo-
logical and practical difficulties while designing and implementing our trials. We will address 
some of the lessons we have learned. 
Variability in intervention and control care
It was not possible to apply the same standardisation as in single intervention studies (like 
drugs trials), as there was no uniformity of care in the intervention or control group. Drugs 
trials are simpler in design, because a certain drug is provided at a specific dose, frequency 
and treatment duration. Here, however, we were faced with a much more complex and vari-
able design: a variety of disciplines were involved, which provided a diverse set of therapies 
at a variable intensity, frequency, and duration of treatment. In addition, our multispecialty 
approaches were delivered in a tailored fashion, based on each patient’s individual needs. 
This complexity was further increased by the choice of control intervention. Pharmacologi-
cal trials often include a placebo or ‘gold standard’ treatment. Yet, ‘usual care’ in PD does not 
include such a straightforward control. This even occurred in the IMPACT trial (Chapter 8), 
as many control patients received allied health treatment in the community, and this may 
have masked greater benefits for the intervention patients in this trial. Other variables that 
increased the complexity of our team-based approaches included the skill mix among all 
healthcare professionals involved and the inclusion of different clusters of care as controls. 
Study design
Randomised controlled designs are regarded as the highest level of evidence and the gold 
standard for clinical trials. However, due to the complexity of integrated interventions as 
described above, a randomised design is not always feasible. For example, in the IMPACT 
trial, a better matching for baseline disease severity could have been achieved using a fully 
randomised design within a single participating region, but this was impossible because of 
a risk of contamination. Specifically, if we had randomised within a single region, control 
patients could have gained access to specialised allied health treatment offered by the 
regional professional networks. In the Guttman trial (Chapter 7), we did use a randomised 
design to evaluate the effectiveness of the intervention. Nevertheless, this trial had other 
methodological constraints. For example, no data on drop-outs were gathered and therefore 
an intention-to-treat analysis could not be performed.  
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Choice of outcome measures
Another difficulty in this particular area of research is the choice of outcome measures. Our 
interventions were aimed at a range of both motor and non-motor symptoms of PD, and 
were indivually tailored, i.e the menu of interventions varied considerably across individual 
patients. This makes it very difficult to assess the effectiveness of such a multifaceted and indi-
vidually tailored approach using one overarching outcome that applies equally well to each 
study participant. More specific outcome measurements that reflect the actual intervention 
more closely (e.g. gait speed for those that received physiotherapy) might be more suitable 
for capturing the effect. However, these were impossible to select as overall outcome meas-
urements in our trials since each patient received an individually tailored set of interventions 
that differed enormously across individuals. Also, the focus of one primary outcome will not 
be sufficient to determine the full extent of treatment effects and individual improvements of 
complex healthcare. Perhaps, a better alternative would be to include a combination of multi-
ple outcome measures.32,68 Additionally, mixed methods designs, including both quantita-
tive and qualitative methods, might offer a more suitable methodology to evaluate complex 
healthcare interventions. These mixed designs might also improve the fit between research 
on the one hand, and participants and clinical practice on the other. Bridging this gap might 
positively affect inclusion rates and the translation of research results into clinical practice. 
Also, the use of complementary qualitative data will be valuable in explaining differences 
between expected and observed results that are left undetected by quantitative methods, 
for example by identification of barriers that hampered uptake or adherence to interventions 
under study.69 Frequently, outcomes are chosen from the researchers’ perspective. However, 
it might be a better alternative to select outcomes from the participants’ perspectives as well, 
because patients may have different views about what an important or meaningful outcome 
is. 32,68-70
Process evaluation 
Ideally, process evaluations should be included as an integral element of clinical trials.71-72 This 
is particularly true for the evaluation of complex interventions like multifactorial fall preven-
tion programmes.73 These evaluations might be useful for exploring the actual implementa-
tion of the interventions and might explain discrepancies between expected and observed 
effects. In the IMPACT trial, the process evaluation provided transparency about the health-
care interventions that were delivered, indicating that both patient groups received care 
by multiple disciplines. In addition, it showed that some patients were not interested in the 
comprehensive assessment at our expert centre. Without our process evaluation we would 
not have had such a robust description of the actual delivery of the intervention, which ulti-
mately helped us to explain the limited contrast between the groups. 
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Conclusion: Towards a multifaceted approach! 
The work included in this thesis describes the multidimensional nature of PD and provides 
the basis for a multifaceted approach in the management of this broad symptom complex. A 
team-oriented approach including pharmacological and non-pharmacological interventions 
provided by multiple disciplines appears to be warranted, and we offer some new insights 
into the actual effectiveness of various care models. There is increasing scientific support for 
the use of allied healthcare interventions as a complementary approach to standard medical 
management. The possible clinical implications of allied healthcare interventions were illus-
trated in this thesis for physiotherapy, occupational therapy and speech-language therapy. 
Although multispecialty approaches are increasingly acknowledged as representing the opti-
mal management of the motor and non-motor symptoms in PD, there is no known standard 
or best template for organising these team models of healthcare. We described two large, 
controlled trials on the effectiveness of two different types of organisation that were imple-
mented in two different settings. The results underlined previous positive experiences and 
pointed in favour of team/specialist intervention. These trials did not, however, offer the 
final answer on how to optimally design team-based care in PD management, but instead 
provided an initial inventory of the scientific evidence of comprehensive healthcare models in 
PD. Fortunately, further research on the effectiveness of multispecialty team interventions in 
PD is currently underway.74-76 This is a new, emerging and exciting field that offers challenges 
to both clinical practice and scientific research, and which offers hopes for PD patients who 
crave for better treatments of this often debilitating disease. 
Multispecialty team care
There is no standard template or model to design multispecialty care for PD. There are many aspects 
that have to be considered while organising such a team approach, including which disciplines need 
be involved and how many therapists (e.g. a small versus a comprehensive team); how the various team 
members should collaborate (whether this should be organised as incidental consultation of experts who 
work independently, or towards more formalized and complex approaches based on shared decision 
making); at what stage (early versus late, or tailored to patients’ needs); and whether care should be deliv-
ered integrally by one centre or via collaboration with community-based networks. 
Multispecialty team approaches are not only complex to design, these models also offer significant chal-
lenges for the scientific evaluation due to the complex nature of these interventions with multiple active 
and interacting components. The scientific evaluations of team care in PD are thus far inconsistent, but do 
generally point towards possible benefits of multispecialty interventions. However, there are only a limited 
number of controlled trials, and comparison between these studies is difficult because of the wide hetero-
geneity across studies, with varying team members, differences in duration and intensity of the interven-
tions, as well as differences in outcome measures that have been used.
Pending further evidence, we feel that the complex nature of PD (with a diverse set of motor and non-
motor symptoms) plus the evidence presented in this thesis warrant a judicious application of a multispe-
cialty approach to optimally manage the complexity of PD. 
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De ziekte van Parkinson is een invaliderende aandoening, waarbij een scala van motorische en 
niet-motorische symptomen voorkomt. Dit brede palet aan symptomen, gecombineerd met 
het individuele ziektebeeld en ziektebeloop, maakt de behandeling van deze aandoening tot 
een complexe uitdaging voor medisch specialisten. Het centrale thema  van dit proefschrift 
is de complexiteit van de ziekte van Parkinson. Eerst hebben we deze complexiteit geschetst 
aan de hand van twee symptomen van de ziekte: ongewenst gewichtsverlies en valpreven-
tie. Vervolgens hebben we de integrale behandeling van het gehele ziektebeeld met de vele 
verschillende symptomen besproken. De complexiteit bij de ziekte van Parkinson vraagt om 
een teamgerichte aanpak, waarbij verschillende zorgverleners samenwerken. Echter, het is 
nog niet bekend wat de meest optimale organisatie van teamzorg is voor Parkinsonpatiën-
ten en hun mantelzorgers. Daarom hebben we binnen dit proefschrift ook gekeken naar de 
effectiviteit van paramedische zorg bij de ziekte van Parkinson en de effectiviteit van twee 
verschillende vormen van organisatie van teamsamenwerking.  
Gewichtsverlies 
Hoofdstuk 2 en 3 hebben betrekking op ongewenst gewichtsverlies. Ongewenst gewichts-
verlies is een veel voorkomend probleem bij Parkinsonpatiënten. Deze twee hoofdstukken 
beschrijven zowel de complexiteit van dit gewichtsverlies, middels een opsomming van de 
verschillende oorzaken, als de evidentie dat Parkinsonpatiënten een lagere Body Mass Index 
(BMI) hebben vergeleken met controlepersonen. 
Hoofdstuk 2 betreft een review van de literatuur naar de verschillende mogelijke facto-
ren van ongewenst gewichtsverlies bij de ziekte van Parkinson. Deze review liet zien dat 
verschillende Parkinsonsymptomen de energiebalans kunnen verstoren, met als resultaat 
een  verminderde inname, verminderde absorptie of verhoogd energieverbruik. De factoren 
die ongewenst gewichtsverlies bij de ziekte van Parkinson veroorzaken zijn niet alleen de 
factoren die rechtstreeks betrekking hebben op het ziekteproces in de hersenen bij Parkinson 
(zoals motorische problemen, verminderde reuk en cognitieve problemen), maar ook secun-
daire factoren die vaak voorkomen maar niet direct gerelateerd zijn aan het neurodegene-
ratieve proces (zoals misselijkheid en andere bijwerkingen van medicatie). Omdat gewichts-
verlies en een laag lichaamsgewicht geassocieerd zijn met een verhoogd risico op ziekte en 
sterfte, is het belangrijk gewichtsveranderingen tijdig te herkennen om adequaat te kunnen 
Een progressieve, neurodegeneratieve aandoening
De ziekte van Parkinson is een neurodegeneratieve aandoening. Dit houdt in dat er een afbraakproces 
plaatsvindt in verschillende delen van de hersenen. Hierdoor is er een tekort aan dopamine, een stof die 
in bepaalde hersendelen noodzakelijk is voor het overbrengen van zenuwimpulsen. Door dit tekort is de 
zenuwbesturing van het lichaam, waaronder de aansturing van de spieren, aangedaan. Parkinson is een 
progressieve aandoening, wat inhoudt dat de schade in de hersenen gedurende de ziekte toeneemt. 
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11behandelen. Hiertoe hebben we in dit hoofdstuk ook enkele therapeutische mogelijkheden en aanbevelingen beschreven, waaronder het frequent aanbieden van voeding tussen de maaltijden door en het gebruik van smaakversterkers om de voedingsinname te verbeteren. Daarnaast kunnen aanpassingen in de medicatie zinvol zijn om mogelijke bijwerkingen met 
een negatieve invloed op de energiebalans te beperken. Ook kunnen voedingssupplementen 
voorgeschreven worden om te zorgen voor een adequate inname. De complexiteit en de vele 
oorzaken van ongewenst gewichtsverlies bij de ziekte van Parkinson vragen samenwerking 
tussen zorgverleners. Deze complexiteit is echter niet uniek voor Parkinson, maar is ook te 
zien bij andere neurodegeneratieve aandoeningen. Dit hebben we geïllustreerd aan de hand 
van de onderliggende pathofysiologie van ongewenst gewichtsverlies bij de drie meest voor-
komende neurologische aandoeningen – de ziekte van Parkinson, de ziekte van Alzheimer 
en de ziekte van Huntington - door zowel de gemeenschappelijke, generieke factoren als de 
ziektespecifieke factoren voor deze drie aandoeningen te beschrijven.  
Ongewenst gewichtsverlies bij de ziekte van Parkinson wordt veroorzaakt door een 
complexe interactie van verschillende factoren. Voor adequate behandeling is een tijdige 
herkenning belangrijk en inbreng vanuit verschillende disciplines. 
Meta-analyse van de literatuur over lichaamsgewicht van Parkinsonpatiënten en 
controlepersonen 
Ongewenst gewichtsverlies bij Parkinsonpatiënten is veelvuldig beschreven. Het is echter niet 
geheel duidelijk of patiënten een lager gewicht hebben dan controlepersonen, aangezien 
deze verschillen in de literatuur niet altijd statistisch significant waren. Daarom hebben we 
een meta-analyse uitgevoerd om vast te stellen of Parkinsonpatiënten inderdaad een lager 
gewicht hebben vergeleken met controlepersonen (Hoofdstuk 3). Daarnaast hebben we 
gekeken naar mogelijke determinanten. Na een literatuuronderzoek hebben we 12 studies 
geïncludeerd die aan onze inclusiecriteria voldeden. Deze studies tezamen lieten zien dat 
Parkinsonpatiënten een lagere BMI hebben van 1.73 (95% betrouwbaarheidsinterval 1.11 tot 
2.35) vergeleken met controles. Ziekte-ernst was gerapporteerd in zeven studies (deze ziek-
te-ernst is uitgedrukt in Hoehn & Yahr (HY) stadium; hoe lager het HY stadium des te minder 
gevorderd de ziekte is). De gepoolde dataset van deze zeven studies toonde een relatie met 
BMI: patiënten met HY stadium 3 hadden een significant lagere BMI dan patiënten met een 
HY stadium 2 (3.9, 95% betrouwbaarheidsinterval 0.1 tot 7.7). Analyses met andere determi-
nanten konden niet uitgevoerd worden omdat de waardes inconsistent gerapporteerd waren 
binnen de verschillende studies.   
Patiënten met de ziekte van Parkinson hebben een lager gewicht dan controlepersonen. 
Ziekte-ernst is één van de mogelijke determinanten van gewichtsverlies. 
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Valpreventie
De complexiteit van de ziekte van Parkinson wordt in dit proefschrift ook geïllustreerd aan 
de hand van de valrisicofactoren die bij deze aandoening voorkomen. Valincidenten zijn 
een veelvoorkomend en relevant probleem bij Parkinson, waardoor valpreventie noodzake-
lijk is. Hoofdstuk 4 geeft een uitgebreid overzicht van de valrisicofactoren bij de ziekte van 
Parkinson met aanbevelingen om deze te onderzoeken en te behandelen. Dit overzicht is 
gebaseerd op consensus. Eerst hebben we een concept ontwikkeld, dat vervolgens geëvalu-
eerd is tijdens twee rondes. Tijdens de eerste ronde werd het overzicht geëvalueerd door 27 
professionals vanuit verschillende disciplines, die allen actief betrokken zijn bij de klinische 
zorg van deze patiëntengroep. Vervolgens hebben 12 experts op het gebied van vallen bij 
de ziekte van Parkinson, eveneens vanuit verschillende disciplines, het overzicht beoordeeld. 
Voor iedere risicofactor hebben zij de volgende items beoordeeld: de methode voor diagnos-
tiek; disciplines die betrokken moeten zijn bij diagnostiek en behandeling; en welke inter-
venties ingezet kunnen worden. Deze items en de risicofactoren werden opgenomen binnen 
het definitieve overzicht van aanbevlingen als tenminste 66% van de beoordelende experts 
instemde. De uiteindelijke versie omvat 31 valrisicofactoren. Dit zijn zowel generieke factoren 
(o.a. leeftijd, bijwerkingen van medicatie en posturale hypotensie) als Parkinson-specifieke 
factoren (zoals verminderde mobiliteit, loopproblemen en houdingsinstabiliteit). Voor bijna 
alle risicofactoren geldt dat een multidisciplinaire samenwerking nodig is voor valpreventie, 
waarbij de neuroloog en de Parkinsonverpleegkundige een centrale rol vervullen. 
Het expertpanel gaf de voorkeur aan een individueel toegespitste benadering  (waarbij eerst 
gekeken wordt naar een specifiek valtype, en screening en behandeling hierop aanpast 
worden), boven een ‘one-size-fits-all’ benadering (waarbij alle riscofactoren bij iedere patiënt 
onderzocht worden). Regelmatige beoordeling van alle valrisicofactoren blijft voorbehouden 
aan risicopatiënten zonder eerdere valincidenten, of voor patiënten met een onverklaarbare 
oorzaak van vallen.   
Op consensus gebaseerde aanbevelingen zijn nu beschikbaar voor de screening en 
behandeling van vallen bij de ziekte van Parkinson, welke gericht zijn op de klinische 
praktijk. Valpreventie bij de ziekte van Parkinson is complex omdat zowel generieke, 
leeftijd gerelateerde factoren als ziektespecifieke risicofactoren bij kunnen dragen. 
Vandaar dat een multidisciplinaire benadering nodig is en de behandeling aangepast 
zou moeten worden aan de persoonlijke risicofactoren van de individuele patiënt. 
Een nieuw systeem om valincidenten bij te houden: de Valtelefoon 
Om de prevalentie van vallen en de effectiviteit van valpreventieprogramma’s te evalueren 
is nauwkeurige informatie nodig over het aantal valincidenten. In hoofdstuk 5 hebben we 
de evaluatie beschreven van een geautomatiseerd telefoonsysteem dat valincidenten regi-
streert. Zo’n systeem kan een voordelige methode zijn om vallen binnen longitudinale studies 
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11bij te houden. Deze zogeheten “Valtelefoon” werkt als volgt: een computergestuurd systeem neemt - met een door de onderzoeker vastgestelde frequentie - automatisch telefonisch contact met deelnemers op, waarbij de deelnemer het aantal valincidenten over een vooraf-gaande periode intoetst op de telefoon. 
De sensitiviteit, specificiteit en gebruikerservaringen van deze Valtelefoon hebben we 
bepaald middels een evaluatiestudie. Hierbij belde het systeem met wekelijkse intervallen. 
119 Parkinsonpatiënten (niet dementerend, zelfstandig wonend) werden gevolgd gedurende 
1 tot 40 weken (gemiddeld 20,7 telefoongesprekken per patiënt). In totaal vonden er 2465 
automatische telefoongesprekken plaats. Van deze gesprekken is de invoer van 173 ‘geen val’ 
meldingen en 115 ‘val’ meldingen geverifieerd middels persoonlijke telefonische interviews 
door de onderzoeker. Tijdens dit interview controleerden we of de invoer correct doorgeko-
men was binnen het systeem en of het ingetoetste aantal overeen kwam met het daadwerke-
lijk aantal vallen in de voorafgaande week. Alle ‘geen val’ meldingen werden bevestigd en 78% 
van de ‘val’ meldingen. De sensitiviteit van het systeem om vallen te detecteren was 100% en 
de specificiteit was 87%. Door deze hoge specificiteit kan de Valtelefoon tijdsintensieve en 
kostbare persoonlijke follow-up vervangen voor de ‘niet-vallers’.   Ook hebben we gebruikers-
ervaringen geëvalueerd in een subgroep van 90 patiënten middels telefonische interviews. 
Hierbij hebben we vragen gesteld over verschillende aspecten rondom gebruiksvriende-
lijkheid van het systeem en mogelijke alternatieve methodes besproken die vaak gebruikt 
worden om vallen te registreren, waaronder een valkalender, tweewekelijkse valkaarten, en 
een ‘val-hotline’. De resultaten toonden aan dat de gebruikers de Valtelefoon beoordeelden 
als een eenvoudig en gebruiksvriendelijk systeem om vallen te kunnen registreren. Daarnaast 
hebben we inschattingen van de kosten van het systeem gegeven. Uitgaande van een fictieve 
studie van 50 personen met wekelijkse intervallen gedurende een jaar zou de Valtelefoon 
kosten kunnen besparen, voornamelijk op personele inzet. 
  
De Valtelefoon biedt een effectief, gebruiksvriendelijk en betrouwbaar systeem om valin-
cidenten bij te houden in populatiestudies met patiënten met de ziekte van Parkinson, 
en mogelijk ook voor andere aandoeningen waarbij vallen voorkomen. 
Teamsamenwerking binnen de zorg
Het complexe karakter van de ziekte van Parkinson en de beperkingen van de huidige medi-
sche zorg om alle symptomen voldoende onder controle te houden, vragen om een bredere 
benadering vanuit verschillende disciplines boven een behandeling door één enkele specia-
list. Een teamgerichte aanpak wordt steeds meer beschouwd als het optimale model om een 
complexe aandoening als Parkinson te behandelen. Er is alleen nog geen standaardmodel dat 
aangeeft hoe zo’n bredere aanpak dan georganiseerd moet worden. Ook is er maar weinig 
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wetenschappelijk bewijs om te onderbouwen dat teamzorg beter is. De hoofdstukken 6, 7 
en 8 zijn toegespitst op de voordelen van een bredere aanpak met aanvullende interventies 
naast reguliere medische behandeling. 
Het wetenschappelijke bewijs voor paramedische behandelingen (fysiotherapie, logopedie 
en ergotherapie) en multidisciplinaire behandelingen bij de ziekte van Parkinson was 
samengevat in hoofdstuk 6. Paramedische zorg biedt een toegevoegde waarde naast 
medische zorg, door een andere insteek op focus, doel en werkingsmechanisme: paramedici 
kijken naar de invloed van de symptomen op het dagelijks functioneren van de patiënt  in 
plaats van naar het primaire ziekteproces; het doel van de behandeling is het verbeteren van 
de participatie tijdens alledaagse activiteiten in plaats van het verminderen van symptomen 
met medicatie; en het werkingsmechanisme is anders aangezien paramedische zorg de 
beschadigde basale ganglia omzeilt en gebruik maakt van de alternatieve netwerken in de 
hersenen die nog intact zijn. Tegenwoordig is er steeds meer bewijs voor de effectiviteit van 
fysiotherapie, logopedie en ergotherapie als afzonderlijke, ‘monodisciplinaire’ behandeling 
(klasse II bewijs voor fysiotherapie en logopedie en klasse III bewijs voor ergotherapie). 
 
Ondanks het feit dat paramedici en medisch specialisten overlappende behandeldoelen 
hebben, werken ze veelal afzonderlijk van elkaar. Een teambenadering, waarbij verschillende 
disciplines samenwerken, biedt waarschijnlijk de meest optimale behandeling voor het brede 
palet aan symptomen dat de ziekte van Parkinson kenmerkt. Echter, tot nu toe is er maar weinig 
wetenschappelijk bewijs en zijn er slechts enkele gecontroleerde studies die behandeling 
door een team van zorgverleners bij de ziekte van Parkinson geëvalueerd hebben.     
Het wetenschappelijke bewijs voor afzonderlijke, ‘monodisciplinaire’ paramedische 
behandelingen neemt toe. Samenwerking tussen specialisten is waarschijnlijk effectiever 
dan wanneer iedere specialist afzonderlijk te werk gaat. Ondanks het feit dat er een alge-
meen gevoel heerst dat een dergelijke multidisciplinaire aanpak nodig is en voordelen 
biedt, is er tot nu toe slechts weinig onderzoek gedaan om deze gedachte te onderbou-
wen.     
Verschillende soorten van samenwerking
Zorgverleners kunnen op verschillende manieren samenwerken, varierend van het uitwisselen van kennis 
en adviezen op basis van een indivudele patient tot het leveren van teamsamenwerking, waarbij alle zorg-
verleners hun kennis inbrengen tijdens gezamenlijke bijeenkomsten en samen tot een behandeladvies 
komen. 
Binnen teamsamenwerking is er nog onderscheid te maken tussen multidisciplinair, interdiscipinair en 
een integrale aanpak. Bij multidisciplinaire samenwerking zijn verschillende zorgverleners betrokken, die 
ieder hun eigen deel van de behandeling waarnemen. Deze vorm van zorg kan uitgebreid worden naar 
interdisciplinaire zorg, waarbij er regelmatig overleg en bijeenkomsten plaatsvinden en er vanuit de groep 
beslissingen genomen worden. Het integrale model van zorg is gebaseerd op een gezamenlijk opgesteld 
behandelplan dat vanuit consensus van de verschillende teamleden ontstaat. Hieraan draagt iedere zorg-
verlener bij met zijn/haar expertise en wordt ook de patient betrokken binnen het team. 
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11Een gespecialiseerde teambehandeling met meerdere disciplinesHoofdstuk 7 beschrijft de evaluatie van een multidisciplinair team model. De interven-tie bestond uit gespecialiseerde zorg verleend door een bewegingsstoornissenspecialist, Parkinsonverpleegkundige en maatschappelijk werker, wiens inbreng toegespitst was op de 
individuele behoeftes van de patiënt. We onderzochten de effectiviteit van deze multidisci-
plinaire behandeling (interventiegroep, n=51) middels een eenzijdig geblindeerd, gerando-
miseerd onderzoek met een controlegroep (n=49, wachtlijst) waarin patiënten zorg van een 
algemene neuroloog ontvingen.  
Na 8 maanden verbeterden de patiënten in de groep die multidisciplinaire zorg ontving. 
Deze groep verbeterde op kwaliteit van leven (PDQ-39, verschil 3.4, 95% betrouwbaarheids-
interval 0.5 tot 6.2) en motor score (UPDRS III, 4.1, 95% betrouwbaarheidsinterval 0.8  tot 
7.3) in vergelijking met patiënten in de controlegroep. Ook waren er verbeteringen in totale 
UPDRS score (5.6, 95% betrouwbaarheidsinterval 0.9 tot 10.3), depressie (MADRAS, 3.7, 95% 
betrouwbaarheidsinterval 1.4 tot 5.9) en psychosociaal functioneren  (SCOPA-PS, 2.1, 95% 
betrouwbaarheidsinterval 0.5 tot 3.7). De belasting voor de mantelzorgers (gemeten met de 
CSI) was niet verschillend tussen de groepen (1.5, 95% betrouwbaarheidsinterval -1.2 tot 4.2). 
Dit is een van de eerste gerandomiseerde gecontroleerde onderzoeken die meerwaarde voor 
multidisciplinaire/gespecialiseerde behandeling aantoont. 
Gespecialiseerde zorg van een multidisciplinair team bestaande uit een specialist in 
bewegingsstoornissen, Parkinsonverpleegkundige en maatschappelijk werker biedt 
meerwaarde op verschillende domeinen (kwaliteit van leven, motorisch functioneren, 
depressie en psychosociaal functioneren).  
Richting een geïntegreerd model van Parkinsonzorg 
Hoofdstuk 8 beschrijft een omvangrijk onderzoek met een gecontroleerd design. Het doel 
van dit onderzoek was het evalueren van de effectiviteit van een integrale organisatie van 
teamzorg. Dit zorgmodel omvatte twee complementaire delen: (a) een beoordeling in een 
expertisecentrum waarbij behandeladviezen gegeven worden, die geïmplementeerd kunnen 
worden in (b) regionale netwerken van samenwerkende paramedici. Patiënten werden uitge-
nodigd voor een driedaagse screening door een team van zorgverleners, wiens inbreng 
toegespitst was op de individuele behoeftes en prioriteiten van de patiënt. Verschillende 
disciplines waren betrokken: specialisten in bewegingsstoornissen, Parkinsonverpleegkun-
digen, maatschappelijk werker, fysiotherapeuten, ergotherapeuten, logopedisten, slaapspe-
cialisten, diëtisten, seksuologen, neuropsychologen, neuropsychiaters, revalidatieartsen en 
geriaters. De behandeladviezen werden tijdens een gezamenlijke bijeenkomst opgesteld. 
Deze adviezen konden in de eigen leefomgeving van de patiënt geïmplementeerd worden 
door gespecialiseerde paramedici (fysiotherapeuten, ergotherapeuten en logopedisten) die 
samenwerken binnen regionale ParkinsonNet netwerken. De belangrijkste elementen van 
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deze netwerken zijn specifieke training, behandeling volgens evidence-based richtlijnen, 
structurering van verwijsprocessen en optimalisatie van onderlinge communicatie en samen-
werking tussen de verschillende specialisten.
   
We hebben een gecontroleerd onderzoek opgezet, waarbij een interventieregio met het 
hierboven beschreven zorgmodel (n=150) vergeleken werd met reguliere zorg in controlere-
gio’s (n=151). De effectiviteit hebben we geëvalueerd over een periode van 4 tot 8 maanden 
na de startmeting. De primaire uitkomstmaten, activiteiten van dagelijks leven en kwaliteit 
van leven, waren significant verbeterd (ALDS 1.3, gelijk aan een verschil in logit van 0.1, 95% 
betrouwbaarheidsinterval 0.003 tot 0.2; PDQL 3.0, 95% betrouwbaarheidsinterval 0.4 tot 
5.6). Deze verbeteringen waren echter klein en waren niet langer aanwezig als gecorrigeerd 
werd voor ziekte-ernst tijdens de startmeting. Er was geen verandering in motorische score 
(UPDRSIII) en mantelzorgerbelasting (BELA-A-k) als secundaire uitkomstmaten. Een scala aan 
tertiaire gezondheidsmaten, waaronder niet-motorische symptomen, angst en depressie, en 
algemene gezondheidsperceptie, lieten ook positieve, maar kleine verbeteringen zien.  De 
kosten van zorg (meegenomen vanuit het maatschappelijke perspectief ) lieten geen statis-
tisch significant verschil zien tussen de groepen over de 8 maanden studieperiode (gemid-
deld verschil €742, 95% betrouwbaarheidsinterval -€489 tot €1950).
Een integrale organisatie van Parkinsonzorg, met een expertise centrum en regionale 
netwerken van gespecialiseerde therapeuten, bood weinig meerwaarde. Naast het feit 
dat de verbeteringen klein waren, verdwenen de effecten na correctie voor ziekte-ernst 
bij aanvang van de studie. Deze studie levert daarom geen onomstotelijk bewijs dat de 
integrale organisatie van zorg die wij geëvalueerd hebben meer te bieden heeft dan 
reguliere zorg door verschillende therapeuten.
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BEDANKT ALLEMAAL! 
Bondig en zeker wetend dat ik niemand zal vergeten, maar ik kan één van de meest gelezen 
delen van een proefschrift natuurlijk niet zo kort houden. En met teamwerk als centrale thema 
binnen mijn proefschrift kan mijn dankwoord hierin al helemaal niet achterblijven. Het is 
ondenkbaar om zo’n traject alleen uit te voeren, en dat hoefde gelukkig ook niet. Zonder 
alle hulp van collega’s en patiënten was dit boekje niet tot stand gekomen. Ik ga een aantal 
mensen in het bijzonder noemen, maar voor alle mensen die in de afgelopen jaren hebben 
bijgedragen: bedankt!  
Allereerst wil ik de deelnemers aan alle onderzoeken bedanken, ook voor de onderzoeken 
die hier niet beschreven staan. Alle patiënten en partners die geheel vrijwillig deel hebben 
genomen, tijd vrij hebben gemaakt om onze vragenlijsten in te vullen en veelal met goede 
kleding en opperbest humeur naar de metingen zijn gekomen. De vele leuke gesprekken, 
attente briefjes en (kerst)kaartjes; zo motiverend en bijzonder! 
En dan terug naar het begin: mijn sollicitatiegesprek. Marten, Bas, Monique, op volgorde 
hoe jullie van links naar rechts voor me zaten. Later gestart met het gesprek dan gepland, 
en de vragen die ik kreeg; achteraf gezien een goede weerspiegeling van wat er zou komen. 
Bedankt dat jullie mij toen uit die stapel brieven de kans hebben gegeven om dit promotietra-
ject aan te gaan en de opzet van ParC en ParkinsonNet van dichtbij mee te mogen maken. Een 
bijzondere tijd, met name in het begin, om onderdeel te zijn van de enthousiaste ParC familie! 
Ik las laatst een uitspraak dat het ‘in de wetenschap niet zozeer belangrijk is om nieuwe feiten 
te ontdekken als wel nieuwe manieren te ontdekken om hierover na te denken.‘  Voor mij een 
passende uitspraak bij jullie innovatieve manier van denken. Zodra er ook maar ‘nieuw’ of ‘dat 
is niet gebruikelijk’ of  ’dat doen anderen niet’  gezegd werd, zag ik het enthousiasme bij jullie 
al weer toenemen.  Ondanks het feit dat de moed me soms in de schoenen zakte - omdat ik 
de bergen werk al weer op me af zag komen – kan ik er achteraf gezien alleen maar met veel 
trots terugkijken dat het allemaal gelukt is!  
Monique & Maarten, als mijn eerste kamergenoten. Maarten, bedankt dat ik zoveel formats 
van je over heb mogen nemen voor mijn “extended version” van jouw onderzoek, en wat 
mooi dat we ook aan kunnen tonen dat er iets in zit. Zoals jij al treffend verwoordde in jouw 
proefschrift, werd IMPACT de evaluatieslag tussen jullie beide: ParC en ParkinsonNet. Het 
harde werken is beloond, IMPACT heeft impact!  Bedankt voor al jullie adviezen en natuurlijk 
ook voor de gezelligheid! 
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Sebastiaan, je bent iets later in mijn traject erbij gekomen, maar ik kan wel zeggen dat je 
één van de meest waardevolle bijdrages hieraan hebt geleverd. Bedankt voor het schieten 
op mijn teksten, je steun en je kritische blik om de stukken van goed toch nog weer beter te 
maken. Door jouw inbreng hebben we de artikelen en dit proefschrift op een hoger niveau 
kunnen brengen, dank je wel hiervoor!  
Ik wil ook alle medewerkers van het ParC Dagcentrum bedanken, zonder jullie inzet was mijn 
onderzoek niet mogelijk geweest! Het wordt te veel om iedereen afzonderlijk te noemen, 
maar een paar mensen wil ik in het bijzonder noemen en bedanken voor de gezellige lunches, 
etentjes, inbreng en/of de bemoedigende woorden om stug vol te blijven houden: Lidy, 
Carina, Rianne, Bart, Bart, Hanneke (“gaat helemaal goed komen” – en dit is ook zo!) en Heleen, 
bedankt! Ook de “overburen” bij GDD bedankt voor de gezellige lunchtijd, en natuurlijk ook 
mijn huidige collega’s bij de onderzoeksgroep van de Geriatrie.   
Het onderzoeksteam: Marloes, Michel, Nadine en Margit, bedankt voor jullie ondersteuning 
binnen de studie! Jullie hebben als onderzoekassistenten veel werk verricht en heel wat kilo-
meters afgelegd om data te verzamelen (ik heb het aantal kilometers een keer berekend voor 
een presentatie om een beeld te geven: twee retourtjes naar Maleisië! En dat naast de ruim 
2500 vragenlijst- en meetboeken). Marlies, Poortje, Leonie en Christa: jullie stages en bijdra-
gen aan het onderzoek waren onmisbaar, bedankt daarvoor. Nathalie en Sabina, bedankt 
voor jullie hulp bij de data-invoer. Ook de hulp van alle betrokkenen vanuit de andere ziek-
enhuizen, de neurologen, de verpleegkundigen (Jolique en Ria), en de ondersteuning vanuit 
de secretariaten, was onmisbaar. Bedankt voor jullie ondersteuning en de bereidheid om ons 
te helpen! George en Wim, dank voor alle hulp bij de analyses, de vlotte reactie en de pret-
tige samenwerking. Wat was het fijn om van jullie “komt wel goed” te horen als ik weer even 
helemaal vast zat in de gigantische dataset. 
Ik wil ook alle co-auteurs bedanken met wie ik de publicaties heb mogen opschrijven. Dear 
Mark, thank you for the possibility to write the paper on the “Guttman” trial, as Bas and I named 
it. It was a privilege to publish one of the first RCT’s on multispecialty team care in Parkinson’s 
disease with you. And also, even more important, to show others that it has potential! I also 
want to thank Michael Okun, Ergun Uc, Nir Giladi, Susan Lindvall, and the members of the NPF 
Falls Task Force for their time and collaboration within the projects and publications. Ahmed 
Aziz, professor Roos, Marcel OldeRikkert, Laura A’Campo, Yvette Grimbergen en Take van der 
Hoek, bedankt voor de samenwerking bij de artikelen. Ook wil ik de manuscriptcommissie - 
Professor Smit, Professor Westert en Professor Roos - bedanken voor hun bereidheid om het 
manuscript te beoordelen.
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En natuurlijk alle andere onderzoekers van de Parkinsongroep die ik nog niet genoemd heb, 
bedankt voor de samenwerking op het werk en tijdens de verschillende congresbezoeken, 
maar ook buiten het werk. Het is goed om te weten dat er meer mensen in hetzelfde schuitje 
zitten. Alle kamergenoten op de 1e & 2e verdieping en begane grond (met name Maartje, 
Marlies, Arlène en Katrijn) bedankt voor het delen van ervaringen, samen overleggen en de 
gezelligheid. En natuurlijk ook collega’s van de andere afdelingen (o.a. Marisca) voor de inte-
ressante en leuke overleggen en onderonsjes. 
En dan MAAIKE. Met hoofdletters, haha! Je dacht waarschijnlijk dat ik steeds een grapje 
maakte, maar je bent het dubbel en dwars waard. Bedankt voor je ondersteuning, je interesse 
en het meedenken, maar bovenal de gezelligheid! Zonder jouw inbreng, was mijn promo-
tie-traject lang niet zo’n leuke tijd geweest. We zijn dan wel geen directe collega’s meer, maar 
de vriendschap gaat gewoon door buiten het werk. 
En dan natuurlijk mijn lieve vrienden! Bedankt voor jullie steun tijdens de goede en ook de 
minder goede momenten, jullie interesse en de nodige afleiding tijdens mijn promotietra-
ject. In het bijzonder, Marijke. Vanaf groep 3 ben je al mijn BTV! Wat hebben we al een hoop 
meegemaakt samen. Altijd weer lachen om je relativerende opmerkingen in stressvolle tijden 
(we zijn inderdaad geen zuurkool aan het ontwarren of bananen aan het plat slaan!). De 
“brandende toortsen” zijn niet meer nodig, haha (nou ja, misschien nog in een andere baan). 
Heleen, bedankt voor je altijd eerlijke interesse en attentheid, voor je lieve berichten toen ik 
het nodig had. Voor de leuke tijd in Wageningen, en natuurlijk voor het feit dat je mijn para-
nimf wilt zijn op deze dag! 
Ook al kon ik niet zo vaak afspreken als dat ik wilde, allemaal bedankt voor de nodige afleiding 
buiten het werk: Marijke & Sietse (de gezellige etentjes), Jess & Es (op de spaarzame dagen dat 
we af konden spreken met 3 volle agenda’s), Ester (voor de vele uurtjes Martial Fit om de frus-
traties eruit te trappen en slaan), en Tamara (mijn gezellige buurvrouw tijdens het edelsmeden 
maar vooral ook ernaast), Sven & Ria (alle (oud&nieuw) etentjes en verjaardagsfeesten, en  “die 
onderzoekster was net een Marjolein” neem ik maar als compliment op), Edwin, Gerjan, Merijn 
& Bettine, en Arjen & Inge. Ik mag mijn ‘mede-edelsmeders’ op de dinsdagmiddag hierbij niet 
vergeten: bedankt voor de nodige afleiding, het houdt me inderdaad van de straat!   
En dan mijn familie. Bedankt voor de interesse die jullie getoond hebben, al is het soms maar 
moeilijk te begrijpen wat ik aan het doen was. Mijn schoonfamilie - Jessie, George, Rob  en 
Yvette. Jessie, eigenlijk ben ik dankzij jou op deze plek gekomen door de stage in het AzM 
waar mijn Parkinson-periode begonnen is!  Anton, dankzij jou ben ik helemaal up-to-date 
over buxussen en trikes. Zet er maar vast weer één in de verzekering, want ik heb tijd over 
straks! 
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En ook de liefste nichtjes van de wereld, Vera en Iris! Heerlijk om met jullie samen slapend en 
brabbelend op de bank te zitten, te spelen en te knuffelen. En natuurlijk alle digitale knuffels, 
handkusjes en houdoe’s tijdens onze Skypedates.  
Lieve paps, mams en Eef. Mijn boekje is afgerond, en dat van de dochter en zus die altijd zei 
niet te gaan studeren, in een ziekenhuis te gaan werken, of te promoveren. Ja ja, niet gedacht, 
maar ik kan toch echt wel verrassend zijn! Bedankt voor het fijne en het vertrouwde nest thuis 
en het feit dat jullie me altijd de mogelijkheid hebben gegeven om te doen wat ik wilde. 
Helaas is de format inmiddels gewijzigd, maar die ‘andere dunne’ kan trots op ons zijn!  
En dan, zoals je zelf laatst al aangaf, de belangrijkste als laatste: Frank! Ook al luisterde je niet 
altijd naar de inhoud zoals je zelf altijd zegt, ik vond het wel fijn om iemand te hebben om 
tegen aan te praten. Je sleurde me de afgelopen jaren (en nu nog) dwars door alle hobbels en 
bobbels heen, zowel figuurlijk als letterlijk, werk en privé. Ondanks mijn luid gemopper - als 
je me weer eens met mijn hoogtevrees de Preikestolen, vulkaan en pyramides etc. opjaagt, 
of me van het werk afhield om tijd vrij te maken voor andere dingen - heb ik je steun altijd als 
bijzonder ervaren. Al bijna 11 jaar samen. Het klinkt zo lang, maar eigenlijk is de tijd samen zo 
snel en gemakkelijk voorbij gegaan. We vullen elkaar aan en ik kan me niet voorstellen hoe 
het zou zijn zonder jou. Eindelijk is mijn boekje af, tik ‘m aan! Nu weer tijd voor elkaar en de 
leuke dingen! Maar, nu eerst feesten! 
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